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ABSTRACT 
Graves’ disease (GD) is an antibody-mediated autoimmune disease 
caused by thyroid stimulating antibodies (TSAbs) activating the 
thyrotropin receptor (TSHR). Both genetic and environmental factors 
contribute to pathogenesis and one such factor is the infectious agent, 
Yersinia enterocolitica. Two high affinity TSAbs, (KSAb1, IgG2b/κ; KSAb2, 
IgG2a/κ), developed from an experimental murine model of GD, share 
common germline Ig genes and thus are derived from the same precursor 
B cell clone which diversified through somatic hypermutation.  
The shared germline genes were expressed as recombinant (r) Fab 
germline and did not display measurable binding to TSHR in three assay 
systems: radioreceptor assay, flow cytometry and cAMP stimulation 
bioassay. Hence the precursor B cell clone was not endowed with 
autoreactive potential. To assess the individual contribution of KSAb1’s 
heavy and light chains to TSHR reactivity chimeric rFab constructs were 
created. The interaction and stimulation of TSHR was dependent on the 
mature heavy chain. 
Significantly, antigen recognition studies of rFab germline, KSAb1 and 
KSAb2 showed binding to OmpA, OmpC and OmpF of Y. enterocolitica. 
Our findings raise the possibility that the clonal expansion of B cell 
populations that acquire autoreactivity in the periphery may be associated 
with the porin proteins of Y. enterocolitica.   
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1 CHAPTER ONE: General introduction 
1.1 Immunity 
1.1.1 Innate immunity 
The immune system is vital for protection against infection. It functions to 
eliminate potentially damaging pathogenic organisms and toxic 
substances from the body whilst avoiding autoimmune responses against 
the host’s self antigens. There are two arms of the immune system: the 
innate and the adaptive responses (Chaplin, 2010).  
The innate response is the first line of defence against pathogens 
(Pancer and Cooper, 2006), acting quickly but without conferring 
memory. Innate mechanisms include physical barriers such as the skin, 
mucous, cilia, the acid pH of the stomach and bacteriolytic enzymes in 
secretions such as tears. Cellular and humoral aspects of the innate 
immune system enhance physical barriers and intervene when they are 
breached. A limited number of innate immune receptors expressed on 
cells are encoded by germline genes and recognise molecular structures 
found in many pathogens but not in human cells. The innate receptors 
are termed pattern recognition receptors (PRRs) e.g. TLRs (Figure 4), 
and the microbial components are termed pathogen associated molecular 
patterns (Janeway, 1989).  
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1.1.2 Adaptive immunity 
The adaptive immune response is comprised of antigen-specific immune 
responses and thus is slower to develop than the innate response but 
generates long-lasting immunity (Pancer and Cooper, 2006). T and B 
cells comprise the adaptive immune response and recognise specific 
pathogens via their receptors, the T cell receptor (TCR) and the B cell 
receptor (BCR), or immunoglobulin (Ig), respectively (Boehm, 2011). 
Each TCR and BCR is generated by random somatic gene 
Figure 1: Toll-like receptors and their ligands. 
TLRs are PRRs expressed on the cell surface or intracellularly to 
respond to a diverse range of viral and bacterial products. The function 
of TLR10 is unknown. Certain TLRs such as TLR7 and TLR9 have 
been implicated in autoimmunity. 
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rearrangements with genes chosen from many possible germline-
encoded genes thus creating a huge repertoire of antigen specificities 
(Chaplin, 2010). Like the innate immune response, there are cellular and 
humoral arms of adaptive immunity. Specific proteins, antibodies, 
produced and secreted by B cells, mediate humoral adaptive immunity. 
The cellular arm of the adaptive immune response involves cytotoxic T 
(Tc) cells and helper T (TH) cells and the release of pro-inflammatory 
cytokines.  
1.1.3 Antigen presentation 
Both B and T cells require the family of human leukocyte antigen (HLA) 
glycoproteins to recognise and respond to antigen. This region is 
encoded on chromosome 6p21, and represents the most gene-rich region 
of the human genome, with many important immunity-related genes 
expressed. HLA molecules or major histocompatibility molecules (MHC) 
molecules in mice, and are highly polymorphic.  
HLA molecules are divided into 2 classes: HLA class I and HLA class II. 
HLA class I and class II proteins are both involved in antigen 
presentation, but differ in the peptides they present and the cells on which 
they are expressed (Neefjes et al., 2011). Cells expressing HLA class I 
present antigen to CD8+ Tc cells, whilst cells expressing HLA class II 
present to CD4+ TH cells. 
HLA class I molecules are heterodimeric proteins, formed of α-chain and 
β2-microglobulin, and are expressed on all nucleated cells and bind to 
intracellular antigenic peptides, typically from infected cells. HLA class I 
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molecules are encoded by three classical genes: HLA-A, -B and –C, with 
HLA-C being the least expressed of the three, three non-classical genes, 
HLA-E, -F and –G, and 12 pseudogenes (Shiina et al., 2009). The 
majority of peptides to be presented are degraded by the 26S 
proteasome after which they are transported by a transporter associated 
with antigen presentation to the endoplasmic reticulum. Here peptides 
may be trimmed to an approximate length of 8-10 amino acids, and are 
folded by tapasin protein and bound by stabilising chaperone proteins to 
allow loading onto HLA class I molecules. The HLA-peptide complex is 
then transported to the cell membrane for presentation (Neefjes et al., 
2011).   
HLA class II molecules are encoded for by three genes: -DRαβ, -DQα1β1 
and –DPα1β1 (Shiina et al., 2009). Unlike HLA class I, the expression of 
HLA class II is more restricted; it is primarily expressed by professional 
APCs such as macrophages, dendritic cells (DCs) and B cells, but may 
be induced by IFN-γ stimulation of non-APCs. The majority of studies to 
understand the HLA class II pathway have involved HLA-DR, and the 
pathways for the other two genes may differ from that described here. 
HLA class II consists of transmembrane α- and β-chains paired with an 
invariant Ii chain. This complex is translocated to the late endosomal 
compartment where Ii is degraded and a residual class II associated Ii 
peptide (CLIP) is left in the HLA class II binding pocket. HLA-DM swaps 
CLIP for an exogenous peptide, degraded in the endosome, and the HLA 
class II/peptide complex is transported to the cell membrane for antigen 
presentation (Neefjes et al., 2011). 
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It is currently unknown why certain HLA alleles are associated with 
autoimmune disease for example, HLA-B27 is strongly associated with 
ankylosing spondylitis (Reveille, 2011), this may be due to the process of 
antigen presentation (Wucherpfennig and Sethi, 2011).  
1.2 T cell development 
Developing T cells in the thymus may be derived from one of two distinct 
lineages, defined by expression of either a γδ TCR or an αβ TCR, with 
both lineages derived from the same CD4-CD8- precursor thymocytes. 
Thymocytes expressing an αβ TCR are most commonly found in the 
thymus and lymph nodes (Ciofani and Zúñiga-Pflücker, 2010) and will be 
discussed further with regard to their role in adaptive immunity and 
autoimmunity. 
1.2.1 T cell central tolerance 
TH cells are CD4
+ and respond to antigen presented in the context of HLA 
class II molecules. Tc cells are CD8+ and respond to antigen in the 
context of HLA class I molecules (Miller, 2011). Before leaving the 
thymus to enter the periphery, T cells must undergo rigorous positive and 
negative selection as part of central tolerance mechanisms to ensure a 
robust response to foreign antigens, and to prevent autoimmunity. 
The thymus provides a specialised microenvironment for developing T 
cells and consists of a medulla region surrounded by a cortex (Ladi et al., 
2006). The survival and antigen education of developing T cells are 
dependent on the presentation of self-antigen in the context of HLA class 
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I and HLA class II molecules expressed by cortical thymic epithelial cells 
(cTECs). Any CD4+CD8+ cells, derived from CD4-CD8- cells, which do not 
engage in HLA contact, due to lack of or no affinity for antigen, die 
through lack of positive survival signals. Approximately 80-90% of 
thymocytes die by this mechanism. CD4+CD8+ cells which have an 
intermediate affinity for antigen receive positive selection signals from 
cTECs, commit to either the CD4 or CD8 lineage and migrate to the 
medulla by up-regulating the chemokine receptor, CCR7, to interact with 
DCs and medullary TECs (mTECs) (Klein et al., 2009; Ladi et al., 2006).  
Negative selection occurs in the thymic medulla, where any T cell clones 
that recognise tissue-restricted self-antigens presented by mTECs, many 
under the control of the transcription factor, Aire (autoimmune regulator), 
are deleted (Derbinski et al., 2001). Deletion or mutation of the Aire gene 
results in severe organ-specific autoimmune disease in mice and 
humans, the autoimmune polyendocrine syndrome type 1 (Akirav et al., 
2011; Mathis and Benoist, 2009). The self-antigens presented in the 
thymus may be derived from the bloodstream entering the thymus, 
resident thymic DCs or by DCs migrating there from the periphery (Klein 
et al., 2009; Li et al., 2009). This increases their presentation to 
thymocytes and increases tolerance induction (Koble and Kyewski, 2009) 
The T cells emigrating from the thymus should only recognise foreign 
antigen when expressed in the context of a self-HLA molecule, be 
tolerant to self-antigen and should not respond in the periphery to cause 
autoimmune responses.  
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1.2.2 T cell peripheral tolerance 
Central tolerance mechanisms are not infallible so control mechanisms 
exist in the periphery to prevent autoimmune disease. 
Regulatory T cells (Tregs)  
Natural (n) Tregs develop alongside other conventional CD4
+ T cells, 
following intermediate to high affinity ligation of the TCR in the thymus. 
These cells are CD4+ and express Foxp3 and CD25 (Sakaguchi et al., 
2010; Sakaguchi et al., 1995; Wing and Sakaguchi, 2009). IL-2 has been 
shown to be an essential co-factor in nTreg development in the thymus, as 
has the NF-κB pathway (Feuerer et al., 2009). CD8+ FoxP3+ Tregs have 
also been shown to exist to down-regulate CD4+ T cell responses (Hu et 
al., 2011). Tregs may also be induced (iTregs) in the periphery through the 
plasticity of other subsets following exposure to certain chemicals and 
cytokines e.g. retinoic acid, TGF-β, vitamin D and indoleamine 2, 3-
dioxygenase (Kushwah and Hu, 2011). 
The importance of Tregs is demonstrated by the severe proliferation of 
lymphocytes and multi-organ autoimmune disease observed in scurfy 
mice and immunodysregulation polyendocrinopathy and enteropathy, X-
linked syndrome (known as IPEX syndrome) in humans, a monogenic 
disease caused by the deletion of the foxp3 gene (Feuerer et al., 2009; 
Godfrey, 1991; Wildin et al., 2001). Similarly, altered numbers or function 
of Tregs have been found and implicated in the development of numerous 
immune disorders (Buckner, 2010). Current in vitro assays used to 
measure the suppressive activity of Tregs do not accurately reflect their 
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suppressive activity in vivo, so it is not known exactly how Tregs interact 
with and control the responses of other cells. Further proposed Treg 
subsets include TH1 Tregs, TH2 Tregs (Duhen et al., 2012) and DN Tregs 
(Kushwah and Hu, 2011). 
1.2.3 T cell activation 
This discussion of T cell activation will focus on cell surface markers and 
their interactions rather than intracellular signalling events in the interest 
of brevity. 
In the periphery, T cells require multiple signals and co-ligations to 
activate and respond to antigen. Signal 1 comes from peptide in the 
context of HLA engaging the TCR. It is thought that peptide-HLA 
complexes can sequentially engage multiple TCRs to amplify the signal 
and reach the necessary activation threshold. Signal 2 comes from 
ligation of accessory molecules, for example, CD28 on the T cell binding 
CD80/CD86 on the APC (Alegre et al., 2001). Signal 2 is likely a fine 
balance between pro- and anti-stimulatory signals and results in T cell 
proliferation and cytokine release. CD28 is constitutively expressed by 
resting and activated T cells and its ligands, CD80 and CD86, are 
expressed on activated APCs. CD28 increases TCR-mediated T cell 
survival, proliferation, cytokine release and ability to help B cells (Walker 
and Sansom, 2011). CD28 signalling may lower the TCR threshold 
necessary for T cell activation, possibly by decreasing the contact time 
with APCs (Iezzi et al., 1998). This contrasts with the function of cytotoxic 
T lymphocyte antigen 4 (CTLA4). A third signal comes from inflammatory 
  29 
cytokines and determines the type of cell differentiation into TH or Tc cells 
(Kalinski et al., 1999) (Figure 2, page 29). 
 
CTLA4 competes with CD28 for CD80/CD86 binding to function as a 
negative regulator of T cell signalling (Walker and Sansom, 2011). It is 
up-regulated by T cells several days after activation in mice and humans 
(Linsley et al., 1992), and is constitutively expressed by resting and 
activated regulatory T cells (Tregs) (Read et al., 2000; Takahashi et al., 
2000). CTLA4 has a higher affinity and avidity than CD28 for 
CD80/CD86; CTLA4-CD80 represents the strongest ligand interaction, 
CD28-CD86 the weakest (Collins et al., 2002) therefore CTLA4 
Figure 2: T cell activation. 
T cells are activated following multiple signals. Signal 1 is provided by 
the ligation of the TCR with its cognate antigen presented in the 
context of self-HLA expressed by an APC. Signal 2 is a fine-balance 
between the ligation of the pro-stimulatory molecule CD28 with 
CD80/CD86 and the anti-stimulatory molecule CTLA4 with two ligands, 
CD80/CD86. Signal 3 comes from the cytokine milieu and may 
determine the T cell subset differentiation. Figure is adapted from 
(Alegre et al., 2001). 
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antagonises CD28 binding. Variants in CTLA4 have also been implicated 
in multiple autoimmune diseases including type 1 diabetes (T1D), 
rheumatoid arthritis (RA) and GD (Karumuthil-Melethil et al., 2010; Liu et 
al., 2011; Takahashi and Kimura, 2010). 
The TH cell subsets mentioned in this thesis, their defining transcription 
factor and cytokines are summarised in Figure 3, page 30. 
 
Figure 3: T helper cell subset differentiation. 
Naive CD4+ T cells (TH0) may differentiate into numerous possible 
‘helper’ subsets following antigenic challenge and depending on the 
cytokine milieu. T cell subsets are defined by their transcription factors 
and cytokines. 
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1.3 B cell development 
B cells develop in the foetal liver and adult bone marrow from 
haematopoietic stem cells. In the periphery, B cells form an integral part 
of the humoral immune system by secreting antigen-specific antibody, 
acting as APCs and producing pro- and anti-inflammatory cytokines.  
1.3.1 Antibody structure and subtypes 
Antibody molecules belong to the Ig superfamily and consist of two 
glycosylated heavy (H)-chains and two non-glycosylated light (L)-chains, 
connected by disulphide bridges. H-chains comprise 3-4 constant (C) 
regions (CH1-4), and one variable (V) region (VH), whilst L-chains 
comprise one C-region (CL) and one V-region (VL). A hinge region links 
CH1 and CH2. H-chain has a molecular weight (MW) of 55 kDa, whilst an 
L-chain has a MW of 25 kDa.   
The antigen binding, Fab, region of the antibody is formed of the entire L-
chain with VH and CH1. The V-region of the Fab portion differs between 
the H- and L-chains. The V-region of the H-chain (immunoglobulin heavy 
chain Variable region; IGHV) is formed of three genes, Variable (V), 
Diversity (D) and Joining (J) genes, whilst the immunoglobulin light chain 
variable region (IGLV) is formed of the V and J genes, without a D gene. 
The V-region may also be subdivided into four framework (Fw) regions 
and three hypervariable complementarity determining regions (CDRs), 
with CDR 3 being the most variable and largest (Figure 4, page 32). The 
V gene encodes Fw 1-3 and CDRs 1-2 and the N-terminus of CDR3, the 
J gene segment continues CDR 3 and the complete Fw 4, the D gene 
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segment is found in CDR 3 between the C-terminus of the V gene and 
the N-terminus of the J gene (Figure 4) (Schroeder Jr and Cavacini, 
2010). 
The specific subtype of antibody is determined by the Fc portion, and 
may be IgM, IgD, IgA, IgE or IgG. IgG is the predominant antibody in 
serum and is further subdivided to IgG1, IgG2, IgG3 and IgG4 in humans, 
and IgG1, IgG2a, IgG2b and IgG3 in mice (Mix et al., 2006). IgM is the first 
antibody generated and is secreted in pentameric form, linked by a J 
chain; monomeric IgM has a lower affinity for antigen than the pentameric 
form (Weinstein et al., 2004). IgD’s function is not fully understood (Chen 
and Cerutti, 2011). IgA is the main antibody found in mucosal locations. 
IgE is found in only trace amounts in serum but cause hypersensitivity 
reactions when bound to basophils causing their degranulation. 
(Weinstein et al., 2004).  
 
Figure 4: Immunoglobulin G 
structure.  
An IgG molecule contains two H-
chains and two L-chains. The H-chain 
is encoded by VH, DH and JH genes 
and 3-4 CH genes. The L-chain is 
encoded by VL and JL genes. The Fab 
portion of the antibody is involved in 
antigen binding and the Fc portion is 
involved in signalling. CDRs shaded in 
light blue in the H and L chain V 
regions, Schroeder Jr and Cavacini, 
2010. 
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1.3.2 VDJ recombination 
To become functional, B cells must assemble and express a functional Ig 
molecule, from germline V, D and J genes. There are multiple VDJ genes 
to choose from and their random selection and rearrangement ensures a 
diverse cell population.  
H-chain recombination 
Recombination occurs firstly in the H-chain locus on chromosome 14q32, 
with DH and JH genes chosen at random and recombined together (Jung 
et al., 2006). The DJH gene segment is then combined with a randomly 
selected VH gene. All other unused genes are excised as excision circles 
and a primary transcript is synthesised with a C-region gene.  
All recombination events are under the control of the recombinase 
activating genes (RAG) 1 and 2. RAG 1 and 2 create double strand 
breaks at specific recombination signal sequences (RSSs), which are 
found at the 3` end of the V genes, 5` end of the J genes and both sides 
of the D genes. Which VDJ genes are selected and recombined is 
determined based on the RSSs that flank them, termed the 12/23 rule. 
RSSs may be either 12 or 23 base pairs (bp) long spacer sequences 
separating conserved heptamer or nonamer sequences; a gene flanked 
by a 12 bp RSS will be recombined with another gene segment flanked 
by a 23 bp RSS. Typically, RAG 1 will recognise e.g. the 12 bp spacer, 
RAG 2 then associates with RAG 1 and the same happens to the 23 bp 
spacer and a synaptic complex is formed (Schroeder Jr and Cavacini, 
2010).  
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The RAG proteins nick a single strand of DNA at the heptamer sequence 
forming a hairpin loop, which is subsequently nicked again, and several 
nucleotides are removed from the end to create a 3’ overhang. The 
overhang may be further modified for example by terminal 
deoxynucleotidyl transferase (TdT) which inserts non-germline encoded 
nucleotides at random, and is subsequently repaired (Figure 5) 
(Schroeder Jr and Cavacini, 2010). The random selection and 
rearrangement of VDJ genes is the first step in the creation of a diverse 
antigen receptor repertoire, known as recombinatorial diversity. Further 
junctional diversity is created by the random insertion of ‘N’ nucleotides at 
the junctions between VDJ genes by TdT. VDJ recombination is 
summarised in Figure 5. 
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L-chain recombination 
There are two types of L-chain: the κ chain locus encoded on 
chromosome 2p11 and the λ chain encoded on chromosome 22q11. 
Initial rearrangements begin at the L-chain κ locus and it is only if this 
locus proves unsuccessful and all possible Vκ and Jκ genes are 
exhausted, that the λ locus is rearranged. To ensure B cells express Ig 
with only one type of L-chain, non-productive κ genes are silenced by 
allelic exclusion (Gonzalez et al., 2007). The pairing of assembled 
functional H- and L-chains generates a surface IgM molecule and At this 
Figure 5: VDJ recombination. 
VDJ recombination is initiated by the binding of RAG 1 and 2 gene 
complexes to RSSs flanking gene segments. Heptamer sequences are 
nicked and a hairpin loop is formed, aided by high mobility group 
proteins. The hairpin is cleaved, modified by TdT and repaired by 
enzymatic machinery, Schatz and Ji, 2011. 
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developmental stage, immature B cells may now leave the bone marrow 
to recirculate through the secondary lymphoid organs to search for 
antigen (Pillai et al., 2011).  
1.3.3 Germinal centre 
B cells express CXCR5 to gain entry to the lymphoid organ follicles, in 
response to the expression of its ligand, CXCL13, expressed by follicular 
stromal cells (Gatto and Brink, 2010).  
Germinal centre reaction 
Antigen-specific B cells seed the GC following ligation of the B cell-
expressed CD40 with CD40L expressed by activated T cells, as well as 
the action of cytokines secreted by T cells that promote B cell proliferation 
and differentiation. GCs are formed of a dark zone and light zone, named 
according to their histological appearance and are surrounded by outer 
and marginal zones (Figure 6, page 38). B cells become centroblasts in 
the dark zone, where they down-regulate their surface Ig and undergo 
rapid proliferation. Centroblasts express high levels of CXCR4, and its 
ligand, CXCL12, is in high abundance within the dark zone. Here they are 
close to the T cell zone where they receive help from TFH cells; B cells 
express EB12 and CCR7 to distribute along this boundary, whilst T cells 
upregulate CXCR5 and Bcl-6 (Gatto and Brink, 2010; Vinuesa et al., 
2005). Bcl-6 is the master regulator of GC localisation and prevents 
plasma cell differentiation by suppressing Blimp-1 expression (Crotty et 
al., 2010).  
  37 
Centroblasts undergo the process of somatic hypermutation (SHM) to 
increase their affinity for cognate antigen. The enzyme, activation-
induced deaminase (AID), is expressed primarily in the dark zone and 
demethylates deoxycytidine residues in IGHV and IGLV genes, which are 
excised by uracil DNA glycosylase. The excised uracil residues are 
replaced at random by an error-prone polymerase, which alters the 
specificity and affinity of the BCR for its antigen. This process of SHM 
may introduce mutations which decrease the BCR’s affinity for antigen, or 
which introduce self-reactivity. The mutations may be silent or 
replacement: silent mutations do not alter the amino acid sequence of the 
BCR, whilst replacement mutations result in a change in amino acid and 
thus can have a dramatic impact on the structure and binding of the 
receptor. A high ratio of replacement to silent mutations indicates an 
antigen-driven response. 
In the GC light zone, centroblasts become centrocytes mediated by 
CXCR5 and CXCL13 (Gatto and Brink, 2010). Light zone B cells are 
small and express surface Ig that they use to process antigen from FDCs 
and present to TFH cells to elicit help (Figure 6, page 38). TFH cells 
provide signals for differentiation and survival such as IL-21 (Zotos et al., 
2010), CD40-CD40L and ICOS-ICOSL interactions. IL-21, in combination 
with anti-CD40 antibody, induces increased mitogenesis and 
differentiation into antibody-secreting cells in vitro. T cells stimulated by 
the TCR and ICOS secrete IL-10 which also acts to promote proliferation 
and differentiation of B cells (Vinuesa and Cyster, 2011; Vinuesa et al., 
2005). In the absence of antigen-specific TFH cells, centrocytes are 
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deleted and thus T cell help in GCs is a critical checkpoint for peripheral 
B cell tolerance. GC B cells that fail to receive survival signals can be 
rescued from apoptosis by CD40 ligation. Apoptotic cells are removed by 
tingible body macrophages, as they may be immunogenic and promote 
an autoreactive response to DNA antigens displayed as the B cell 
apoptoses (Basten and Silveira, 2010). 
 
Class-switch recombination 
As mentioned previously in Section  1.3.1, there are numerous subtypes 
of antibody, defined by their Fc region. The light zone is also the location 
Figure 6: Germinal centre reaction. 
B cells encounter antigen in the follicle and become initially activated 
with T cell help. They undergo intense proliferation and SHM in the 
dark zone. In the light zone B cells with improved affinity for antigen 
receive survival and differentiation signals from FDCs and TFH cells 
and undergo CSR to change their subtype. B cells then become either 
memory or plasma cells and leave the GC. Figure is adapted from 
Kuppers, 2003. 
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where antibodies undergo class-switch recombination (CSR) to become 
IgA, IgE or IgG-expressing cells following cytokine stimulation. CSR 
occurs between switch (S) regions upstream of their paired CH genes, 
except Cδ, located downstream of the VDJH segment.  S regions are the 
specialised targets as CSR is eliminated in cells with deleted S regions. 
The CH gene is part of a transcription unit, comprising an upstream 
intronic promoter, non-coding exon, S region, CH gene and germline 
transcript. CSR is initiated from the intronic promoter and finishes at the 
3’ end of the CH gene (Stavnezer et al., 2008). Like in the process of 
SHM, AID is an important enzyme, and acts in a similar manner 
(Muramatsu et al., 2000). It deaminates cytosines to convert them to 
uracil residues; these are removed to introduce DNA breaks in the donor 
(Sµ) and acceptor (downstream) S regions. Ku70 and Ku80 proteins bind 
to the ends of the DNA to allow end processing and joining (Stavnezer et 
al., 2008).  
Ectopic GC 
Follicular structures which resemble GCs and contain FDCs have been 
reported in the thymus of myasthenia gravis patients (Zuckerman et al., 
2010), in chronically inflamed tissues such as the synovium in rheumatoid 
arthritis (Huizinga et al., 2009) and in murine SLE models (Nacionales et 
al., 2009). These structures are termed ectopic GCs.  
Intrathyroidal lymphocytic infiltrates are a characteristic feature of GD 
pathogenesis. Suspended lymphocytes (McLachlan et al., 1983) and 
tissue sections (Warford et al., 1984) from GD thyroids have shown 
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varying degrees of infiltration between patients, without a striking 
difference in the proportions of B cell, TH, Tc and APC compartments. 
Interestingly, stained thyroid tissue sections showed a diffuse T cell 
infiltrate whilst B cells tended to aggregate together (Warford et al., 
1984). Ectopic GCs have been demonstrated in the thyroids of 
autoimmune thyroid diseases (AITD) patients, including those with GD. In 
Hashimoto’s thyroiditis (HT), the ectopic structures are large and similar 
to the GCs observed in tonsils; however in GD the structures are small 
and similar to those in lymph nodes. There was a positive correlation 
between the presence of ectopic GC in thyroids and anti-thyroid antibody 
titre (Armengol et al., 2001). 
As ectopic GCs are outside the traditional secondary lymphoid organs, 
they may be able to escape normal peripheral tolerance mechanisms 
more easily than typical GCs and thus contribute to or initiate the 
pathogenesis of autoimmune disease. 
1.3.4 B cell tolerance 
Tolerising B cells is important, not just for their functional roles in antibody 
secretion, antigen presentation and source of pro- and anti-inflammatory 
cytokines, but also because of the random nature of generating a diverse 
repertoire. The random nature of VDJ recombination and SHM inevitably 
leads to the development of autoreactive cells that must be removed or 
silenced. There are several overlapping tolerance mechanisms at several 
‘checkpoints’ at which self-reactivity may be tested for and tolerance 
imposed. 
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1.3.4.1 B cell central tolerance 
More than 50% of all early B cells in the bone marrow are poly- or 
autoreactive, yet only 5-20% of circulating mature B cells are autoreactive 
in healthy individuals (Wardemann et al., 2003).  
B cell central tolerance is exerted within the bone marrow by deletion and 
receptor editing of B cells expressing receptors with a medium to high 
avidity for antigen. The earliest tolerance checkpoint may occur at the 
pro- to pre-B cell stage. Cells with autoreactive Ig H-chains may be 
removed by a poorly understood tolerance mechanism (Kohler et al., 
2008). Pro-B cells with unproductive VDJ rearrangements that have 
exhausted all possible VH alleles are deleted. Similarly, pre- or immature 
B cells expressing receptors with too high an avidity for antigen are also 
deleted. Self-reactive immature cells revert back to the pre-B cell stage, 
re-express the RAG genes and begin rearranging the L-chain locus as 
part of the receptor editing process (Pillai et al., 2011). New upstream VK 
and downstream JK genes are rearranged and replace the original self-
reactive rearrangement. If the new rearrangement continues to recognise 
self-antigen then further rearrangements occur, if all possible κ genes are 
exhausted, then the κ locus is deleted and rearrangements begin at the λ 
locus. This process is mediated by the κ deleting element in humans 
(Siminovitch et al., 1985). Receptor editing is the predominant method of 
central tolerance within the bone marrow, with cells that remain 
autoreactive being clonally deleted (Halverson et al., 2004; Pelanda et al., 
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1997). Defects in the receptor editing process have been demonstrated in 
SLE and type 1 diabetes patients (Panigrahi et al., 2008). 
1.3.4.2 B cell peripheral tolerance 
Due to the random nature of VDJ recombination and the large number of 
poly- and auto-reactive B cells produced in the bone marrow, it is 
unsurprising that some may escape central tolerance mechanisms. 
Indeed compared to naїve B cells, the memory B cell compartment is 
enriched with auto- and polyreactive clones (Tiller et al., 2007). Thus 
further tolerance mechanisms exist in the periphery (Figure 7, page 45).  
Clonal deletion and anergy 
Transitional B cells that react with high avidity to self-antigens in the 
secondary lymphoid organs are clonally deleted in a Bim-dependent 
manner. Cells with low avidity for self-antigen become anergic and 
acquire a T-3 phenotype (IgDhi IgMlo CD93+) (Pillai et al., 2011). Anergic 
B cells cannot enter follicles and undergo apoptosis as the anergy is not 
reversible by ligation of co-stimulatory molecules or TLRs. Cells with very 
low avidity are ignored and do not receive survival signals, such as B cell 
activating factor (BAFF) (Basten and Silveira, 2010). 
Survival signals 
BAFF is a crucial survival factor for T and B cells. In the periphery 
autoreactive cells must compete with non-autoreactive cells for BAFF 
signals (Liu and Davidson, 2011; Stadanlick and Cancro, 2008).  
Experiments in transgenic mice show that BAFF levels control the 
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selection stringency after the T1 stage. Excess of BAFF has no effect 
prior to the T1 stage where it rescues anergic autoreactive cells, 
promoting their differentiation along the follicular and marginal zone 
pathways. Mature autoreactive B cells seem to have a greater need for 
BAFF for survival over non-autoreactive cells (Liu and Davidson, 2011).  
In an induced murine model of GD (Gilbert et al., 2006a), soluble decoy 
receptors blocked BAFF binding and significantly reduced induced GD as 
shown by a decrease in anti-TSHR antibodies, indicating that BAFF is an 
important mediator of hyperthyroidism and BAFF blockade is an attractive 
therapeutic intervention (Gilbert et al., 2006c). More recently BAFF has 
been implicated in patients with GD and its complication Graves’ 
orbitopathy (GO). Serum basal BAFF levels were significantly higher in 
GD patients compared to controls (Vannucchi et al., 2012). 
Germinal centre tolerance checkpoints 
The GC is a key peripheral checkpoint in B cell development; GC B cells 
have a pro-apoptotic phenotype, down-regulating Bcl-2 and up-regulating 
Bim, ensuring their deletion if they do not receive survival signals from 
TFH cells. There may be a tolerance checkpoint after the GC reaction 
before cells can differentiate into plasma cells. In FcγRIIb-deficient mice, 
an accumulation of autoreactive GC B cells secreting somatically mutated 
antibody was observed. The authors suggest that FcγRIIb contributes to 
the removal of autoreactive B cells within the GC (Tiller et al., 2010), this 
may be because FcγRIIb is typically up-regulated by antigen-experienced 
B cells and it limits both the differentiation and reactivation of memory 
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cells and the survival of plasma B cells (Mackay et al., 2006; Xiang et al., 
2007). The bone marrow plasma cell compartment has a significantly 
lower proportion of auto- or polyreactive B cells suggesting a tolerance 
checkpoint before plasma cells can enter the bone marrow (Scheid et al., 
2011).   
Regulatory B cells 
A subset of B cells with suppressive capacity was first reported several 
decades ago (Zembala et al., 1976). In recent years there has been a 
renewed interest in this subset (Mauri and Bosma, 2012) which has 
resulted in the characterisation of IL-10-producing CD5hi CD1dhi B10 cells 
(Yanaba et al., 2008) and CD19+ CD24hi CD38hi Bregs (Blair et al., 2010). 
These cells are capable of suppressing both B and T cells, possibly by 
the induction of FoxP3+ Tregs (Carter et al., 2012). Selective knockout of 
B10 cells in chimeric mice resulted in exacerbated arthritis, decreased 
FoxP3+ Tregs and increased TH1 and TH17 cells. Altered pro- and anti-
inflammatory T cell ratios were only resolved on subsequent transfer of 
wildtype B10 cells (Carter et al., 2011). B cells presenting self-antigen in 
mice have been shown to be capable of inducing FoxP3+ Tregs (Morlacchi 
et al., 2011; Zheng et al., 2010) rather than anergy or clonal deletion, 
which was induced by DCs presenting self-antigen (Morlacchi et al., 
2011). 
It is unknown whether clinical autoimmunity is a result of a breach in one 
or multiple tolerance checkpoints.  
  45 
 
Figure 7: B cell development and tolerance checkpoints. 
B cells develop initially in the bone marrow and migrate to the periphery 
following rearrangement of their BCR. Central and peripheral tolerance 
checkpoints are numbered. (1) Pro-B cells expressing unproductive 
rearrangements are deleted; (2) pre-B cells displaying high avidity 
antigen interactions are clonally deleted; (3) autoreactive immature B 
cells revert to the pre-B cell stage and undergo receptor editing; (4) 
transitional cells that react with high avidity are deleted and cells that 
react with low avidity are rendered anergic; additionally B cells must 
compete for survival factors such as BAFF; (5) marginal zone B cells 
contain Breg populations; (6) unknown checkpoint for entry to bone 
marrow plasma cell compartment.  
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1.4 The thyroid gland 
The thyroid gland functions to synthesise and secrete the hormones, 
thyroxine (T4) and triiodothyronine (T3). For this function, the thyroid 
stimulating hormone receptor (TSHR) in the basolateral membrane of 
thyroid follicular cells is ligated by its hormone, thyroid stimulating 
hormone (TSH), to trigger hormone synthesis and release. Iodine is an 
essential part of hormone formation and is transported as iodide into the 
thyroid follicular cell by the sodium iodide symporter expressed in the 
basolateral membrane. Efflux of iodide across the apical membrane and 
into colloid is likely to be mediated by the chloride exchanger, pendrin 
(Gillam et al., 2004). Thyroid peroxidase (TPO) oxidises iodine allowing it 
to bind tyrosyl groups of the scaffold molecule, thyroglobulin (Tg), in the 
presence of H2O2. TPO also catalyses the coupling of iodotyrosyl 
residues within the Tg molecule to form 3-monoiodotyrosine (MIT) and 
3,5`-diiodothyrosine (DIT). Within the Tg molecule the prohormone, T4, is 
formed following the coupling of two DIT molecules, whilst small amounts 
of the active hormone, T3, are formed of one MIT molecule coupling with 
one DIT molecule (Dunn and Dunn, 2001) (Figure 8, page 47).  
In the periphery, thyroid hormones enter target cells in a transporter-
dependent fashion and T4 is converted to active T3 hormone where 
needed by type 2 iodothyronine deiodinase, whilst this conversion is 
prevented by type 3  iodothyronine deiodinase (Bianco and Kim, 2006). 
Active T3 hormone binds to thyroid hormone nuclear receptors which 
regulate the relevant T3-targeted genes which control such processes as 
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protein synthesis, metabolism, thermogenesis (Bassett and Williams, 
2008) and prevents cretinism (Weetman, 1990).  
 
In euthyroid individuals thyroid hormone levels are regulated by a 
negative feedback loop of the hypothalamic-pituitary-thyroid axis, with 
ligation of TSH with the TSHR promoting thyroid hormone production 
whilst peripheral thyroid hormones negatively feedback to down-regulate 
thyroid releasing hormone and TSH production (Kopp, 2001).        
Figure 8: Thyroid hormone synthesis. 
To synthesis hormone, iodide is transported into the cell by the NIS 
and TPO catalyses its coupling to Tg. TPO further catalyses the 
iodotyrosol molecules within Tg, MIT and DIT, to form T4 and T3 
hormones which are then released into the periphery.  
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1.5 Autoimmune thyroid disease 
The thyroid gland is particularly susceptible to autoimmune processes 
and AITD represent the most common of the autoimmune diseases, 
affecting 2-5% of the Caucasian population (Simmonds and Gough, 
2004a). The two main forms of AITD are GD and HT. Both conditions 
feature lymphocytic infiltration of the thyroid gland; however only in HT is 
the thyroid gland destroyed, as although GD thyroids develop foci of 
lymphocytes, the architecture of the gland remains intact. HT is 
characterised by goitre, hypothyroidism and autoantibodies against TPO 
and Tg antigens. The destruction of the thyroid follicles is a result of 
infiltrating Tc lymphocytes, and possibly death receptor-mediated 
apoptosis of thyroid cells (Stassi et al., 1999; Weetman, 2004b).  
1.6 Thyroid autoantigens 
The development of autoantibodies to thyroid components is a key 
feature of AITD, the autoantigens involved are long known and have been 
well characterised. The main autoantigens are Tg, TPO and TSHR. In HT 
autoantibodies to Tg and TPO develop, leading to the destruction of 
thyroid follicles and causing a hypoactive thyroid gland, while in GD 
agonist autoantibodies to the TSHR develop, causing a hyperactive 
thyroid (Simmonds and Gough, 2004b; Smith et al., 1988; Weetman, 
2004a). However antibodies to all three autoantigens may be found in 
both GD and HT patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
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1.6.1 Thyroglobulin 
Tg is expressed in the thyroid where it is the most abundant protein. It is 
the largest known autoantigen in the human body at 2749 aa (660 kDa) 
and anti-Tg antibodies were the first of the thyroid autoantibodies to be 
discovered (Campbell et al., 1956). Tg undergoes extensive post-
translational modifications such as iodination. Indeed the level of 
iodination is related to the antigenicity of the molecule, with T cells only 
responding to iodinated Tg (Barin et al., 2005; Li and Carayanniotis, 
2006). Tg is found in the peripheral blood but in its poorly iodinated, 
poorly antigenic form (Schneider et al., 1983). Furthermore, Tg has been 
implicated as an autoantigen in the extrathyroidal complication of GD, 
Graves’ orbitopathy (GO). Tg was fist implicated in GO four decades ago 
(Kriss et al., 1967) and has recently been confirmed by a study showing 
Tg expression by fibroblasts in culture (Fernando et al., 2012).  
1.6.2 Thyroid peroxidase  
TPO is a large glycoprotein of 933 aa (107 kDa) found in the apical 
membrane of the thyroid follicular cell (Hadj-Kacem et al., 2009). It was 
the second thyroid autoantigen to be discovered following the seminal Tg 
findings. Antibodies to the thyroid microsomal antigen were shown to be 
anti-TPO antibodies (Banga et al., 1986; Czarnocka et al., 1985). 
Autoantibodies to TPO are found in the serum of AITD patients, are 
associated with complement fixation (Blanchin et al., 2003; Rebuffat et 
al., 2008; Weetman, 1990) and are markers of thyroid dysfunction 
(McLachlan and Rapoport, 2007). 
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1.6.3 Thyroid stimulating hormone receptor (TSHR) 
The tshr gene is located on chromosome 14q13 and codes for a 764 
amino acid (aa) protein. It is encoded by 13 exons and 12 introns 
(Kakinuma and Nagayama, 2002). The TSHR is expressed on the 
basolateral surface of thyroid follicular cells. A computer modelled 
structure of the TSHR is in Figure 9, page 52. 
 The TSHR belongs to the superfamily of G protein-coupled receptors, 
and forms a distinct subgroup of glycoprotein hormone-binding receptors 
with follicle stimulating hormone receptor (FSHR) and leutinising hormone 
receptor. The three receptors share approximately 70% amino acid 
similarity in their transmembrane domains and 39-45% similarity in their 
ectodomains (Kopp, 2001). Despite this similarity there is no cross-
reactivity between the hormones and receptors. The TSHR is unique 
among this receptor family as it is a heterodimeric protein, comprising the 
A subunit and the B subunit (transmembrane domain), linked by 
disulphide bonds 
Molecular cloning of the TSHR was achieved in 1989 and 1990 by three 
independent groups using various cloning methods (Frazier et al., 1990; 
Misrahi et al., 1990; Nagayama et al., 1989). The A-subunit is heavily 
glycosylated (40%) (Oda et al., 1999) and further comprises two cysteine-
rich repeats flanking nine leucine-rich repeats in a horseshoe-shaped 
structure of α-helices and β-sheets arranged in parallel (Parmentier et al., 
1989). The protein comprises a 21 aa leader sequence, a large A-
subunit, seven transmembrane domains and an intracellular cytoplasmic 
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tail (Rapoport et al., 1998). The TSHR has an 8 aa insertion at its N-
terminus (residues 38-45) and 50 aa at the C-terminus of the A-subunit 
(residues 316-366), the latter forms the proteolytic cleavage site of the 
receptor (Rapoport et al., 1998) not seen in the other receptors. 
The TSHR undergoes intramolecular cleavage and shedding of the A-
subunit (Loosfelt et al., 1992; Misrahi et al., 1994). The reasons for A-
subunit shedding are as yet unknown. It has been suggested that release 
of the A-subunit into the blood may trigger autoimmunity in susceptible 
individuals (Chen et al., 2003; Mizutori et al., 2009). Confirmation of the 
antigenicity of the A-subunit comes from agonist anti-TSHR antibodies 
preferentially recognising the A-subunit rather than the full-length TSHR 
holoreceptor (Chen et al., 2003). Injection of mice with Ad-TSHR289 
resulted in a greater incidence of experimental GD than mice immunised 
with holoreceptor (Chazenbalk et al., 2002; Chen et al., 2004; Gilbert et 
al., 2006b; Mizutori et al., 2009). It has been postulated that the shed A-
subunit could trigger or enhance the anti-TSHR immune response in the 
periphery (Rapoport and McLachlan, 2007); detectable levels have been 
observed in the culture medium of primary thyrocytes (Couet et al., 1996) 
however detectable levels of shed A-subunit have not been found in 
murine serum (Pichurin et al., 2006). In humans, two single nucleotide 
polymorphisms (SNPs) in intron 1 of the TSHR gene lead to the 
generation of truncated soluble variants of the TSHR which may be 
secreted, increasing the immunogenicity of the receptor in genetically 
susceptible individuals (Brand and Gough, 2010; Płoski et al., 2010). 
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1.6.3.1 TSHR activation and signalling 
TSHR activation by TSH results in thyroid hormone synthesis, iodide 
uptake and cellular growth. The transmembrane region of the TSHR is 
involved in transmitting the activating signal across the membrane 
following TSH ligation. The receptor is coupled to Gsα and adenylyl 
cyclase is activated and cyclic adenosine monophosphate (cAMP) levels 
are increased. The rise in cAMP gives rise to phosphorylation of protein 
kinase A and the subsequent activation of factors in the cytosol and 
nucleus (Dremier et al., 2002; Kopp, 2001). Higher doses of TSH couple 
Figure 9: Computer-modelled structure of the TSHR. 
In common with other glycoprotein hormone receptors, the TSHR 
comprises an ectodomain (A subunit) linked to 7 transmembrane 
domains (TMD, or B subunit). The ectodomain is composed of 9 
leucine-rich repeats (LRRs) and may be shed following proteolytic 
cleavage. The cleavage region is unique to the TSHR amongst other 
similar receptors. Figure is adapted from (Davies et al., 2005). 
A-subunit 
B-subunit 
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the TSHR to Gq/11, activating phospholipase C-dependent 
diacylglycerol/inositol 1,4,5 triphosphate pathway which results in H2O2 
generation and iodination (Laurent et al., 1987). Following TSH binding 
the receptor is internalised and accumulates in endosomes before being 
recycled to the cell surface again (Singh et al., 2004).  
Many G protein-coupled receptors are constitutively active and some may 
signal without ligand interactions (Farid and Szkudlinski, 2004). The 
TSHR transmembrane domain displays a high level of constitutive 
activity, with a truncated form displaying constitutive activity, despite 
lacking 98% of the A-subunit. This constitutive activity was suppressed in 
part by rejoining the truncated receptor with the A-subunit, suggesting 
that the A-subunit inhibits the constitutive activity of the transmembrane 
domain. (Zhang et al., 2000). Zhang et al proposed a ‘two-state’ model of 
receptor activation, whereby the two subunits of the receptor are in 
equilibrium between an inactive “closed” state and a constitutively active 
“opened” state that can associate with Gs in the absence of TSH and 
trigger downstream signalling pathways. Furthermore, TSH preferentially 
binds “open” receptors and stabilises them, switching the A-subunit from 
an inverse agonist to a full agonist of the transmembrane domain (Zhang 
et al., 2000). 
1.7 Graves’ disease 
1.7.1 History, pathogenesis and aetiology 
Caleb Hillier Parry first described GD in 1825 after noticing patients with 
goitres, palpitations and exophthalmos (Larner, 2005). The clinical 
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features were further elucidated and defined independently by Karl Adolf 
Von Basedow and Dr Robert Graves in 1835, the latter after whom the 
disease was named (Weetman, 2000). Evidence for the autoimmune 
nature of GD was provided by the discovery that long-acting thyroid 
stimulation in GD patient sera was associated with serum Ig (Adams and 
Purves, 1956). It is now accepted that the hyperthyroidism associated 
with GD is a result of IgG autoantibodies directed against the TSHR. 
GD is characterised by agonistic thyroid stimulating antibodies (TSAbs) 
binding and stimulating the TSHR in a manner similar to TSH, preventing 
TSH binding and stimulating the receptor. An excess of T4 and T3 
hormone production and release results in hyperthyroidism (Smith et al., 
1988). The hypothalamus detects the rise in T4 and T3 levels in the blood, 
reduces thyroid releasing hormone secretion and, consequently, the 
pituitary gland reduces TSH secretion. However as stimulation of the 
thyroid gland in GD patients is being caused TSAbs by rather than TSH, 
there is no change in thyroid hormone synthesis and release, causing an 
excess of T4 and T3 within the body (Brent, 2008; McIver and Morris, 
1998). Clinical features caused by the excess of T4 and T3 include goitre 
and the features of hyperthyroidism, namely palpitations and increased 
cardiovascular risk (Nyirenda et al., 2005), nervousness, heat intolerance, 
weight loss and excess sweating (Brent, 2008; Simmonds and Gough, 
2004a).  
GD typically develops in the 4th through 6th decades of life (Manji et al., 
2006), although can occur at any age, and exhibits a female 
predominance, affecting women and men in a 7-10:1 ratio (Brent, 2008), 
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however men undergo a more severe disease pathogenesis (Manji et al., 
2006). The Whickham survey has shown there to be an annual incidence 
of GD of 50 in every 100,000 women and 10 in every 100,000 men 
(Tunbridge et al., 1977). 
1.7.2 Antibody repertoire in GD 
Anti-TSHR autoantibodies are present in very low levels in the serum (<1 
µg/mL) (de Forteza et al., 1994; Nakatake et al., 2006; Zakarija, 1983) yet 
are still able to induce hyperthyroidism and thus are biologically powerful 
stimulants. The autoantibody repertoire in GD is diverse, with three 
varieties of antibody TSAbs inhibit TSH stimulation, induce cAMP 
production and bind discontinuous epitopes; Thyroid stimulating blocking 
antibodies (TSBAbs) block TSH binding but may also act as weak 
agonists and recognise discontinuous  and linear epitopes and are 
typically polyclonal (Kim et al., 2000; Smith et al., 1988); neutral 
antibodies bind to linear epitopes in the hinge region between 316-366 
aa. They neither block TSH binding nor induce cAMP production, but may 
be involved in thyrocyte apoptosis (Morshed et al., 2010a). It is the sum 
activity of these antibodies which contributes to clinical presentation of 
the disease (de Forteza et al., 1994). It is thought that differing epitope 
recognition is the key for the differing biological activities.  
Crystallisation studies of the TSHR A-subunit in complex with the Fabs of 
a human TSAb and a TSBAb have demonstrated that there are several 
aa residues along the leucine rich repeats that are important for TSHR 
binding. Furthermore such studies have shown the differing epitope 
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binding of the two types of antibody. The TSAb, M22, bound towards the 
N-terminus of the receptor whilst the TSBAb, K1-70, bound towards the 
TSHR C-terminus; the epitopes of both antibodies overlapped in the 
middle (Sanders et al., 2007; Sanders et al., 2011) (discussed further in 
Section  1.7.9). 
Antibodies to Tg and TPO are also found in GD patients. They are found 
in high titres in HT patients, are polyclonal and recognise conformational 
epitopes. Their presence correlates with the degree of lymphocytic 
infiltration into the thyroid gland.  
It is not known whether the antibodies arise from rogue individual B cells 
that have escaped tolerance or from a limited number of B cell clones. 
Evidence suggests an oligoclonal response with IgG1 and λ L-chain 
restriction (Weetman et al., 1990; Williams et al., 1988; Zakarija, 1983). 
Thus defects in B cell development or in the GC reaction could contribute 
to the generation and expansion of autoreactive B cells.  
1.7.3  Extrathyroidal complications 
A subset of patients develop extrathyroidal complications, including GO 
(also known as Graves’ ophthalmopathy, thyroid-associated 
ophthalmopathy, thyroid eye disease) and localised thyroid dermopathy, 
particularly on the shins (pretibial myxoedema) (Ai et al., 2003) (Figure 
10). 
GO is a potentially sight-threatening complication affecting 16 women and 
3 men in 100,000 (Bartley, 1994). Some degree of GO manifestation may 
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be observed in almost all GD patients but is clinically relevant in 
approximately 50%, with 3-5% of patients developing severe disease 
(Wiersinga and Bartalena, 2002). GO is a result of increased orbital fat 
and extraocular muscle volume in the orbit displacing the eye. Disease 
hallmarks include expansion of orbital muscle and adipose tissue, 
mononuclear cell infiltrates in the muscle and adipose tissue and tissue 
remodelling, including fibrosis.  
GO is poorly understood although progress has been made in recent 
years in understanding the underlying molecular pathogenesis. Orbital 
fibroblasts are believed to be the key targets and protagonists in disease 
pathogenesis (Sisson et al., 1973). They represent a unique subtype of 
fibrocyte with distinct phenotypic and functional characteristics, including 
elevated pro-inflammatory responses in responses to IL-1β and CD40L 
treatment (Smith et al., 2008). Following stimulation with anti-TSHR 
antibody or the TH1-type cytokines, IFN-γ and TNF, orbital fibroblasts 
secrete hyaluronan, IL-16 and RANTES (Pritchard et al., 2002), and a 
subset (Thy-1-) may differentiate into pre-adipocytes (Sorisky et al., 
1996), leading to expansion of ocular muscle and adipose tissues. A 
second autoantigen, in addition to TSHR, insulin growth factor 1-receptor 
(IGF1-R), has been proposed to contribute to GO pathogenesis. It is 
known that IGF1-R can co-localise with TSHR (Tsui et al., 2008) and its 
stimulation on orbital fibroblasts results in chemokine and hyaluronan 
secretion (Pritchard et al., 2003). It is unknown whether there are two 
distinct antibody populations, each recognising a distinct antigen, one 
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population that recognises both, or whether the co-localised antigens 
form a neo-antigen (Wiersinga, 2011). 
 
Little is known about the pathogenesis of thyroid dermopathy (Rapoport 
et al., 2000). It is characterised by a localised thickening of the skin and 
may be due to autoantibody stimulation of TSHR expressed by dermal 
fibroblasts. Indeed thyroid dermopathy patients have increased levels of 
TSHR expression by pretibial fibroblasts (Daumerie et al., 2002). As in 
B A 
C D 
Figure 10: Extrathyroidal complications. 
A subset of patients develop extrathyroidal complications such as GO 
and thyroid dermopathy. Axial images of computer tomography scans 
display (A) a normal orbit and (B) enlarged extraocular muscles in a 
GO patient. (C) Photograph of patient with GO. (D) Photograph of a 
patient’s pretibial myxoedema. Panels A-C taken from (Bahn, 2010) 
and Panel D taken from (Ai et al., 2003). 
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the case of GO, dermal fibroblasts may subsequently secrete 
glycosaminoglycans in response to TSHR stimulation, causing local 
oedema (Ai et al., 2003; Rapoport et al., 2000).    
1.7.4 Genetics 
GD is a multi-factorial disease with both genetic and environmental 
factors contributing to its onset and pathogenesis (Hasham and Tomer, 
2012). There is certainly a genetic component to GD as shown by the 
observed clustering of autoimmune diseases in families, and 40-50% of 
AITD patients report another family member with a thyroid disorder 
(Boelaert et al., 2010; Brix et al., 1998a; Brix et al., 1998b). A Danish twin 
study found a concordance rate of 35% in monozygotic twins and 3% in 
dizygotic twins (Brix et al., 1998a) and a Californian twin study found 
concordance rates of 17% and 1.9% in monozygotic and dizygotic twins, 
respectively (Ringold et al., 2002).  
There is marked phenotypic variation amongst GD patients including 
disease severity, goitre size and the presence and severity of GO (Manji 
et al., 2006) which is likely the result of the complex gene-environment 
combinations and interactions. HLA genes were the first candidate genes 
to be analysed for a role in AITD. Initial studies found a significant 
association between HLA-DR3 and GD (Baldet et al., 1974; Zamani et al., 
2000). The susceptibility haplotype has been further delineated as 
DRB1*03-DQB1*02-DQA1*0501 (Gough and Simmonds, 2007). 
Molecular studies analysed the reasons behind this association as 
hypotheses suggest that certain HLA alleles may allow binding and 
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presentation of autoantigens. An arginine residue at position 74 of the 
HLA-DRβ1 chain was shown to be the key aa in conferring GD 
susceptibility (Ban et al., 2002; Menconi et al., 2008; Simmonds et al., 
2005).  
The first report of CTLA4’s association with autoimmunity came from a 
GD candidate gene study (Yanagawa et al., 1995). CTLA4 has 
subsequently been confirmed as a susceptibility gene in many other 
autoimmune conditions (Jacobson and Tomer, 2007). The CTLA4 gene is 
highly polymorphic and the three SNPs most commonly associated with 
autoimmunity are an AT-repeat in the 3` untranslated region 
microsatellite, an A/G SNP named CT60 downstream of the AT-repeat 
and an A/G SNP in the signal peptide (Ueda et al., 2003).  
PTPN22 is located on chromosome 1p13 and encodes the lymphoid 
tyrosine phosphatase protein, a cell signalling molecule which inhibits T 
cell activation (Cohen et al., 1999). The R620W SNP encodes a loss of 
function mutation (Zhang et al., 2011).   
 The TSHR has been confirmed as the first thyroid-specific gene to be 
associated with GD. Japanese studies have found a consistent 
association, including SNPs in introns 1, 7 and 8 (Akamizu et al., 2000; 
Hiratani et al., 2005; Sale et al., 1997). In a multinational Caucasian study 
of subjects with GD, an association was found with a SNP in intron 1, and 
was independently confirmed in a large (>2,000 GD patients) UK 
Caucasian case-control cohort (Dechairo et al., 2005), and a Caucasian 
cohort of three European nations (Płoski et al., 2010).  
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1.7.5 Non-genetic factors 
The concordance rate amongst twins is not 100% and statistical 
modelling as revealed a contribution of 21% from non-genetic factors 
(Brix et al., 1998a; Brix and Hegedüs, 2012). Non-genetic susceptibility 
factors may be constitutional or environmental. 
1.7.5.1 Constitutional factors 
The peak ages for diagnosis of GD are between the 4th and 6th decades 
of life (Manji et al., 2006). Women have a 7-10 times greater risk of 
developing GD than men (Vanderpump et al., 1995) however men are 
more likely to develop more severe disease (Manji et al., 2006). Proposed 
constitutional mechanisms to explain this divide include sex hormones, 
foetal microchimerism and X chromosome inactivation.  
The reported contribution of foetal microchimerism to AITD has been 
inconsistent. An increased incidence of foetal microchimerism was 
observed in two independent reports comparing thyroid sections from 
AITD patients and normal controls by detecting the sex determining 
region of the Y chromosome by ELISA-PCR or fluorescence in situ 
hybridisation (Ando et al., 2002; Renne et al., 2004). Two studies which 
state no correlation between foetal microchimerism and HT did not 
directly evaluate the presence of foetal cells in the thyroid, but rather tried 
to correlate the number of previous pregnancies (parity) with the 
presence of anti-TPO and anti-Tg antibodies (Pedersen et al., 2006; 
Walsh et al., 2005). A twin study analysed the effect of in utero transfer of 
cells between dizygotic twins (cases) and the presence of anti-TPO, -Tg 
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and –TSHR antibodies. Whilst this study showed an increased 
prevalence of anti-thyroid antibodies in dizygotic twins, it did not examine 
thyroid biopsies for the presence of microchimerism, and did not establish 
a correlation between microchimerism and the development of an AITD 
(Brix et al., 2009). 
Skewed and extremely skewed X chromosome inactivation has been 
found in numerous autoimmune diseases such as SLE (Huang et al., 
1997), scleroderma (Özbalkan et al., 2005) and juvenile idiopathic 
arthritis (Uz et al., 2009). In AITD skewed inactivation was found in 37% 
of GD patients and 34% of HT patients, which was statistically 
significantly higher than external controls, in a small Danish twin study of 
n=32 concordant female twin pairs with AITD (Brix et al., 2005). A Turkish 
study of similar size (n=29 GD patients and n=83 HT patients) found 31% 
of GD patients and 34% of HT patients with skewed X chromosome 
inactivation. This skewing was statistically significant (Ozcelik et al., 
2006). 
1.7.5.2 Exogenous factors  
Exogenous environmental factors have been implicated in predisposition 
to and the pathogenesis of GD.  
Iodine deficiency results in an increased risk of GD in the elderly whereas 
iodine excess may result in GD manifesting at a younger age (Camargo 
et al., 2008; Laurberg et al., 1991). The trace element selenium is an 
essential micronutrient, and selenoproteins are involved in thyroid 
hormone metabolism. Smoking activates B and T cells and enhances IL-2 
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production and results in an increased risk of GO in current and ex-
smokers with GD (Brix et al., 1998a; Manji et al., 2006; Vestergaard et al., 
2002). Stress drives the antibody-producing immune response. 
Retrospective studies on the role of stress in GD have suggested that GD 
is often preceded by stressful life events which promote a pro-
inflammatory cytokine response (Tsatsoulis, 2006; Vos et al., 2008; 
Winsa et al., 1991). However a recent prospective study of euthyroid 
female relatives of an AITD patient found that stressful life events did not 
predispose to AITD (Effraimidis et al., 2012).  
The concept that infections may trigger autoimmune conditions has 
become increasingly relevant (Ercolini and Miller, 2009). Microbial agents 
have long been implicated in various autoimmune conditions 
(Chervonsky, 2010). In the case of GD, Yersinia enterocolitica infection 
has been reported as a potential environmental agent for many decades 
(Bech et al., 1974). Whilst it remains a controversial topic with 
inconsistent findings (Effraimidis et al., 2011), recent bioinformatics data 
has reported significant amino acid similarity between Y. enterocolitica 
proteins and the TSHR (Guarneri et al., 2011; Wang et al., 2010). GD 
patient sera and a neutral anti-TSHR mAb were shown to display binding 
to a Y. enterocolitica protein identified as outer membrane porin F 
(OmpF) (Wang et al., 2010). Bioinformatics data has also reported on 
amino acid similarity between the TSHR and Borellia burgdorferi proteins. 
However there is no biological data to support this (Benvenga et al., 
2004).  
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The role of infectious agents and Y. enterocolitica in particular are 
discussed in greater detail in Chapter 5. The contribution of genetic and 
environmental factors to GD susceptibility are summarised in Figure 11. 
 
1.7.6 Current treatment options 
Treatment options for patients with GD have not changed for the past 60 
years and include anti-thyroid drugs, radioiodine ablation of the thyroid 
Figure 11: Genetic and environmental contributions to GD 
susceptibility and pathogenesis. 
Twin studies and biometric statistical modelling has shown that 75% of 
the phenotypic variation in GD is due to genetics, and the remaining 
25% due to non-genetics factors. Non-genetic factors may include 
constitutional and exogenous factors. It is the combination of these 
factors which will contribute to disease susceptibility and pathogenesis. 
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gland and thyroidectomy (Banga et al., 2008). Anti-thyroid drugs interfere 
with thyroid hormone synthesis and form the first-line treatment in the 
majority of countries outside the US, where radioiodine is the most 
common therapy. Thyroidectomy represents the least common treatment, 
but can be used for patients who have declined radioiodine treatment or 
for whom anti-thyroid drugs are unsuitable (Bahn, 2012; Brent, 2008). 
However, current treatment options only target the symptoms of GD 
rather than the underlying pathological condition. Thyroidectomy and 
radioiodine therapy render the patients hypothyroid necessitating life-long 
thyroid hormone replacement and anti-thyroid drugs, at the correct 
dosage, promote euthyroidism but are associated with serious side-
effects. 
1.7.6.1 Emerging therapies 
TSBAbs isolated from patients undergoing thyroid disease (Evans et al., 
2010; Sanders, 2008) are capable of blocking TSAb-mediated stimulation 
of the thyroid and could be developed for specific blocking therapy (Bahn, 
2012; Furmaniak et al., 2012a). Indeed injection of K1-70, into rats 
following a dose of M22, completely inhibited any stimulatory effects 
(Furmaniak et al., 2012b). Recently small molecule therapy has been 
proposed as a new therapeutic intervention. Advantages of small-
molecules are that they can be administered orally and produced in high 
quantities at low cost. Antagonist and inverse agonist molecules have 
been developed that bind to an allosteric site in the TSHR 
transmembrane domain without interfering with TSH binding (Neumann et 
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al., 2010a; Neumann et al., 2010b; Neumann et al., 2009; Neumann et 
al., 2008).  
Rituximab is a humanised chimeric anti-CD20 biological agent (Reff et al., 
1994) that is an effective therapy in other autoimmune conditions (Nielsen 
et al., 2007). There have been 3 non-randomised control trials thus far 
assessing rituximab in GD (El Fassi et al., 2009; El Fassi et al., 2007; 
Salvi et al., 2007). These studies suggest that rituximab may prolong the 
remission rates of patients with mild hyperthyroidism and low anti-TSHR 
antibody levels prior to treatment (El Fassi et al., 2007). There was no 
effect on total IgG levels and only a moderate reduction in the level of 
anti-TSHR antibodies with a specific decrease in the stimulatory capacity 
of anti-TSHR antibodies (El Fassi et al., 2009). Two randomised control 
trials are currently underway (Bahn, 2010).  
1.7.7 Mouse models 
The difficulties in isolating anti-TSHR mAbs from patients have 
necessitated the use of experimental models of disease, such as mice. 
However GD is a human-only condition and does not occur 
spontaneously in animals, including great apes (Dağdelen et al., 2009; 
McLachlan et al., 2011b). Whilst studies have included hamsters (Ando, 
2003), the mouse remains the most popular induced disease model. 
Methods of induction have included injection of syngeneic cells, plasmids 
or adenoviruses encoding TSHR cDNA and electroporation and have 
resulted in varying degrees of success. Success of the animal model can 
also depend on the strain of mice used. C57BL/6 mice are normally 
  67 
resistant to GD induction except in the case of Treg depletion followed by 
immunisation with an adenovirus construct expressing aa 22-289 of the 
TSHR A-subunit (Ad-TSHR289) (Saitoh et al., 2007; Saitoh and 
Nagayama, 2006), however the disease-susceptible strain, BALB/c, do 
not develop more severe disease on Treg depletion (Saitoh and 
Nagayama, 2006). 
There have been many stumbling blocks on the path to developing 
murine models of GD and in trying to isolate mAbs from both mice and 
humans (Banga, 2007; McLachlan and Rapoport, 2004). These mAbs 
needed to inhibit TSH binding, stimulate cAMP production in TSHR-
expressing cells or block stimulation of TSH and TSAbs. Murine mAbs to 
the TSHR were developed with varying degrees of success (Dağdelen et 
al., 2009). Disadvantages of experimental models to date include a lack 
of extrathyroidal complications such as dermopathy and GO. Anatomical 
differences between the human and mouse orbit could explain the lack of 
GO observed in experimental models. Isolated murine mAbs are 
described in Table 1. 
1.7.8 Early models  
The first murine model of hyperthyroid GD, termed the Shimojo model, 
was described in 1996 (Shimojo et al., 1996) and was successfully 
replicated by other groups (Dağdelen et al., 2009). AKR/N mice were 
immunised with fibroblasts co-expressing TSHR and MHC class II and 
although a small proportion of mice became hyperthyroid, no mAbs were 
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isolated and several months are required for development of the model 
(Rao et al., 2003).  
1.7.8.1 Plasmid cDNA injection delivery model  
Costagliola et al injected BALB/c mice with naked plasmid encoding 
TSHR cDNA and despite the animals remaining euthyroid, stimulating 
autoantibodies were induced (Costagliola et al., 1998). Another group, 
using the same procedure in NIMR mice, generated three TSAbs, 
TSmAbs 1-3, derived from the same mouse with identical germline V-
region gene usage (Sanders et al., 2002).  
1.7.8.2 Adenovirus-DNA injection delivery model 
The use of adenovirus as a method of TSHR holoreceptor gene delivery 
was shown to result in a 50% disease incidence in female BALB/c mice 
(Nagayama et al., 2002). This method was further improved by the 
serendipitous discovery that TSAbs preferentially recognise the TSHR A-
subunit (aa 1-289; TSHR289) over the holoreceptor (Chazenbalk, 2002). 
Immunisation of BALB/c mice with Ad-TSHR289 increases the disease 
incidence to 80% (Chen et al., 2004). 
This method of gene delivery facilitated the isolation of two TSAbs with 
powerful agonist properties, KSAb1 (IgG2b/κ) and KSAb2 (IgG2a/κ), from a 
single mouse undergoing experimental GD (Gilbert et al., 2006a). Both 
mAbs are full agonists with activity in a nanomolar range, display TSH 
binding inhibiting Ig properties and have a high affinity for TSHR but 
KSAb1 is the more powerful of the two mAbs. Injecting non-immunised 
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mice with µg doses of KSAb1 and KSAb2 caused the mice to become 
hyperthyroid within 7 hs. Histological analysis of recipient mice showed 
no thyroidal lymphocytic infiltrate and no ocular pathogenesis. However 
these features may require chronic disease activity to develop (Flynn et 
al., 2007). 
1.7.8.3 Electroporation of plasmid cDNA injection delivery model  
In vivo electroporation was recently described as an improved method of 
plasmid cDNA gene delivery, with disease incidence improving from 12% 
to 32% using the TSHR holoreceptor, and from 80% to 95% using the 
TSHR A-subunit (Kaneda et al., 2007). Another advantage of this model 
compared to the adenovirus delivery model is the long-lasting antibody 
response. This model was replicated by this laboratory and importantly, 
mice also developed signs of orbital fibrosis (Zhao et al., 2011).  
1.7.8.4 Adoptive transfer of splenocytes 
Immunisation of mice with murine TSHR (mTSHR) is not sufficient to 
break tolerance and anti-mTSHR antibodies are not induced, and neither 
is hyperthyroidism (Nakahara et al., 2010). However, as described above, 
immunisation with human TSHR (hTSHR) can induce potent TSAbs and 
GD-like symptoms. This is because hTSHR has high sequence similarity 
with mTSHR, but it is not a true murine autoantigen as the aa sequence 
similarity is not 100%.  
A recent mouse model has been proposed to counter-act this issue of the 
inauthentic autoantigen, hTSHR, and create an authentic autoimmune 
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model with mTSHR as the autoantigen. In this case, spleens from TSHR 
knockout mice immunised twice with Ad-TSHR289 are adoptively 
transferred into TSHR-sufficient immune-deficient athymic nude BALB/c 
mice. Transfer efficiency was improved by prior depletion of Tregs in 
recipient mice. Whilst 70% of donor mice were anti-TmSHR antibody 
positive, only 46% of recipient mice were antibody positive and only 21% 
developed hyperthyroidism. More than half of the mice eventually 
became hypothyroid. Hyperthyroid glands were diffusely enlarged, 
hypertrophied and some developed small lympocytic infiltrations. 
(Nakahara et al., 2012). 
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Table 1: Summary of isolated murine anti-TSHR monoclonal antibodies. 
 
A summary of the monoclonal antibodies with varying stimulatory capacity isolated from mice undergoing experimental GD. The V-
region gene usage, L-chain and subclass are described. There is considerable V-region gene restriction amongst murine anti-
TSHR antibodies.  
  mAb VH DH JH VL JL Subclass Activity  
Gilbert, 2006a KSAb1 1S135 4-1*02 2 6-13 2 IgG2b/κ Agonist 
KSAb2 1S135 4-1*02 2 6-13 2 IgG2a/κ Agonist 
Costagliola, 2004  IRI-SAb2 1S135 3-2*01 2 6-13 5 IgG2a/κ Agonist 
IRI-SAb3 1S135 4-1*02 2 6-13 5 IgG1/κ Partial agonist  
Sanders, 2002 TSmAbs 1-3 1S135 4-1*02 4 23-48 5 IgG/κ  
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1.7.9 Human anti-TSHR monoclonal antibodies 
As described previously in Section  1.7.2, anti-TSHR antibodies are found 
in GD patients at very low serum concentrations and have thus been 
notoriously difficult to isolate (McLachlan and Rapoport, 2004). 
The landmark first report of a human monoclonal TSAb came in 2003 
(Sanders et al., 2003) and the group of Rees Smith have subsequently 
isolated a monoclonal TSBAb from a patient with post-partum thyroiditis 
(Sanders et al., 2005) and both a TSAb and a TSBAb from the same GD 
patient (Evans et al., 2010). The isolation of such mAbs has allowed for 
their genetic and physiological analysis. As with previous studies using 
total Ig (Weetman et al., 1990; Williams et al., 1988), isolated mAbs were 
restricted to the IgG1 isotype although there is no obvious restriction of κ 
or λ L-chain usage. There is some degree of V-region gene usage 
restriction, with 3 of 4 mAbs using the VH5 family and 3 of 4 using the VL1 
family. Interestingly both TSBAbs, 5C9 and K1-18, use JH4 genes (Table 
2). However it is difficult to draw definitive conclusions on gene usage 
from such a small repertoire of isolated mAbs. 
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Table 2: Isolated human monoclonal antibodies to the TSHR. 
 
A summary of the monoclonal antibodies isolated from GD patients. The V-region gene usage, L-chain and subclass are described. 
There is less V-region gene restriction than that observed for murine anti-TSHR antibodies but there is some restriction amongst VH 
genes. 
mAb VH DH JH VL JL Subclass Agonist activity Reference  
M22 5 6-13 5 1-11 3b IgG1/λ TSAb (Sanders et al., 2003) 
5C9 3-53 2-2 4 1-39 2 IgG1/κ TSBAb (Sanders et al., 2005) 
K1-18 5-51*01 3-16*02 3*02 or *01 3-20*01 1*01 IgG1/κ TSAb 
(Evans et al., 2010) 
K1-70 5-51*01 1-7*01 4*02 1-51*01 7*1 IgG1/λ TSBAb 
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1.7.9.1 Atomic structure of human mAbs and the TSHR 
As FSHR is the closest G protein-coupled receptor homologue to the 
TSHR, modelling of TSH interacting with TSHR was based on the 
interactions of FSH and FSHR (Fan and Hendrickson, 2005; Núñez 
Miguel et al., 2008). However the atomic structure of the TSHR A-subunit 
in complex with M22 has been resolved (Sanders et al., 2007). The 
atomic structure of M22 Fab and part of the TSHR A-subunit (aa 22-260; 
TSHR260) was analysed by X-ray diffraction at a resolution of 2.5 Å. 
TSHR260 is a curved helical tube made of leucine-rich repeats. The inner 
surface of the tube is lined with hydrophobic residues and the concave 
surface is formed of an 11-stranded untwisted β sheet. The convex 
surface contains eight small strands that form two 3-stranded β sheets 
and one 2-stranded β sheet. The convex surface also contains five 
glycosylation sites distant from the TSH binding site so there is no 
interference. There are no α-helices in the structure (Sanders et al., 
2007), see Figure 12, page 77. 
Crystallisation of a TSAb in complex with the TSHR 
M22 Fab binds the concave surface of the TSHR260 at 90˚ to the helical 
tube axis (Figure 12, page 77). The interaction between the receptor and 
M22 is formed of an extensive network of polar, hydrophobic bonds with 
the M22 H-chain having more residues interacting with TSHR260 than 
the L-chain. The majority of the residues interacting with TSHR260 are in 
the H- and L-chain CDRs. There was very little movement in atoms of 
bound M22 residues compared to unbound M22 suggesting ‘lock and 
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key’ binding (Sanders et al., 2007). The M22 L-chain mimics the binding 
of TSHα whilst the H-chain mimics the binding of TSHβ, based on 
comparative modelling (Nunez Miguel et al., 2009). 
Mutation of the TSHR residues R80A, E107A, R109A, K129A, K183A, 
Y185A and R225A had a significantly detrimental effect on M22 Fab-
TSHR260 interactions. Mutation of R28D in the M22 H-chain affected its 
stimulatory activity. The manipulation of these mutations opens up an 
opportunity to develop small molecules that block them, thereby 
preventing M22 and other TSAbs with similar surface structures binding 
to, and activating, the receptor (Sanders et al., 2007). 
Crystallisation of a TSBAb in complex with the TSHR 
The atomic structure of K1-70 Fab has been resolved in complex with 
TSHR260 at a resolution of 1.9 Å (Figure 12). The structure of TSHR260 
is very similar in both crystallisations studies, although there is improved 
resolution of the crystal in the more recent study.  
The antigen-binding site of K1-70 is irregular in that acidic residues lie on 
one side whilst basic residues are on the other side. There are 12 L-chain 
and 15 H-chain residues in direct contact with TSHR260, and 24 TSHR 
residues in total in direct contact with K1-70 Fab. K1-70, like M22, binds 
to the concave surface of TSHR260 but differs in that it binds towards the 
N-terminus; whilst M22 bound towards the C-terminus, there is however 
overlap of the two mAbs’ epitopes in the middle of the concave surface.  
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TSHR mutations K58A, I60A, E61A, Y82A, R109A and K183A all interact 
with K1-70 Fab and their mutation resulted in a loss of or decrease in K1-
70’s antagonist function. Mutation of K1-70 H-chain residues W97A and 
N100A markedly decreased the antagonism of TSH stimulation of cAMP 
production in TSHR-transfected cells. The mutation of L-chain residue 
R94D and H-chain residues Y99A and N32A also affected K1-70 function 
but to a lesser extent. The combination of all 5 mutations resulted in a 
complete loss of K1-70 function (Sanders et al., 2011). 
Comparison of TSAb and TSBAb binding to TSHR A-subunit 
The resolution of the atomic structures of stimulating and blocking 
antibodies has allowed for the comparison of how the differing types of 
antibody interact with the TSHR. The TSBAb, K1-70 does not interact 
with the extreme N-terminus of TSHR260, but has more contact with the 
N-terminus than the TSAb, M22. M22 is directed more towards the C-
terminus; however both antibodies, as well as TSH, have extensive 
overlap of interactions with TSHR residues. The functional differences of 
the antibodies are likely a result of the precise TSHR amino acid residues 
bound by antibodies (Figure 12, page 77). 
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Figure 12: Comparison of the atomic structure of TSHR 
ectodomain in complex with M22 Fab and K1-70 Fab. 
The atomic structure of the Fab regions of K1-70, a TSBAb, and M22, 
a TSAb, in complex with the TSHR ectodomain, aa residues 22-260 
was resolved. These studies have shed important light on the ‘lock 
and key’ binding interactions of mAbs and the TSHR. M22 binds to the 
entire leucine rich repeat region whilst K1-70 is positioned towards the 
N-terminus. Residues essential for antibody binding have been 
identified and may lead to targeted therapeutic intervention. Figure is 
taken from (Furmaniak et al., 2012a). 
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1.8 Aims of thesis 
The isolation of murine and human mAbs has provided new insights into 
the pathogenic antibodies in GD allowing greater understanding of their 
mechanism of action. Despite the data indicating a restricted usage of 
germline Ig genes in the TSAb repertoire, the germline Ig genes encoding 
anti TSHR antibodies have not been previously investigated. 
Furthermore, recent genetic linkage analyses in inbred strains of mice 
have highlighted a role for the IGHV genes in predisposing to the 
development of TSAbs. Therefore new knowledge on germline genes and 
their rearrangements is greatly needed. As both KSAb1 and KSAb2 are 
disease-associated and derived from the same precursor B cell clone, it 
was important to establish the antigen specificity of the primary B cell 
clone which through SHM events, develops reactivity with TSHR. This 
antigen specificity could either be the target autoantigen, (TSHR) or an 
infectious agent.  
The aims of thesis were to evaluate the antigen specificity of the germline 
genes predisposing to two potent TSAbs, by expressing them as 
recombinant Fab. We aimed to identify where in the chain of SHM events 
pathogenicity arose and whether or not an infectious agent contributed to 
the break in tolerance allowing disease to occur. 
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2 CHAPTER TWO: Materials and methods 
2.1 Materials 
2.1.1 Medium and growth supplements 
Ham’s F12 and foetal calf serum (FCS) were purchased from Invitrogen, 
UK. FCS was heat inactivated at 56C for 30 minutes prior to use in all 
experiments.  
2.1.2 Chemicals 
Chemicals were purchased from the following companies: 
Sigma-Aldrich, Dorset, UK: Ammonium molybdate, ampicillin, 
benzamidine, boric acid, Bovine Heart Infusion medium, bovine serum 
albumin (BSA), cell dissociation solution, CaCl2.2H2O, chloramphenicol, 
CoCl2.6H2O, Coomassie blue R250, CuSO4, dimethyl sulphoxide 
(DMSO), DNase I, ethidium bromide, FeSO4, glucose, hen egg lysozyme, 
H2O2, imidazole, KCl, MgCl2, molecular biology water, MnCl2, MOPS, 
NaOx, PMSF, TEMED, tetracycline, thiamine, trichloroacetic acid, Trypsin 
EDTA, Triton-X-100, Tween-20, ZnSO4. 
Invitrogen, Paisley, UK: Novex® Sharp Pre-stained Protein Standard, 
Phosphate buffer solution (PBS), Geneticin G418, fungizone (PSF). 
VWR International, UK: Ethanol, glycine, HEPES, isopropanol, KH2PO4, 
MgSO4.7H2O, NaAc, NaCl, NaHCO3, Na2HPO4, NaOH, NH4Cl, 
(NH4)2S2O8, SDS, sucrose, Tris base. 
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New England Biolabs Ltd, Herts, UK: BsrGI, ColorPlus prestained protein 
marker, EcoRI, HindIII, Protein Ladder (10-250 kDa), Quick-Load® 1 kB 
DNA Ladder, T4 DNA Ligase, 10X T4 DNA Ligase Reaction Buffer. 
Protogel was purchased from National Diagnostics, UK. 
Novagen: DNA ladder 
2.1.3 Sterile tissue culture plastic ware 
Cells were cultured in sterile tissue culture flasks and 96-well plates 
(CELLSTAR®, Greiner Bio-One, GmbH, Germany) as described below. 
2.1.4 Cells 
2.1.4.1 Chinese hamster ovary (CHO) cells 
Chinese hamster ovary (CHO) cells expressing the full-length TSHR at an 
approximate density of 90,000 TSHR/cell and called JP09 cells, were 
donated by Professor G Vassart, Brussels (Perret et al., 1990). CHO cells 
expressing the TSHR A-subunit anchored by a 
glycosylphosphatidylinositol (GPI) moiety, and expressing the TSHR A-
subunit at an approximate density of 500,000/cell (Metcalfe et al., 2002) 
were donated by Dr Phillip Watson, University of Sheffield, and called 
GPI9-5 cells.  
The JP09 cells were used for cAMP stimulating bioassays and the GPI9-
5 cells were used in flow cytometry assays. Cells were cultured in Ham’s 
F12 medium containing 10% FCS and 0.01% PSF. The cells in culture 
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were supplemented with Geneticin G418 to a final concentration of 200 
µg/mL. 
2.1.5 Bacterial serotypes 
Y. enterocolitica serotype O:3 was kindly provided as serotype Ye58/O3 
by Professor Brendan Wren (London School of Hygiene and Tropical 
Medicine, UK) and serotype O:8 was provided as serotype 8081 was 
kindly provided by Dr. Steve Atkinson (University of Nottingham, UK). 
Both serotypes were cultured in a category two laboratory in the School 
of Molecular and Medical Sciences, University of Nottingham with the 
assistance and guidance of Mr Marco Grasso and Dr Steve Atkinson. 
2.2 Methods  
2.2.1 DNA preparation 
2.2.1.1 Isolation of KSAb1 and KSAb2 from BALB/c mice 
A mouse model of GD was established and KSAb1 and KSAb2 isolated 
according to published protocols (Gilbert et al., 2006a). Briefly, female 
BALB/c mice were immunised with Ad-TSHR289 and hybridomas created 
from their splenocytes  
The H- and L-chains of KSAb1 and KSAb2 were prepared and cloned in 
pAK19 vector (Carter P, 1992; Padoa et al., 2003; Padoa et al., 2010). 
The vector pAK19 synthesises the H- and L-chains as an rFab protein 
using a phoA promoter and heat stable enterotoxin II leader sequence 
following removal of phosphate in the growth medium. rFabs are secreted 
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into the periplasm of the bacterial cell where disulphide bonds are created 
by disulphide isomerase to link the H- and L-chains (Knappik and 
Pluckthun, 1995).  
2.2.1.2 Design and synthesis of germline gene construct 
The rearranged germline gene construct was designed based on the 
germline gene matches identified by the IMGT® database of Ig (and 
TCR) germline genes (Lefranc et al., 1999). The H-chain is formed of 
IGHV1S135, IGHD2*01 and IGHJ4*02 and the L-chain is formed of 
IGKV6-3*01 and IGKJ4*01. The vector used for expression, pAK19, 
requires the L-chain sequence to precede the H-chain, thus in the 
construct, the L-chain sequence is first and is separated from the H-chain 
by a pAK19 linker sequence. An EcoRI restriction enzyme site precedes 
the L-chain; the H-chain sequence is followed by 5 histidine residues 
(penta His tag), pAK19 sequence and a HindIII restriction enzyme site. 
The construct is 1680 bp in length and was synthesised by Genscript 
(USA) cloned in a pUC57 vector. The lyophilised germline-pUC57 DNA 
construct was reconstituted with 100 µL molecular biology water.  
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2.2.1.3 Transformation of XL10 Gold Ultracompetent cells 
For each competent cell transformation with plasmid: 
i. A 15 mL polypropylene centrifuge tube (VWR International, UK) 
was pre-chilled on ice.  
ii. 50 µL of XL10 Gold Ultracompetent cells (Stratagene, Stockport, 
UK) were thawed on ice and incubated with 2 µL -
mercaptoethanol in the tube for 10 minutes on ice.  
Figure 13: Germline gene cassette nucleotide sequence for 
synthesis. 
The nucleotide sequence of the germline gene cassette was optimised 
for protein expression and synthesised. The L-chain nucleotide 
sequence is coloured in blue and the H-chain nucleotide sequence is 
coloured in green. Restriction enzyme sites are in red and the penta 
his tag is in purple. Intervening plasmid sequence is in black.  
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iii. 50 ng of plasmid DNA was added and incubated on ice for 30 
minutes.  
iv. The tubes were heat-pulsed at 42C for 30 seconds and then 
incubated on ice for two minutes.  
v. 450 µL of preheated SOC medium (Appendix 1) was added and 
incubated for 1 h at 37C with shaking at 250  rpm.  
vi. 50 µL of transformation mixture was grown on LB-ampicillin 
(Appendices 1 and 3) agar plates. The plate was incubated for 18 
h at 37C. 
2.2.1.4 Overnight bacterial cultures  
i. A single colony was picked from agar plates and grown for 16 h at 
37C in 5 mL Luria Bertani (LB) medium (Appendix 1) containing 
100 µg/mL ampicillin (Appendix 3) in an orbital shaker at 300  rpm. 
2.2.1.5 Glycerol stocks of bacterial cultures  
A glycerol stock of each colony grown in LB was prepared by adding 600 
µL bacterial culture to 400 µL 50% glycerol (Appendix 1) and stored at -
70C. 
2.2.1.6 Mini-prep purification of bacterial cultures  
Plasmid DNA was purified from bacterial cultures using Mini-Prep Spin 
Columns (Qiagen, West Sussex, UK) according to the supplier’s protocol:  
i. 5 mL bacterial culture was added to a microcentrifuge tube (Fisher 
Brand, Fisher Scientific, UK) and spun in a microcentrifuge 
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(Biofuge Fresco, Heraeus Instruments) at 13,000 g for 1 minute at 
4C.  
ii. The supernatant was discarded and the pellet dried and 
resuspended in 250 µL buffer P1.  
iii. 250 µL of buffer P2 was added followed by 350 µL of buffer N3. 
The microcentrifuge tube was spun for 10 minutes at 13,000 g.  
iv. The supernatant was added to a spin column and incubated for 
one minute at room temperature.  
v. The flow through was discarded and 0.75 mL of buffer EB added 
before centrifuging at 13,000 g for one minute.  
vi. The flow through was discarded and 0.5 mL of buffer added and 
the tube was centrifuged for 5 minutes at 13,000 g.  
vii. Flow through was discarded and the tube was centrifuged again 
for one minute to remove any excess EtOH.  
viii. The spin column was applied to a fresh microcentrifuge tube and 
30 µL of dH2O was added directly to the filter and incubated for 
one minute at room temperature before centrifuging at 13,000 g.  
ix. The flow through contains purified plasmid DNA. 
2.2.1.7 DNA quantification by nanodrop  
The ‘Nucleic Acid’ program of nd-1000-v3.7 Spectrophotometer (Thermo 
Fisher Scientific) was used to quantify the amount of purified plasmid 
DNA. Adding 1.2 µL of dH2O first cleaned the pedestals and was then 
used as a blank. DNA was measured by applying 1.2 µL of purified 
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plasmid to the pedestal and the absorbance read at 260 nm. DNA 
concentration was measured in ng/mL. 
2.2.1.8 Sequencing  
The DNA sequencing of germline, KSAb1 and KSAb2 V-region genes 
cloned in pAK19 was performed by Geneservice (Cambridge, UK) using 
Sanger sequencing. Primers (Sigma-Aldrich, Dorset, UK) were designed 
in conjunction with Dr. Shuang-xia Zhao, KCL. The sequence analysis 
was performed using SeqMan software (DNAStar, Inc, Madison, WI, 
USA). 
Table 3: Sequencing primers. 
 
2.2.1.9 Restriction enzyme digest 
For restriction enzyme digests, 1 µg of purified DNA was digested with 1U 
of enzyme and 10X reaction buffer for 1.5 h at 37°C in a water bath. 
To create constructs of L-mature and H-mature in pAK19, 2 µg of each of 
germline and KSAb1 V-region gene constructs in pAK19 were digested 
with 2 U EcoRI and 2 U BsrGI and 10X reaction buffer for 3 h at 37°C.  
Primer Primer sequence Length (bp) 
F1 5’ AGCTGTCATAAAGTTGTCACG 3’ 21 
R1 5’ GGGTATCTAGAGGTTGAGGTG 3’ 21 
F2 5’ AAACGCGTACGCTGAGAT 3’ 18 
R2 5’ CAGTTAAATTGCTAACGCAG 3’ 20 
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2.2.1.10 DNA electrophoresis  
To analyse restriction enzyme digests and isolate separated DNA bands, 
digested DNA samples were resolved by agarose gel electrophoresis 
alongside 1 kB DNA ladder. DNA digested with EcoRI and HindIII were 
analysed by 0.8% agarose gels containing 10 µg/mL ethidium bromide 
whilst DNA digested with EcoRI and BsrGI were analysed by 1.2% 
agarose gels (Appendix 2). Gels were run in 1X TAE buffer (Appendix 2) 
at 110 V for approximately 45 minutes, or until the bromophenol blue 
loading dye had reached the end of the gel.  
2.2.1.11 Gel visualisation 
The agarose gels were viewed under UV light, for as brief a time as 
possible, and a photograph was taken (Gene Flash, Syngene Bio 
Imaging). 
2.2.1.12 Gel extraction 
To excise the bands of DNA from the agarose gel, the gel was placed in a 
UV light box (UV Transilluminator, UVP inc) and the required DNA bands 
were excised with a scalpel and stored in microcentrifuge tubes.  
i. The samples were purified using Wizard® SV Gel and PCR Clean-
Up System (Promega, UK).  
ii. The excised agarose slices were weighed and 10 µL of membrane 
binding buffer was added for every 10 µg of agarose. The slices in 
membrane binding buffer were heated to 60°C or until the agarose 
had completely melted.  
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iii. This mixture was applied to the filter membrane of a spin column 
and incubated for one minute at room temperature before 
centrifuging at 13,000 g for one minute.  
iv. The supernatant was discarded, 0.5 mL of elution buffer was 
added and the tube centrifuged for one minute at 13,000 g.  
v. The supernatant was discarded and 0.75 mL of elution buffer was 
added and tube centrifuged at 13,000 g for five minutes.  
vi. The supernatant was discarded and the tube was centrifuged 
again for one minute at 13,000 g to remove any remaining ethanol.  
vii. 15 µL of dH2O was applied directly to the membrane and 
incubated for one minute at room temperature.  
viii. The tube was then centrifuged as before and the DNA 
concentration measured by nanodrop. 
2.2.1.13 Ligation 
The concentrations of plasmid and insert DNA were calculated using the 
following formula to give a 3:1 ratio of insert to vector: 
Insert (ng) = 
         
           
 
The insert and plasmid were ligated with 1 µL T4 ligase and 10X ligase 
buffer and incubated overnight at 4°C. 
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2.2.2 Protein expression  
2.2.2.1 Constructs for rFab expression 
Purified DNA constructs were transfected in optimised competent cells for 
expression as rFab proteins. Germline, L-mature, H-mature and L-
irrelevant constructs were expressed as rFab, alongside KSAb1 as 
positive control.  For use as an irrelevant control antigen, Dr Michael 
Christie (KCL) donated the Fab construct of a human anti-islet cell 
antigen 2 (IA-2) mAb, 96/3, cloned in pAK19. To create the L-irrelevant 
construct, Dr Christiane Hampe (University of Washington, USA) donated 
the Ti-401 rFab which recognises a bacterial antigen. 
Table 4: Constructs used for rFab expression in this thesis. 
Construct H-chain L-chain 
KSAb1 Mature  Mature  
Germline Germline  Germline 
L-mature Germline Mature 
H-mature Mature Germline 
L-irrelevant Mature (KSAb1) Mature (Ti-401) 
96/3 (anti-IA2) Mature Mature 
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2.2.2.2 Transformation of Rosetta2 cells 
Purified DNA was transformed into Rosetta2 competent cells (Merck-
chemicals, Darmstadt, Germany). Rosetta2 cells encode tRNAs for rare 
codons which are not normally expressed in E. coli. Thus Rosetta2 cells 
allow for the expression of proteins whose translation might be inhibited 
by the codon usage of E. coli.  
i. 1 µL of purified DNA was incubated on ice with 20 µL of Rosetta2 
cells for 5 minutes.  
ii. The cells were then heat-shocked for 30 seconds at 42°C. 
iii. The cells and plasmid were incubated on ice for 2 minutes. 
iv. The transformed cells were incubated with 0.8 mL SOC medium 
(supplied in kit) in an orbital shaker for 1 h at 37°C with 250 rpm 
shaking.  
v. The transformation mix was spread on agar plates containing 100 
µg/mL ampicillin and 3.4 µg/mL chloramphenicol (Appendix 3), and 
incubated overnight at 37°C. 
2.2.2.3 rFab expression method 1 (2 day) 
It was necessary to establish suitable methods for optimal rFab 
expression. Three methods were studied. 
i. A fresh single colony was selected and grown in 10 mL LB with 20 
µL 5 mg/mL tetracycline (Appendix 3) for 6-8 h, or until the medium 
became cloudy, at 37°C with 300 rpm shaking.  
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ii. The LB culture was split between two 2 L flasks of 500 mL 1X 4-
morpholinepropanesulphonic (MOPS) acid medium with 
phosphate (Appendix 4) and grown overnight under the same 
conditions.  
iii. Cultures were centrifuged at 8,000 g for 5 minutes at 4°C and the 
supernatants discarded. 25 mL samples were taken to test for 
rFab expression in non-induced cultures.  
iv. Each pellet was resuspended in 500 mL 1X MOPS without 
phosphate (Appendix 4) and grown for 4 h at 30°C with 300 rpm 
shaking.  
v. Cultures were centrifuged at 8,000 g for 10 min and the 
supernatants discarded. 25 mL samples were taken to use as an 
expression check for induced samples.  
vi. Pellets were frozen at -20°C. 
vii. This expression protocol was adapted by Dr Kerry McLaughlin, 
KCL from published methods (Padoa et al., 2003; Padoa et al., 
2010). 
2.2.2.4 rFab expression method 2 (4 day)  
i. A fresh single colony was selected and grown in 5 mL LB with 10 
µL 5 mg/mL tetracycline overnight at 37°C with 300 rpm shaking.  
ii. This was inoculated in 100 mL 1X MOPS with phosphate and 
grown overnight at 37°C with 300 rpm shaking.  
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iii. This was then split between two 2 L flasks each containing 450 mL 
1X MOPS with phosphate and grown at 37°C with 300 rpm 
shaking until an OD600 of 0.6 was reached.  
iv. The cultures were centrifuged at 8,000 g for 5 minutes at 4°C and 
the supernatants discarded. 25 mL samples were taken to test for 
rFab expression in non-induced cultures.  
v. Each pellet was resuspended in 500 mL 1X MOPS without 
phosphate and grown overnight at 30°C with 300 rpm shaking.  
vi. Cultures were centrifuged at 8,000 g for 10 minutes and the 
supernatants discarded. 25 mL samples were taken to use as an 
expression check for induced samples.  
vii. Pellets were frozen at -20°C. 
2.2.2.5 rFab expression method 3 (LB broth) 
i. A fresh single colony was selected and grown for 6-8 h in 5 mL SB 
medium with 10 µL 5 mg/mL tetracycline overnight at 37°C with 
300 rpm shaking.  
ii. This was then split between two 2 L flasks each containing 450 mL 
LB medium and grown at 37°C with 300 rpm shaking overnight. 
iii. The cultures were centrifuged at 8,000 g for 5 minutes at 4°C and 
the supernatants discarded. 25 mL samples were taken to test for 
rFab expression in non-induced cultures.  
iv. Each pellet was resuspended in 500 mL 1X MOPS without 
phosphate and grown overnight at 30°C with 300 rpm shaking.  
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v. Cultures were centrifuged at 8,000 g for 10 minutes and the 
supernatants discarded. 25 mL samples were taken to use as an 
expression check for induced samples.  
vi. Pellets were frozen at -20°C. 
2.2.2.6 Measuring OD600 of bacterial cultures  
To measure the OD600 of bacterial cultures, 1 mL samples were analysed 
every h in cuvettes in a spectrophotometer (Ultrospec 2000, UV/Visible 
Spectrophotometer, Pharmacia Biotech) at 600 nm. Once the OD600 had 
reached 0.5 it was measured every 15 minutes until the OD600 reached 
0.6.  
2.2.2.7 Purification of rFab proteins  
i. Pellets from 500 mL cultures were thawed on ice and re-
suspended in 12.5 mL extraction buffer (Appendix 4).  
ii. 50 mg/mL hen egg lysozyme was prepared in extraction buffer and 
added to a final concentration of 1 mg/mL and left to stir gently at 
4°C for 30 minutes.  
iii. 1% Triton-X-100 made in dH2O was added to a final concentration 
of 0.1% and left to stir for 5 minutes.  
iv. 200 U DNase I was added and the solution left to stir for an 
additional 10 minutes.  
v. The solution was centrifuged at 10,000 g for 15 minutes at 4°C.  
vi. The supernatant (periplasmic extract) was filtered through a 0.22 
µm filter.  
vii. Purification by metal chelation chromatography 
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viii. Purification was performed 1 mL polypropylene columns (Qiagen, 
West Sussex, UK).  
ix. 1 mL of 50% slurry was equilibrated in wash buffer. 
x. The resin was incubated for 30 minutes at room temperature with 
the filtered supernatant with agitation.  
xi. The supernatant and resin were applied to a column and the 
supernatant was allowed to pass through the column.  
xii. The resin was washed in the column three times with 5 mL wash 
buffer (Appendix 4); the buffer was allowed to completely enter the 
resin bed each time.  
xiii. Purified fractions were eluted with 1 mL elution buffer (Appendix 4) 
into microcentrifuge tubes.  
xiv. Purified rFab samples were dialysed overnight against 1X 
phosphate buffered saline (PBS) (Appendix 4) at 4°C with gentle 
stirring to remove imidazole and any proteins <10 kDa. Dialysis 
membrane tubing was prepared by boiling twice in each of sodium 
bicarbonate, EDTA and dH2O and stored in 70% ethanol at 4°C. 
The samples were pipetted into the dialysis tubing and separated 
with plastic clips. 
2.2.2.8 Protein quantification of purified rFab samples 
i. The protein quantification of dialysed purified rFab samples was 
measured using the Bradford Concentration Assay (Novagen). 
ii. 25 µL of each standard and each protein sample was pipetted into 
individual wells of a 96-well plate in duplicate. 
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iii. BCA working reagent was prepared (4 mL BCA solution and 80 µl 
4% cupric sulphate for every 20 wells) 
iv. 200 µL of BCA working reagent was added to each sample. 
v. The plate was mixed on a plate shaker for 30 seconds and then 
incubated for 30 minutes at 37°C. 
vi. The protein quantification was measured by colour densitometry 
with a plate reader at 504 nm wavelength using the Revelation 
program.  
2.2.3 SDS-PAGE  
The apparatus was set up according to the manufacturer’s protocol: 
i. Two glass plates were placed one in front of the other, with the 
smaller plate at the front. Two separators were placed between the 
plates with one on either the side.  
ii. The glass plates and separators were aligned on the alignment 
stage and clicked firmly into place. 
iii. Buffers were prepared as described in Appendix 5.  
iv. The 12% separating gel (Appendix 5) was poured immediately 
after adding TEMED, covered in a layer of 50% isopropanol 
solution and left to set. 
v. Once set, the isopropanol solution was washed off with dH2O and 
the 10% stacking gel (Appendix 5) was poured on top of the 
separating gel. A comb was inserted and the gel left to set. 
vi. The comb was removed and the wells were washed with dH2O 
and the wells were marked on the glass with marker. 
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vii. The gels were placed in the tank with 1X SDS-PAGE running 
buffer (Appendix 5). 
viii. 2X loading buffer (Appendix 5) was added to the samples in an 
equal volume, which were then heated to 100C for 5 minutes. 
ix. The samples and protein markers were loaded. 
x. Gels were run at 70 V for 30 minutes, or until the samples have 
passed through the stacking gel, and 200 V until the loading dye 
reaches the bottom of the gel. 
2.2.3.1 Coomassie blue staining  
The gels were prised from between the plates and left in Coomassie blue 
stain for 1 h. The Coomassie blue stain was then removed and the gels 
were incubated in destain solution (Appendix 5) overnight. To prevent the 
gel from cracking during the process, the gels were incubated in 3% 
glycerol overnight at room temperature. The gel was placed on wet filter 
paper, covered in cling film and dried (Model 583 Gel Drier and 
HydroTech Vacuum Pump, Bio-Rad) at 80°C for 2 h. 
2.2.3.2 Western blotting  
Dialysed samples were assessed for the presence of rFab using a penta-
His HRP-Conjugate (Qiagen, West Sussex, UK) and Western blotting. 
Samples were run on SDS-PAGE gels (as described in 2.6) with coloured 
markers (Fisher Scientific UK Ltd). 
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i. The gel was placed on three sheets of wet 3 mm filter paper on the 
top leaf of the Western blotting cassette (Trans-Blot 
Electrophoretic Transfer Cell, BioRad). 
ii. The gel was covered with a wet Protan Nitrocellulose membrane 
(Scheiler and Schuell, Dassel, Germany), ensuring no air bubbles 
were present by rolling with a pastette. 
iii. Three further sheets of filter paper were placed over the 
membrane and the cassette was closed. 
iv. The cassette was placed in the tank such that the gel-side of the 
sandwich was facing the cathode, and the nitrocellulose 
membrane was facing the anode.  
v. The tank was filled with 1X transfer buffer (Appendix 5), connected 
to the power pack, placed in a polystyrene box containing ice and 
run for 1 h at 100 V, or until the prestained MW ladder had fully 
transferred to the blot. 
vi. Following transfer, the nitrocellulose membrane was blocked for 1 
h at room temperature with PBST/5% marvel milk protein/0.05% 
Tween-20. 
vii. The blocked membrane was incubated with anti-penta His HRP 
Conjugate (Qiagen; 1:1000 dilution), for 1 h at room temperature.  
viii. The membrane was then washed 3 times for 5 minutes each in 
PBST, incubated with AEC developer (Appendix 5) for 5 minutes, 
and rinsed with dH2O to stop the reaction. 
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2.2.4 Assays for measuring binding to TSHR 
2.2.4.1 Radiobinding (TRAK) assay. 
The ability of purified rFabs to displace radiolabelled 125I-TSH from 
binding immobilised TSHR was assayed using commercial kits (Brahms 
TRAK Human RIA, Thermo Fisher Scientific, Germany). Varying 
concentrations of 10–100,000 ng/mL dialysed purified rFabs were diluted 
in normal human serum, as the kits are optimised for performance in 
human serum. All samples were diluted in normal human serum (that did 
not interfere with the assay) from the same donor (JPB). A maximum 
dilution of human serum to 66% was used to ensure kit performance was 
maintained. The experiment was performed on at least three independent 
occasions with independently prepared samples.  
i. 200 µL of Buffer D was added to TSHR-coated tubes, except the 
first two tubes. 
ii. 100 µL of each of standards were added to the appropriate tubes. 
iii. Test samples were prepared by adding 30 µL rFab or IgG to 75 µL 
normal human serum. 100 µL of this was added to the appropriate 
tube. 
iv. If less than 30 µL of sample was added, the sample was made up 
to 105 µL with sterile PBS. 
v. The tubes were incubated for 2 h with shaking at room 
temperature. 
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vi. After washing twice with 2 mL wash buffer, 200 µL of 125I-TSH was 
added to each tube and incubated for 1 h with shaking at room 
temperature. 
vii. The tubes were washed three times with wash buffer and counted 
in a gamma counter (DSLaboratories). 
viii. The inhibition of binding of rFab samples was expressed as 
percentage inhibition of 125I-TSH binding to TSHR. 
2.2.4.2 Flow cytometry 
Flow cytometry analysis was used to detect any weak but measurable 
binding between the rFabs and the TSHR, as expressed on GPI9-5 and 
JP09 cells. Flow cytometry provides a more sensitive method for 
detecting binding than radioimmunoassay. 
i. GPI9-5 cells were used following at least one passage 
following thawing from liquid nitrogen. Low passage cells are 
preferred as TSHR expression may be down-regulated at high 
passage number. 
ii. Cell culture medium was removed and the cells were washed 
twice in sterile PBS. Cells were detached from the tissue 
culture flask using 3 mL warm cell dissociation medium and 
resuspended in 7 mL complete Ham’s F12 medium. 
iii. The cells were counted using a haemocytometer before being 
centrifuged at 1500 g for 8 minutes. 
iv. The cell pellet was resuspended in PBS containing 1% BSA, 
0.05% sodium azide to a cell concentration of 1 x 106 cells/mL. 
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v. 1 mL of cells were transferred to microcentrifuge tubes and 
spun at 4000 g for 1 minute. 
vi. The cell supernatant was removed and the cells were 
resuspended in 100 µL of the appropriate primary antibody: 
vii. Cells were incubated with primary antibodies for 1 h, on ice and 
in the dark. 4C1 (IgG2a, Santa Cruz Biotechnology) was used 
as a gold-standard anti-TSHR positive control. 
viii. The cells were centrifuged and washed twice with cold PBS/1% 
BSA/0.05% sodium azide and resuspended in 100 µL of the 
secondary antibody, goat anti-mouse conjugated to 
phycoerythrin (PE) (AbCam) before incubating on ice for 30 
minutes in the dark. 
ix. Samples were centrifuged and washed three times with cold 
PBS/1% BSA/0.05% sodium azide. Samples were analysed 
immediately and resuspended in 300 µL PBS. 
x. Samples were analysed on the same day using a FACS Canto 
II machine (BD Biosciences).  
2.2.4.3 cAMP stimulation bioassay  
The potencies of purified rFab and their ability to stimulate the TSHR was 
assessed using TSHR stably transfected CHO cells (JP09 cells). The 
intracellular cAMP released into the culture medium was assessed using 
commercial radioimmunoassay kits (R&D Systems or Enzo Life 
Sciences). rFab samples were tested at differing concentrations of 10–
100,000 ng/mL and tested on independent occasions with independently 
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prepared samples. Controls included KSAb1 IgG and IgG2b as an 
isotype-matched control. In addition, forskolin, a direct activator of adenyl 
cyclase, was used to determine the total cAMP stimulation in culture. 
i. JP09 cells, which had been in culture for a minimum of 7 days 
following thawing from liquid nitrogen, were plated in a 96-well 
plate at a density of 30,000 cells/well and incubated overnight at 
37C with 5% CO2. 
ii. The following day, samples were prepared in complete HBSS 
(Appendix 6). 
iii. The cell culture medium was removed and the cells were washed 
once in warm sterile PBS. 
iv. Samples and controls were added to the cells in complete HBSS: 
56.25 µL of each dilution and 93.75 µL of complete HBSS per well 
and 15 µL of 100 µM forskolin and 135 µL complete HBSS was 
added, such that the total volume for each well was 150 µL.  
v. The stimulated cells were incubated for 4 h at 37C with 5% CO2. 
vi. Assay Buffer was prepared by first diluting 1:2 with dH20 and by 
mixing 3:1 with complete HBSS. 
vii. Standards were prepared and diluted in Assay Buffer/complete 
HBSS. 
viii. Standards and samples were added to a plate containing wells 
coated with goat anti-rabbit wells. 
ix. The plate was sealed with a plastic wrap and incubated with 500 g 
shaking for 2 h at room temperature. 
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x. The plate was washed three times with wash buffer diluted 1:20 
with dH2O and 200 µL pNpp substrate was added to each well and 
incubated, covered in foil, for 1 h at room temperature. 
xi. 50 µL Stop solution was added to each well and the colour 
densitometry of the plate was read immediately at 405 nm using 
the Revelation program. 
2.2.4.4 Growth of Y. enterocolitica serotypes 8081 and Ye58/03 on 
Congo Red-Magnesium Oxalate plates 
Glycerol stocks of Y. enterocolitica serotypes 8081 and Ye58/03 were 
streaked on Congo Red-Magnesium Oxalate plates (Riley and Toma, 
1989) prepared by Mr Marco Grasso. Colonies that express pYVe are 
dependent on calcium for growth and also absorb Congo Red from the 
agar medium. The streaked plates were incubated overnight at 37C in 
Yersinia Luria Bertani broth (YLB; Appendix 7). pYVe-positive colonies 
grew and were red in colour; pYVe-negative colonies were white in 
colour. Plasmid expression is unstable so there was a mix of both 
plasmid-positive and –negative colonies. Isolated single red colonies 
were easily obtained for Y. enterocolitica serotype 8081, however it was 
not possible to isolate single colonies for Ye58/O3. 
2.2.4.5 Checking for presence of pYVe plasmid in Y. enterocolitica 
serotypes 8081 and Ye58/03 by PCR 
For Y. enterocolitica serotype 8081, one half of three single isolated red 
colonies were taken using a toothpick for PCR analysis, to confirm the 
presence of pYVe. The remaining half of each colony was taken for 
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overnight growth under conditions described in section  2.2.4.5. For 
serotype Ye58/O3, no easily identifiable single colonies were obtained on 
the streaked plate. Three small streaks of densely packed Ye58/O3 
colonies were taken for PCR analysis. 
Table 5: Primers used for amplification of yscU gene of pYVe 
plasmid. 
Primer Sequence 
Forward 5’ TCTGTACTGTTGGCTTTGTGG 3’ 
Reverse 5’ TTGCGCACAGACTGAACTTGG 3’ 
 
Table 6: PCR cycling conditions for amplification of yscU gene in 
pYVe plasmid. 
Temperature (°C) Time 
95 5 minutes 
95 30 seconds 
54 30 seconds 
72 1 minute 
72 10 minutes 
10 Hold 
 
2.2.4.6 Growth of Y. enterocolitica serotypes 8081 and Ye58/O3 for 
the isolation of Yops 
As described in section  2.2.4.5, half of three single isolated red 8081 
colonies were taken for PCR analysis and the other half of the same 
x30 
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colony was grown overnight in YLB broth. No isolated single colonies of 
Ye58/03 formed so three small streaks of Ye58/03 grown overnight 
instead. The Yop isolation protocol is adapted from a published protocol 
(Trulzsch et al., 2004). 
i. The 8081 colony or Ye58/03 streak was inoculated in 10 mL YLB 
media and grown overnight in an orbital shaker (Gallenkamp 
Cooled Orbital Incubator) at 30C with 200 rpm shaking. 
ii. The following morning this was diluted 1:40 in 10 mL Bovine Heart 
Infusion and grown for 2 h at 37C. 
iii. 20 mM sodium oxalate and 20 mM MgCl2 were added to induce 
Yop secretion and the cultures were grown for a further 3 h at 
37C. 
iv. The cultures were centrifuged at 5000 g for 10 minutes at room 
temperature (Beckman Avanti 30). 
v. 10 mL of supernatant was filtered through a 2 m filter and 
incubated on ice with 1 mL 100% TCA for 30 minutes. 
vi. The mixture was centrifuged at 10,000 g for 10 minutes at 4C and 
the supernatant discarded. 
vii. The pellet was resuspended in 500 µL 10% SDS and 1 mL of ice-
cold acetone was added to the resuspension add incubated for 30 
minutes on ice. 
viii. The mixture was centrifuged at 14,000 g for 30 minutes at 4C and 
the supernatant discarded. 
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ix. The acetone was allowed to evaporate, heating to 37C aided this 
evaporation and the pellet resuspended in 60 µL PBS. 
2.2.4.7 Preparation of whole cell lysates from Y. enterocolitica 
serotypes 8081 and Ye58/03 
Preparation of whole cell lysates: 
i. Y. enterocolitica serotype 8081 and Ye58/03 were grown overnight 
in 10 mL YLB at 30C with 250 rpm shaking. 
ii. 1 mL of cultures was centrifuged at 13,000 g for 1 minute at room 
temperature. 
iii. Pellets were resuspended in 100 µL PBS and 100 µL 2X SDS-
PAGE loading buffer. 
iv. The resuspended pellets were sonicated for 1 pulse every two 
seconds for 1 minute. 
v. Pellets were discarded and 5 µL supernatant were analysed by 
SDS-PAGE. 
Preparation of envelope proteins from Y. enterocolitica serotypes 8081 
and Ye58/O3: 
vi. The protocol for the preparation of envelope proteins was adapted 
from a previous publication (Luo et al., 1993). 
vii. 40 mL overnight cultures of 8081 and Ye58/03 serotypes were 
centrifuged at 5,000 g for 10 minutes. 
viii. The supernatant was discarded and the pellets were resuspended 
in 2 mL PBS. 
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ix. Sonication was performed in ice-water slurry. The first sonication 
involved a one second pulse every two seconds for 1 minute.  
x. Large cellular debris was removed by centrifuging at 7,000 g for 10 
minutes.  
xi. The envelope proteins were isolated by ultracentrifugation of the 
supernatant at 38,500 g for 1 h. 
xii. Pellets were resuspended in 100 µL PBS and 100 µL 2X SDS-
PAGE loading buffer. 
2.2.4.8 Y. enterocolitica protein extract for affinity enrichment 
i. Y. enterocolitica cultures were grown overnight by Mr Marco 
Grasso until an OD600 of 2.5-3 was reached. Cells were then 
collected by centrifugation, frozen and sent to our laboratory. 
ii. Centrifuged cells were thawed on ice and resuspended in 2 mL 
lysis buffer (Appendix 7).  
iii. 40 µL of hen egg lysozyme (50 mg/mL) was added and incubated 
at 37C for 30 minutes with gentle agitation. 
iv. The solution was sonicated on ice for 20-second pulse followed by 
a 20 second pause for a total of 5 minutes.  
v. Cells were centrifuged at 10,000 g for 10 minutes at 4C. 
vi. The supernatant was removed and 20 µL of 100 mM 
phenylmethylsulfonyl fluoride was added.  
vii. The protein extract was incubated with KSAb1 IgG coupled to 
Cyanogen Bromide-activated Sepharose immediately. 
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2.2.4.9 Affinity-enrichment of Y. enterocolitica with affinity matrix-
coupled antibody  
i. Dried Cyanogen Bromide-activated Sepharose 4B (Sigma-Aldrich) 
was swelled and activated in 200 mL cold 1 mM HCl for 30 
minutes. 
ii. The swelled gel was washed with dH2O followed by coupling buffer 
(Appendix 7) in a sintered glass funnel. 
iii. The washed resin was incubated with either KSAb1 IgG or BSA in 
coupling buffer at a concentration of 10 mg/mL overnight at 4C.  
iv. The following day the incubated mix was washed in coupling buffer 
and resuspended in 0.2 M glycine-NaOH pH 8 for 2 h at room 
temperature.  
v. The resin was washed with alternate washes of coupling buffer 
and acetate buffer (Appendix 7) five times. 
vi. The resin was then incubated with Y. enterocolitica protein extract 
(protocol described below in section  2.2.4.10) overnight at 4C. 
vii. The resin was centrifuged and the supernatant removed. The resin 
was washed twice with 1X PBS. 
viii. The resin was incubated with 50 µL 0.1 M glycine-HCl pH 2.5 for 5 
minutes at room temperature.  
ix. 5 µL Tris-HCl pH 8 was added to neutralise the 0.1 M glycine pH 
2.5, the resin was centrifuged and the supernatant collected and 
measured for protein concentration.  
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2.2.4.10 Western blotting of prepared Y. enterocolitica proteins 
i. SDS-PAGE was run as described in section  2.2.3 and transferred 
to a nitrocellulose membrane as described in section  2.2.3.2. 
ii. Following transfer, the blot was incubated for 1 h at room 
temperature in PBST with 5% Marvel non-fat milk. 
iii. The blots were then incubated overnight at 4C with gentle 
agitation with primary antibody. 
iv. Blots were washed three times for 10 minutes each in PBST. 
v. The blots with transferred Yops were then incubated for 2 h at 
room temperature with goat anti-mouse polyclonal IgG conjugated 
to alkaline phosphatase (Sigma-Aldrich) at a 1:1000 dilution. Blots 
with transferred whole cell lysates, envelope proteins or outer 
membrane proteins were incubated with sheep anti-mouse IgG 
HRP-linked species-specific whole antibody (GE Healthcare) at a 
1:5000 dilution. 
vi. Blots were washed again as in step (v). 
vii. The Yop blots were then incubated for 3-5 minutes with BCIP/NBT 
conjugate. Rinsing the blots with dH2O stopped the reaction. 
viii. The other blots were incubated with a 1:1 ratio of Amersham Prime 
Western Blotting Detection Reagents, Solution A and Solution B, 
for 5 minutes. Excess reagent was drained from the blot and the 
blot was wrapped in cling film. 
ix. Blots were exposed to Amersham Hyperfilm. 
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2.2.4.11 MALDI-TOF sequencing analysis 
Bands excised from polyacrylamide gels underwent MALDI-TOF 
sequencing analysis at the University of Leicester Protein Nucleic Acid 
Chemistry Laboratory, using a 4000 Q-TRAP® LC/MS/MS System. The 
band was excised using clean gloves and scalpel, stained with fresh 
Coomassie blue solution and destained in a clean box to prevent 
contamination of the gel with keratin. 
2.2.4.12 Outer membrane porin A synthesis  
The nucleotide sequence of OmpA (Y. enterocolitica 8081) was obtained 
from PubMed using the ‘Protein’ accession number provided by the 
MALDI-TOF analysis (A1JMT3). The nucleotide accession number of 
ompA is nc 008800. The nucleotide sequence of ompA (1,080 bp) was 
optimised for protein expression and subsequently synthesised as a 
synthetic gene by GenScript, USA. The first 21 aa (63 nucleotides) of 
OmpA is a signal sequence which is cleaved by a peptidase(s), 
underlined in Figure 14, page 111. 
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2.2.4.13 Cloning of ompA gene cassette 
The ompA gene insert was digested from pUC57 vector by restriction 
digest with NdeI and XhoI and sub-cloned into pET22b vector (Novagen) 
and One Shot® TOP10 Chemically Competent E. coli cells (Invitrogen). 
pET22b vector and competent cells were kindly donated by Dr Kevin Ford 
Figure 14: Nucleotide and amino acid sequence of OmpA for 
gene synthesis. 
The nucleotide and amino acid sequence of OmpA was found using 
a PubMed search. The 21 aa signal sequence is underlined. The 
nucleotide construct was synthesised by GenScript, USA.  
at gaaaaagacagct at cgcat t agcagt ggcact ggct ggt t t cgct acagt agcgcaa 
 M  K  K  T  A  I   A  L  A  V  A  L  A  G  F  A  T  V  A  Q  
gccgcaccgaaagat aacacct ggt acaccggt ggt aaact gggct ggt ct cagt at caa 
 A  A  P  K  D  N  T  W  Y  T  G  G  K  L  G  W  S  Q  Y  Q  
aat act ggcact ggcggt at ct at ggcgaccaaggcaat gacggt ccaact cat aaagac 
 N  T  G  T  G  G  I   Y  G  D  Q  G  N  D  G  P  T  H  K  D  
caat t aggt gct ggt gcgt t ct t gggt t accaagcaaaccaat acct gggct t t gaaat g 
 Q  L  G  A  G  A  F  L  G  Y  Q  A  N  Q  Y  L  G  F  E  M  
ggat acgact ggct t ggccgt at gcct t acaaaggcgacgt t cgt aacggcgact t t aaa 
 G  Y  D  W  L  G  R  M  P  Y  K  G  D  V  R  N  G  D  F  K  
gcacaaggcgt t caact ggct gcaaaact gagct acccaat t gct caggat t t ggacct g 
 A  Q  G  V  Q  L  A  A  K  L  S  Y  P  I   A  Q  D  L  D  L  
t acacccgt t t aggt ggt at ggt t t ggcgt gcagact caagcgcgt t t gacgcagct act  
 Y  T  R  L  G  G  M  V  W  R  A  D  S  S  A  F  D  A  A  T  
ggcgaccgt caaaacaaccat gat accggt gt t t ct ccact ggt agcact gggt gct gaa 
 G  D  R  Q  N  N  H  D  T  G  V  S  P  L  V  A  L  G  A  E  
t acgcat ggaccaaaaact gggcaacccgt at ggaat accaat gggt t agcaacat cggt  
 Y  A  W  T  K  N  W  A  T  R  M  E  Y  Q  W  V  S  N  I   G  
gat aaagct accgt t ggt gct cgt ccagacaacggcat gct aagcgt aggt gt t t ct t ac 
 D  K  A  T  V  G  A  R  P  D  N  G  M  L  S  V  G  V  S  Y  
cgt t t cggt caggaagat gcagt agct ccaat t gct ccggct ccagct ccagct ccagt t  
 R  F  G  Q  E  D  A  V  A  P  I   A  P  A  P  A  P  A  P  V  
gt t gat accaagcgt t t cacact gaaat ct gacgt gct gt t t gct t t caacaaat caacg 
 V  D  T  K  R  F  T  L  K  S  D  V  L  F  A  F  N  K  S  T  
t t gaaaccagaaggccagcaagct ct ggaccaact gt at gcacaact gagct ct at cgat  
 L  K  P  E  G  Q  Q  A  L  D  Q  L  Y  A  Q  L  S  S  I   D  
cct aaagat ggt t ct gt agt ggt t ct gggct t cgct gaccgt at cggccaaccagct cct  
 P  K  D  G  S  V  V  V  L  G  F  A  D  R  I   G  Q  P  A  P  
aact t agct ct gt ct cagcgt cgt gct gacagcgt gcgt gat t acct ggt t t ct aaaggt  
 N  L  A  L  S  Q  R  R  A  D  S  V  R  D  Y  L  V  S  K  G  
at ccct gct gacaaaat caccgct cgcggt gaaggccaagct aacccagt t acaggcaac 
 I   P  A  D  K  I   T  A  R  G  E  G  Q  A  N  P  V  T  G  N  
acct gt gacaacgt gaaaccacgt gct gct ct gat t gagt gcct ggcaccagat cgt cgc  
 T  C  D  N  V  K  P  R  A  A  L  I   E  C  L  A  P  D  R  R  
gt agagat cgaagt t aaaggct acaaagaagt t gt aact cagccacaggct t aa 
 V  E  I   E  V  K  G  Y  K  E  V  V  T  Q  P  Q  A  -    
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and Dr Joop Gaken, KCL. DNA preparation and cloning protocols used 
were as described in Chapter 2, section  2.2.1, page 82. 
2.2.4.14 Cloning of ompC and ompF genes 
The cDNA of ompC (Y. enterocolitica 8081) and ompF (Y. enterocolitica 
8081) genes were kindly donated by Dr Anna Stenkova, Pacific Institute 
of Bioorganic Chemistry, Russia, cloned in pET32b vector (Novagen) 
using NdeI and BamHI restriction sites. The nucleotide and amino acid 
sequences of OmpC and OmpF are detailed in Figure 15, page 113, and 
Figure 16, page 114, respectively. 
The first 21 aa (63 nucleotides) of OmpC and OmpF are a signal 
sequence which is cleaved by a peptidase(s), underlined in Figure 15 and 
Figure 16. The gene constructs donated by Dr Anna Stenkova do not 
include the signal sequence.  
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Figure 15: Nucleotide and amino acid sequence of OmpC. 
The nucleotide and amino acid sequence of OmpC. The 21 aa signal 
sequence is underlined. The gene construct donated by Dr Anna 
Stenkova does not include this signal sequence. 
at gaaact gcgcgt gct gagcct gct ggt gccggcgct gct ggt ggcgggcagcgcgggc 
 M  K  L  R  V  L  S  L  L  V  P  A  L  L  V  A  G  S  A  G  
gcggcggaaat t t at aacaaagat ggcaacaaact ggat ct gt at ggcaaagt ggat ggc 
 A  A  E  I   Y  N  K  D  G  N  K  L  D  L  Y  G  K  V  D  G  
ct gcat t at t t t agcgat gat aaaagcaaagat ggcgat cagagct at at gcgct t t ggc  
 L  H  Y  F  S  D  D  K  S  K  D  G  D  Q  S  Y  M  R  F  G  
ct gaaaggcgaaacccagat t agcgat cagct gaccggct at ggccagt gggaat at cag 
 L  K  G  E  T  Q  I   S  D  Q  L  T  G  Y  G  Q  W  E  Y  Q  
gcgaacct gaacaaagcggaagat caggat cagggcaact t t acccgcat t ggct t t gcg 
 A  N  L  N  K  A  E  D  Q  D  Q  G  N  F  T  R  I   G  F  A  
ggcct gaaat t t gcggat t at ggcagct t t gat t at ggccgcaact at ggcgt gct gt at  
 G  L  K  F  A  D  Y  G  S  F  D  Y  G  R  N  Y  G  V  L  Y  
gat gt gaccagct ggaccgat gt gct gccggaat t t ggcggcgat acct at ggcgcggat  
 D  V  T  S  W  T  D  V  L  P  E  F  G  G  D  T  Y  G  A  D  
aact t t ct gagccagcgcggcaacggcat ggcgacct at cgcaacaccaact t t t t t ggc  
 N  F  L  S  Q  R  G  N  G  M  A  T  Y  R  N  T  N  F  F  G  
ct ggt ggat ggcct gaact t t gcgct gcagt at cagggcaaaaacggcagcggcaccgaa 
 L  V  D  G  L  N  F  A  L  Q  Y  Q  G  K  N  G  S  G  T  E  
accgat aacggccgcgat gt gcagggccagaacggcgat ggct at ggcat gagcct gagc 
 T  D  N  G  R  D  V  Q  G  Q  N  G  D  G  Y  G  M  S  L  S  
t at gat ct gggct ggggcgt gagcgcgagcgcggcgat ggcgagcagcaaacgcaccgat  
 Y  D  L  G  W  G  V  S  A  S  A  A  M  A  S  S  K  R  T  D  
gaacagaacaacct ggcgt t t ggccat ggcgat cgcgcggat gcgt at agcggcggcct g 
 E  Q  N  N  L  A  F  G  H  G  D  R  A  D  A  Y  S  G  G  L  
aaat at gat gcgaacaacgt gt at ct ggcggcgacct at gcgcagacct at aacct gacc 
 K  Y  D  A  N  N  V  Y  L  A  A  T  Y  A  Q  T  Y  N  L  T  
cgct t t ggcaact t t aaaaacaacaccgat agcggct t t gcgaacaaagcgcagaacat t  
 R  F  G  N  F  K  N  N  T  D  S  G  F  A  N  K  A  Q  N  I   
gaact ggt ggcgcagt at cagt t t gat t t t ggcct gcgcccgagcgt ggcgt at ct gcag 
 E  L  V  A  Q  Y  Q  F  D  F  G  L  R  P  S  V  A  Y  L  Q  
agcaaaggcaaagat ct gggcaacggct at agcgat caggat ct ggt gaaat at gt ggat  
 S  K  G  K  D  L  G  N  G  Y  S  D  Q  D  L  V  K  Y  V  D  
gt gggcgcgacct at t at t t t aacaaaaacat gagcacct at gt ggat t at aaaat t aac  
 V  G  A  T  Y  Y  F  N  K  N  M  S  T  Y  V  D  Y  K  I   N  
ct gct ggat gaaaacgaat t t accaaaaacgcgggcat t aacaccgat gat at t gt ggcg 
 L  L  D  E  N  E  F  T  K  N  A  G  I   N  T  D  D  I   V  A  
gt gggcct ggt gt at cagt t t  
 V  G  L  V  Y  Q  F 
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2.2.4.15 Expression of ompA, ompC and ompF gene constructs 
as recombinant protein  
The ompA gene cloned in pET22b vector, and ompC and ompF cloned in 
pET32b vector were transformed in BL21 (DE3) cells for recombinant 
protein expression. The transformation protocol was the same as that 
Figure 16: Nucleotide and amino acid sequence of OmpF. 
The nucleotide and amino acid sequence of OmpF. The 21 aa signal 
sequence is underlined. The gene construct donated by Dr Anna 
Stenkova does not include this signal sequence. 
at gaagcgcaat at t ct t gcagt agt aat cccagcat t gt t agt agct ggt gcagct aat  
 M  K  R  N  I   L  A  V  V  I   P  A  L  L  V  A  G  A  A  N  
gcagcagaaat ct acaacaaagacggcaacaaact t gacct gt acggt aaagt t gacgca 
 A  A  E  I   Y  N  K  D  G  N  K  L  D  L  Y  G  K  V  D  A  
cgt caccagt t ct ct gacaacgct ggccaagacggcgacgaat ct t at gt t cgt t t cggc  
 R  H  Q  F  S  D  N  A  G  Q  D  G  D  E  S  Y  V  R  F  G  
t t caaaggt gaaacccaaat t act gaccagct gaccggt t acggccagt gggaat acaac 
 F  K  G  E  T  Q  I   T  D  Q  L  T  G  Y  G  Q  W  E  Y  N  
gt t caggct aaccacgct gaat ct caaggcgat aaaggcaacaaaacccgt ct gggct t t  
 V  Q  A  N  H  A  E  S  Q  G  D  K  G  N  K  T  R  L  G  F  
gct ggt ct gaaat t t gct gaat t cggt t cat t cgact at ggccgt aact acggcgt aat c  
 A  G  L  K  F  A  E  F  G  S  F  D  Y  G  R  N  Y  G  V  I   
t at gat gt caacgcat ggact gacat gct gccagt gt t cggt ggt gat t caat ct ccaac 
 Y  D  V  N  A  W  T  D  M  L  P  V  F  G  G  D  S  I   S  N  
t ct gacaact acat gact ggccgt t ct act ggcct ggct act t accgt aacaccaact t c  
 S  D  N  Y  M  T  G  R  S  T  G  L  A  T  Y  R  N  T  N  F  
t t cggt ct ggt t gat ggcct gaact t t gct ct gcaat at caaggcaaaaacgaaaacgat  
 F  G  L  V  D  G  L  N  F  A  L  Q  Y  Q  G  K  N  E  N  D  
cgcagcgct gt t gcaaacggt gt t t acact ggt gacaacct gaaagat cagaacggcgac 
 R  S  A  V  A  N  G  V  Y  T  G  D  N  L  K  D  Q  N  G  D  
ggct t cggt at ct ct t ct act t at gat at cggt t at ggcgt gaact t t ggt gct ggt t t c  
 G  F  G  I   S  S  T  Y  D  I   G  Y  G  V  N  F  G  A  G  F  
t ct t ct t ccaaccgt accaaccaacaaaaagcat t cagcact gct gaaggcgat aaagct  
 S  S  S  N  R  T  N  Q  Q  K  A  F  S  T  A  E  G  D  K  A  
caggcat ggaacgt t ggt gct aaat acgacgcaaacaat gt at acct agct gt aat gt at  
 Q  A  W  N  V  G  A  K  Y  D  A  N  N  V  Y  L  A  V  M  Y  
gct gaaact caaaacat gact ccat at ggcgat gct t ct aat act at cgct aacaagact  
 A  E  T  Q  N  M  T  P  Y  G  D  A  S  N  T  I   A  N  K  T  
cgt gacat t gaaat cact gcacaat accagt t cgact t cggt ct acgt ccat ct t t aggc  
 R  D  I   E  I   T  A  Q  Y  Q  F  D  F  G  L  R  P  S  L  G  
t acgt t cagt ct aaagggaaagat ct t aacgcgaat ggcgat aaccaagat ct gt t gaaa 
 Y  V  Q  S  K  G  K  D  L  N  A  N  G  D  N  Q  D  L  L  K  
t at gt t t ct gt aggt t ct t act act act t caacaaaaacat gt ct acct at gt t gat t ac  
 Y  V  S  V  G  S  Y  Y  Y  F  N  K  N  M  S  T  Y  V  D  Y  
aaaat caact t gct ggacgaaaat gact t cact cgt gcaaacggt ct gaacacagacgac 
 K  I   N  L  L  D  E  N  D  F  T  R  A  N  G  L  N  T  D  D  
gt t gt aggt gt t ggct t ggt t t accagt t ct aa 
 V  V  G  V  G  L  V  Y  Q  F  -    
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used for Rosetta2 cells (see Chapter 2, section  2.2.2.2, page 91) and 
agar plates with ampicillin as a selection marker were used.  
For expression as recombinant protein: 
i. A single colony was inoculated in LB broth containing 100 μg/mL 
ampicillin (Appendix 3) and grown at 37°C overnight with shaking 
at 250 rpm. 
ii. The next morning, overnight culture was diluted 1:100 in fresh LB 
containing 100 μg/mL ampicillin and grown for 3 h at 37°C with 
shaking at 250 rpm. 
iii.  Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.5 mM or 1 mM to induce protein expression and 
grown for 4 h at 37°C.  
iv. Protein expression was confirmed by SDS-PAGE analysis with 
Coomassie blue staining (Chapter 2, section  2.2.3, page 96) and 
Western blotting (Chapter 2, section  2.2.3, page 96 and Chapter 5, 
section  2.2.4.10, page 109).  
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3 CHAPTER THREE: Recombinant Fab expression and evaluation 
of germline genes of thyroid stimulating antibodies.  
3.1 Introduction 
3.1.1 KSAb1 and KSAb2 monoclonal antibodies 
As has been previously described in Chapter 1, section  1.7.2, page 55, 
the antibody repertoire of a GD patient can be very diverse, including 
stimulating, antagonist and neutral antibody populations (Evans et al., 
2010; Morshed et al., 2010b). It is therefore important to evaluate and 
understand these antibodies at a molecular level to appreciate how they 
arise in pathogenesis and how they may be targeted as a specific 
therapy. The paucity of such antibodies in patient serum (de Forteza et 
al., 1994; Nakatake et al., 2006) and the notorious difficulties involved in 
their isolation from human serum (Martin et al., 1997; Pichurin et al., 
2002; Soliman et al., 1995) has made animal models of induced 
experimental disease a necessity (Dagdelen et al., 2009).  
One such model established in this laboratory using Ad-TSHR289 
resulted in the isolation of two potent monoclonal TSAbs with powerful 
agonist properties, KSAb1 (IgG2b/κ) and KSAb2 (IgG2a/κ) (Gilbert et al., 
2006a). The isolation of these antibodies allows for important studies to 
characterise the pathogenic antibody response in the mouse. The 
stimulatory properties of these antibodies in the nanomolar range, their 
strong affinity for TSHR and their in vivo pathogenicity make these 
antibodies comparable to the human mAbs and relevant for study (see 
Chapter 1, Sections  1.7.7 and  1.7.9 for details).  
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The DNA sequence of the V-region genes of KSAb1 and KSAb2 revealed 
the germline gene rearrangements of both mAbs, and their pattern of 
SHM (Padoa et al., 2010). Comparison of the V-region sequences with 
the IMGT® database of Ig (and TCR) germline genes (Lefranc et al., 
1999) revealed that both KSAb1 and KSAb2 shared the same germline 
IGHV and IGLV genes and are high likely to be derived from the same 
original B cell clone. The two antibodies share 21 SHM in their H-chains, 
with 8 additional unique mutations in KSAb1 and 5 additional unique 
mutations in KSAb2 suggesting that following 21 SHM events, the original 
B cell clone diverged into two separate clones, each expressing a 
sequentially different H-chain following additional unique mutations. The 
L-chains of both mAbs do not share any common SHM and thus diverged 
independently, with 8 mutations in KSAb1 and 11 mutations in KSAb2 
(Padoa et al., 2010) as shown in Figure 17. 
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The sequencing of KSAb1 and KSAb2 provided us with an opportunity to 
investigate the stage in their development when TSHR recognition and 
pathogenic activity was acquired, beginning with their original germline 
gene rearrangement. Determining whether the germline revertant of the 
two mAbs could recognise TSHR would reveal whether KSAb1 and 
KSAb2 developed from an already autoreactive precursor antibody, which 
Figure 17: lineage tree illustrating the clonal relationship between 
KSAb1 and KSAb2. 
Both mAbs are derived from the same germline VDJ rearrangement 
and have undergone significant SHM in their H- and L-chains. In the H-
chain (A) there are 21 common mutations before divergence with 8 
unique mutations in KSAb1 and 5 in KSAb2, whilst the L-chain (B) 
diverged immediately with 5 mutations in KSAb1 and 11 mutations in 
KSAb2. Figure taken from (Padoa et al., 2010). 
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would point to a defect in central tolerance allowing autoreactive B cell 
clones to exit the bone marrow, or whether KSAb1 and KSAb2 developed 
from a non-autoreactive precursor which acquired pathogenic activity 
through SHM in the periphery.  
3.1.2 Previous germline revertant studies in other autoimmune 
conditions 
Germline revertant studies in autoantibodies have been evaluated in only 
one other autoimmune condition, SLE, where antibodies to DNA antigens 
have been studied.  Such studies have also discussed the contribution of 
SHM to autoreactivity development.  
Radic et al reverted a murine anti-DNA antibody to the germline 
sequence and found low but measurable binding to double-stranded DNA 
(dsDNA) (Radic et al., 1993). A recent study in a murine SLE model, also 
found evidence for SHM-driven autoreactivity, demonstrating that a single 
non-autoreactive B cell clone can give rise to 15 pathogenic 
autoantibodies through SHM. The same loss of autoreactivity was found 
in the germline revertants of a further 8 autoreactive B cells descended 
from different original B cell clones. However the germline revertant of 
one autoreactive clone displayed only a 50-fold decrease in autoreactivity 
(Guo et al., 2010). Most interestingly, Guo et al postulate that a non-
autoreactive B cell leaving the bone marrow may be more dangerous 
than one leaving with an autoreactive specificity, as the latter may be 
subjected to deleterious or anergic tolerance mechanisms sooner than 
the former. 
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 Reversion of two anti-dsDNA mAbs isolated from SLE patientsto the 
germline sequence resulted in a complete loss of anti-DNA recognition, 
clearly demonstrating the roles of SHM and affinity maturation in driving 
autoreactivity. Furthermore, introduction of selected mutations in the 
germline sequence in one of the mAbs revealed three replacement 
mutations essential for dsDNA binding, 1 mutation in the H-chain, and 
two in the L-chain. Re-introduction of these three mutations alone in the 
germline sequence was sufficient to generate dsDNA binding comparable 
to that of the original antibody (Wellmann et al., 2005). In a later paper, 6 
polyreactive anti-Ro and anti-La autoantibodies and 21 IgG memory B 
cells isolated from a single patient undergoing SLE were reverted to the 
germline sequence. The majority of these antibodies lost reactivity to a 
variety of SLE autoantigens, with only a few antibodies retaining 
autoreactivity (Mietzner et al., 2008). 
To accurately assess the contribution of SHM in the autoantibody 
response in GD, a large database of antibodies and their sequences are 
required both from the same individual and others for comparison to 
detect patterns of mutation, their effects on affinity and to rule out any 
polymorphisms. In the case of GD, four anti-TSHR mAbs have been 
isolated from three patients (Evans et al., 2010; Sanders et al., 2003; 
Sanders, 2008). Whilst there is some restricted usage of VH genes, with 
three of the four mAbs using the VH5 family of genes, this is too small a 
number to examine for trends in mutation and gene usage. It has been 
reported that these antibodies have undergone SHM events, although 
details of the precise mutations have not been published so it is not 
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possible at this stage to comment in any great detail on the role of certain 
somatic mutations, if any, in the human GD antibody response. 
3.1.3 Monoclonal antibody fragment technology 
Recombinant Fab (rFab) fragments consist of the full L-chain (VLCL) and 
the Fd portion of the H-chain (VHCH1) linked by a disulphide bond. rFabs 
are easily produced in prokaryotic expression systems at high levels and 
prove to be a more stable antibody fragment than scFv due to 
cooperation between the variable and constant regions (Röthlisberger et 
al., 2005). Both the IGHV and IGKV genes must be cloned in the 
expression vector and expressed in the same cell which may be bacterial, 
yeast, insect or mammalian (Rahman et al., 1998). In the expression 
system used in this thesis, using the pAK19 vector (Carter et al., 1992), 
each antibody chain is produced as a separate peptide in the bacterial 
cell and a signal sequence in the vector will direct them to the bacterial 
periplasm, where a disulphide isomerase will link the chains with 
disulphide bonds (Knappik and Pluckthun, 1995).  Bacterial expression 
systems do not alter or affect the peptide sequence or structure with any 
post-translational modifications (Rahman et al., 1998). However, a major 
setback of antibody fragments is their monovalency; resulting in fast 
dissociation times from their antigenic target due to lower avidity for 
antigen than their IgG counterparts (Holliger and Hudson, 2005).  
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The rFab expression system was thus chosen for this thesis on the basis 
of ease of expression, relative stability compared to other engineered 
small fragments. It has proven to be successful in producing rFab 
molecules capable of binding antigens involved in T1D: the 65 kDa 
isoform of glutamate decarboxylase (GAD65) (Padoa et al., 2003), IA-2 
(Dr Michael Christie and Dr Kerry McLaughlin, KCL, unpubished) and the 
TSHR (Padoa et al., 2010).  
 
Figure 18: Antibody engineering. 
Monoclonal antibodies and their derivations have been used for 
therapeutic and diagnostic purposes. Adapted from (Holliger and 
Hudson, 2005). 
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3.2 Aims 
The aims of this chapter were to evaluate the antigen specificity of the 
shared germline precursor antibody of two TSAbs, KSAb1 and KSAb2: 
i. The germline genes were expressed and purified as rFab for 
evaluation of antigen-specific binding.  
ii. Once available in purified form, rFab germline was evaluated in the 
following assays: 
a. Radioreceptor (TRAK) assay: binding of the receptor is 
determined by the rFab’s ability to displace radiolabelled 
TSH from binding immobilised TSHR. 
b. Flow cytometry: binding of the receptor is determined by 
rFab binding to CHO cells expressing high levels of TSHR 
A-subunit. 
c. cAMP stimulation bioassay: production of cAMP by CHO 
cells expressing full length TSHR following stimulation by 
rFab preparations. cAMP stimulation signifies not only 
binding of the TSHR, but also pathogenic activity. 
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3.3 Results 
3.3.1 Cloning of synthetic germline construct in pAK19 vector 
The germline construct, comprising the germline IGHV and IGLV gene 
sequence of KSAb1 and KSAb2 was cloned in pUC57 and was received 
with verification of its full nucleotide sequence (not shown). The insert 
was excised by restriction digestion with EcoRI/HindIII followed by 
agarose gel electrophoresis to verify its size as migrating at 1.7 kB 
(Figure 19A). The purified insert was sub-cloned into pAK19 and 
confirmed by agarose gel electrophoresis to ensure that the construct and 
digested pAK19 plasmid were running at the expected sizes of 1.6 kB 
and 6 kB, respectively (Figure 19B) The sub-cloned insert in pAK19 
plasmid was re-sequenced to confirm faithful cloning into pAK19 
(Appendix 8). 
 
Figure 19: Cloning of germline in plasmid pAK19. 
(A) The germline construct in pUC57 was digested with EcoRI and 
HindIII to give a germline construct digest product of 1.6 kB (B) KSAb1 
and germline construct cloned in pAK19 were digested with EcoRI and 
HindIII. The digested products were analysed by 0.8% agarose gel to 
confirm they were of the expected sizes. The insert was 1.6 kB and the 
plasmid was 6 kB. 
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3.3.2 rFab expression 
Following successful cloning of the germline gene cassette in pAK19 
vector, expression of the germline construct as rFab alongside positive 
and negative controls was initiated using the expression protocol 
described by Padoa et al (Padoa et al., 2010). Although the expression 
method described by that study was successful in expressing adequate 
yield of purified rFab KSAb1, the expression method would need to be 
optimised for other rFab constructs used in this thesis, or new expression 
methods developed to ensure optimum rFab expression.  
rFab germline was to be expressed alongside positive and negative 
controls also expressed as rFab. Purified rFab of mAb 96/3 (Dromey et 
al., 2004) to pancreatic islet cell antigen IA-2 (rFab 96/3) (Dr Michael 
Christie, KCL, unpublished), was used as a negative control. Due to the 
number of constructs to be expressed, the large volumes of each 
expression culture and the difficulties involved with the expression of 
constructs (described in detail below), it was decided to express only 
KSAb1, (the more potent of the two TSAbs), for a positive control. For this 
reason KSAb2 was not expressed as rFab for studies in this thesis. The 
methods of rFab expression are summarised in Table 7, page 127 and 
described in detail in Chapter 2, pages 91-93. 
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Table 7: Description of rFab expression methods. 
Expression 
method 
Brief description  
Expression 
method 1 (2 days) 
An LB broth starter culture is inoculated in 1 L of 
complete MOPs medium before induction in 
phosphate-deficient MOPs medium. 
Expression 
method 2 (4 days) 
An LB broth starter culture is inoculated into a 100 
mL starter culture of complete MOPs medium before 
inoculation of 1 L MOPs and induction in phosphate-
deficient MOPs medium. 
Expression 
method 3 (LB 
broth) 
A superbroth starter culture is inoculated in 1 L LB 
broth before induction in phosphate-deficient MOPs 
medium. 
 
3.3.2.1 Expression method 1 (2 days) 
In expression method 1, a single colony was grown in MOPs medium 
(Neidhardt et al., 1974) before sub-culturing in phosphate-deficient 
medium to induce rFab expression (see Chapter 2, section  2.2.2.3) 
(Padoa et al., 2003; Padoa et al., 2005; Padoa et al., 2010). A sample of 
culture was taken both before and after induction to test for rFab 
presence in non-induced and induced cultures to evaluate the efficacy of 
the expression method on the individual constructs. Evaluations were 
  128 
performed by SDS-PAGE analysis with both Coomassie blue staining and 
Western blotting using an anti-penta His tag antibody. The penta His-
tagged H-chain has a MW of approximately 25 kDa and the L-chain has a 
slightly smaller MW. Thus two bands migrating close together at ~ 25 kDa 
are anticipated in Coomassie blue stained gels, and a single band of ~25 
kDa is expected in Western blot analysis.  
 rFab KSAb1 was detected in the induced expression sample with two 
clear bands migrating at 25 kDa following Coomassie blue staining 
(Figure 20, panel A i), and a single band observed at the appropriate MW 
by Western blotting (Figure 20, panel A ii). No rFab band was observed in 
the non-induced sample.  
For rFab germline, positive expression levels were detected in the 
induced sample with two closely spaced bands migrating at ~25 kDa 
following Coomassie blue staining (Figure 20, panel B i) and a single ~25 
kDa band observed by Western blotting (Figure 20, panel B ii). There was 
faint rFab presence observed in the non-induced sample as well due to 
background or ‘leaky’ expression, more clearly observed by Western 
blotting analysis. Leaky expression of rFab through the outer bacterial cell 
membrane in to the culture medium may occur as a result of the bacterial 
strain chosen, expression and induction conditions and also the unique 
amino acid sequence of the individual rFab (Verma et al., 1998). This 
explains why the leaky expression may be seen in some rFab cultures 
and not others, and why leaky expression of some rFabs is higher than 
that seen in others.  
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The presence of rFab 96/3 was confirmed in induced samples as 
observed for rFab KSAb1 and rFab germline. Leaky rFab expression was 
not observed in the case of rFab 96/3 (Figure 20, panel C ii, page 130). 
Although presence of rFab germline, rFab KSAb1 and rFab 96/3 was 
confirmed in induced samples, the rFab levels were not over-expressed 
compared to host cell proteins. It was thought that expression levels 
could be improved over what was obtained using this method of rFab 
expression using an extended method of expression. 
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Figure 20: SDS-PAGE analysis of rFab expression levels in total 
bacterial lysate. 
rFab expression of (A) rFab KSAb1, (B) rFab germline and (C) rFab 
96/3 was analysed in non-induced and induced samples under 
reducing conditions. Expression levels were analysed by (i) 
Coomassie blue staining and (ii) Western blotting using an anti-penta 
His tag antibody. The rFab band is highlighted by a red box and the 
His-tagged H-chain runs at approximately 25 kDa. MWs are in kDa 
and different MW markers were used for Western blotting. 
.. 
(i)          (ii) (i)               (ii) 
(i)                      (ii) 
A B 
C 
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3.3.2.2 Expression method 2 (4 days) 
In an attempt to improve levels of expression and yields of purified rFab, 
two longer starter cultures, measuring the OD600 of the culture growing 
with phosphate, and a longer induction phase were evaluated (Figure 21, 
page 132). This method of expression was devised by Dr Kerry 
McLaughlin, KCL. An expression check of the induced cultures was 
performed prior to purification (see Chapter 2, section  2.2.2.4).  
In this method of expression, a sample of expression culture was taken 
only after induction hence no information was available on the ‘leakiness’ 
of this expression method in non-induced cultures.  The expression levels 
of rFab germline, rFab KSAb1 and rFab 96/3 were analysed by SDS-
PAGE using Coomassie blue staining (Figure 21A) and Western blotting 
using an anti-penta His tagged antibody (Figure 21B). Levels of 
expressed rFab KSAb1, rFab germline and rFab 96/3 were greater than 
those achieved with expression method 1 as more intensely-staining 
bands are observed following Coomassie blue staining. The highest level 
of expression is observed for rFab 96/3 (Figure 21A). The presence of 
rFab was also confirmed by Western blotting with bands observed at 25 
kDa in the induced samples of all three constructs (Figure 21B). This data 
would indicate that expression method 2 is the optimum method of 
expressing rFab germline, rFab KSAb1 and rFab 96/3. 
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3.3.3 Purification of rFabs germline, KSAb1 and 96/3 
3.3.3.1 Purification following expression method 1 
The purification protocol following expression method 1 involved 1 L 
culture volume and 0.5 mL purification resin. This was based on the 
premise that a large culture volume will provide more available rFab for 
purification, whilst a low volume of resin should decrease the surface 
area for non-specific binding. This method of expression and purification 
resulted in an acceptable purity of eluted fractions, although 100% purity 
was not achieved for any rFab preparation. Purified expressed yields 
remained low at 100-150 µg from a litre culture for each rFab.  
Figure 21: Expression check of rFab KSAb1, rFab germline and 
rFab 96/3 following expression method 2 (4 days) in total 
bacterial lysate. 
SDS-PAGE analysis of rFab germline, rFab KSAb1 and rFab 96/3 
under reducing conditions following expression method 2. The levels 
of rFab expression were determined in induced samples by (A) 
Coomassie blue staining and (B) Western blot using an anti- penta His 
tag antibody. The expressed rFab is highlighted by a red box at 25 
kDa. 
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3.3.3.2 Purification following expression method 2 
Expression method 2 had produced high levels of expressed rFab 
germline, rFab KSAb1 and rFab 96/3. Purification resulted in bands of 
rFab at 25 kDa as analysed by Coomassie blue staining (Figure 23A) and 
(i)         (ii) 
Figure 22: Purified rFab preparations following expression method 
1 analysed by SDS-PAGE and Western blot. 
The degree of purity after purification of (A) rFab KSAb1, (B) rFab 
germline and (C) rFab 96/3 was analysed by (i) Coomassie Blue-
stained gel and (ii) Western blot using an anti-penta His tag antibody. 
The expressed rFab is highlighted by a red box at 25 kDa. 
(i)          (ii) A B 
C 
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Western blotting using an antibody to the penta His tag of the H-chain 
(Figure 23B). High levels of purified rFab 96/3 were obtained (1 mg/mL) 
which obscures the presence of the second band of the rFab. This 
combination of expression and purification methods is the optimum for 
expressing and purifying high amounts of rFab 96/3, despite the presence 
of other contaminating E. coli bands. For rFab germline and rFab KSAb1 
there was clear expression of both constructs, although not to the same 
degree as rFab 96/3. There was a high amount of contaminating E. coli 
bands compared to the level of purified rFabs. Of the three constructs, 
rFab germline had the lowest expression levels as seen in the expression 
check suggesting that rFab germline may have lower expression levels 
overall, regardless of the expression method used 
 
The level of purified rFab KSAb1 and rFab germline following expression 
method 1 was comparable to that of the levels of purified rFab KSAb1 
Figure 23: Analysis of purified rFab preparations following 
expression method 2. 
SDS-PAGE analysis of purified rFab germline, rFab KSAb1 and rFab 
96/3 under reducing conditions following expression method 2. The 
purity of rFab expression was determined after purification in by (A) 
Coomassie blue staining and (B) Western blot using an anti-penta His 
tag antibody. The expressed rFab is highlighted by a red box at 25 
kDa. 
  135 
obtained following expression method 2. However there was a purer rFab 
preparations following expression method 1, despite the presence of 
some high and low MW contaminating bands (Figure 22, page 133). 
Therefore expression method 1 and purification was considered the 
optimum conditions for expressing rFab KSAb1 and rFab germline. 
Although the observed yield following the expression method 2 was 
sufficient for testing in functional assays at high concentration, it was not 
taken further as it took longer than expression method 1 without any 
improved results. Purification of rFab 96/3 following expression method 1 
resulted in high purity but did not produce as high a yield of purified rFab 
as expression method 2 (Figure 23). Expression method 2 was chosen as 
the optimum expression method for rFab 96/3. 
3.3.4 Evaluation of integrity of rFab 96/3 preparation 
The ability of purified rFab 96/3 to bind its natural ligand, IA-2, was 
evaluated to ensure that this was a functional rFab capable of binding its 
ligand (Figure 24, page 136). The purified rFab 96/3 was prepared by me 
and the functional assay was performed and analysed by Dr Kerry 
McLaughlin, KCL. This assay was necessary to ensure that if the rFab 
96/3 does not display binding to the TSHR in subsequent assays, it is 
because rFab 96/3 cannot recognise the TSHR, rather than it has not 
folded correctly and cannot recognise any antigen. 
Dr McLaughlin incubated the purified mAb 96/3 (Dromey et al., 2004) with 
radiolabelled IA-2 intracellular region protein alone or with rFab 96/3 at 
varying concentrations. This was incubated with protein A Sepharose, 
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which can bind the mAb 96/3 Fc region and whatever is bound to the 
mAb 96/3 Fab region. Scintillant was added and the counts of 
radioactivity measured on a beta-counter in counts per million (cpm). 
Normal human serum, which should not contain any anti-IA-2 antibodies, 
was used as a negative control. When mAb 96/3 antibody was incubated 
with IA-2 alone, there were radioactivity counts of over 10,000 cpm. In the 
presence of rFab 96/3, even at a 1/100 dilution, the binding of 96/3 
antibody to IA-2 was outcompeted and the radioactivity counts decrease. 
This assay demonstrated that rFab 96/3 is functionally active and can 
bind IA-2 by out-competing its IgG form. 
 
Figure 24: Evaluation of antigen-specificity of rFab 96/3. 
The ability of rFab 96/3 to bind its natural ligand, IA-2 intracellular 
region was first tested to ensure this was a functional rFab. In the 
absence of rFab 96/3, mAb 96/3 IgG is capable of binding 
radiolabelled IA-2. This binding is decreased in the presence of 
varying concentrations of rFab 96/3 as it outcompetes the mAb 96/3 
IgG for binding to IA-2. Dr Kerry McLaughlin, KCL, performed this 
assay. NHS, normal human serum. 
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3.3.5 Evaluation of antigen specificity of rFab germline 
Three different assay systems of varying sensitivity were used to evaluate 
rFab germline for measurable binding to TSHR to ensure that robust 
conclusions could be made of its functional activity, if any.  
3.3.5.1 Interference of E. coli proteins in radioreceptor assay 
The ability of rFab germline to bind the TSHR was evaluated by 
radioreceptor (TRAK) assay, an in vitro assay that can measure the 
inhibition of binding of 125I-TSH to detergent-solubilised TSHR by rFab 
preparations in a commercial kit (Ajjan and Weetman, 2008). The binding 
of the rFab to TSHR is measured by the percentage of 125I-TSH inhibited 
from binding immobilised TSHR coated on tubes.  
As 100% purity was not achieved in any of the purified rFab fractions, we 
first sought to ensure that any contaminating E. coli bands would not 
interfere with any functional assays by measuring the inhibitory capacity 
of rFab in crude bacterial lysates. As it was not possible to determine the 
exact concentration of rFab present in the induced expression culture 
lysates, four volumes of lysate were chosen for testing: 30 µl, 20 µl, 10 µl 
and 3 µl. At a volume of 30 µl, rFab KSAb1 inhibited ≥90% of 
radiolabelled TSH from binding TSHR. This inhibition decreased with 
decreasing volumes of rFab KSAb1. rFab germline did not display any 
ability to compete with radiolabelled TSH for binding to TSHR. 
The results from this preliminary experiment suggest that the presence of 
E. coli bands from the bacterial cell lysate do not interfere with the 
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radioreceptor assay by preventing rFab KSAb1 from binding the TSHR, 
as observed by the ≥90% inhibition of radiolabelled TSH binding. Nor is 
there any non-specific inhibition of TSH as rFab 96/3, the irrelevant 
control, does not display any radiolabelled TSH inhibition. Thus it is likely 
that any contaminating E. coli bands present in the purified rFab samples 
do not interfere with the assay results. 
This experiment was performed on three independent occasions, each 
time with independent rFab preparations. Figure 25 is a representative 
example of these experiments.   
 
Figure 25: Measurement of inhibition of 125I-TSH by rFab total 
bacterial lysates. 
Radioreceptor (TRAK) assay measuring inhibition of 125I-TSH 
binding to immobilised TSHR by rFab lysates. The results are 
expressed as % inhibition of 125I-TSH binding. The cut off for the 
assay is 15%, shown as a dotted line and values above this are 
considered positive in the commercial assay. The assay was 
performed on single samples on three occasions, a representative 
experiment is shown. 
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3.3.5.2 Evaluation of antigen binding specificity of purified rFab 
The preliminary results with rFab bacterial lysates were confirmed using 
purified rFab material of known concentration (Figure 26). At high 
concentrations, purified rFab KSAb1 displays 125I-TSH inhibition 
comparable to that of full-length purified, KSAb1 IgG. At concentrations 
below 30 µg/mL KSAb1 IgG displays a slightly higher level of inhibition. 
At high concentration of purified rFab germline no inhibition of 
radiolabelled TSH is displayed, suggesting that rFab germline does not 
recognise TSHR. However, this radioreceptor assay is insensitive for 
detection of low levels of antibody binding at low levels of inhibition. 
Inhibition of 10-15% of 125I-TSH in the radioreceptor assay kit is 
considered to be in the ‘grey zone’ and hence not amenable to accurate 
measurement. It is possible that rFab germline binds weakly to the TSHR 
but this binding is not detectible using this assay. Flow cytometry and 
cAMP stimulation bioassay were performed as a more sensitive means of 
determining measurable binding of rFab germline to TSHR.  
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3.3.5.3 Evaluation of rFab antigen specificity by flow cytometry  
Flow cytometry was used as a more sensitive method of detecting 
measurable binding of rFab preparations to the TSHR. Flow cytometry 
experiments were performed using GPI9-5 cells, a cell line expressing 
high levels of TSHR A-subunit (500,000 receptors/cell) (Metcalfe et al., 
2002). The GPI9-5 cells already in culture in the laboratory were at a high 
Figure 26: Measurement of inhibition of 125I-TSH by purified rFab 
preparations. 
Radioreceptor (TRAK) assay measuring inhibition of 125I-TSH binding 
to immobilised TSHR by purified rFab.  The results are expressed as % 
inhibition of 125I-TSH binding. The cut off for the assay is 15%, shown 
as a dotted line and values above this are considered positive in the 
commercial assay. The assay was performed on single samples and 
the bars represent SEM of data from three independent experiments.  
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passage number and were observed to be losing their TSHR expression 
(data not shown). Another primary clone of cells at low passage number 
was kindly donated by Dr Philip Watson (University of Sheffield, UK) 
which in flow cytometry experiments showed dramatic improvement in the 
signal of detection.  
The mAb 4C1 (IgG2a) is considered a gold-standard, anti-TSHR mAb and 
was thus selected as the optimum positive control. 1 µg/mL of 4C1 was 
chosen as per the manufacturer’s instructions and titrated with the goat 
anti-mouse IgG secondary antibody conjugated with PE at dilutions of 
1/50, 1,100 and 1/200, as recommended by the manufacturer’s 
specifications. A dilution of 1/100 was shown to be optimal for use with 
IgG preparations whilst a dilution of 1/50 of secondary antibody was 
shown to be optimal for rFab preparations (data not shown). rFab 
germline and other rFab and IgG preparations was tested for measurable 
binding to TSHR at concentrations of 10 µg/mL and 1 µg/mL, based on 
radioreceptor (TRAK) assay data (Figure 26, page 140). Results are 
displayed as percentage of cells bound by antibody (Figure 27A), mean 
fluorescence intensity (MFI) (Figure 27B) and histograms (Figure 27C). 
In Figure 27A, the percentage of cells bound by KSAb1 IgG is higher than 
that for rFab KSAb1 (Figure 27A) at the same concentration. This is not 
surprising as the IgG preparation is divalent and rFab preparations are 
monovalent hence a reduction in avidity is responsible. This response is 
also observed when represented as MFI (Figure 27B). There is a shift to 
the right of the axis away from the negative control peaks for 4C1, KSAb1 
IgG and rFab KSAb1 when displayed as a histogram (Figure 27C). In 
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histogram figures the negative control’s peak is shaded in grey and the 
histogram of the preparations of interest is shown as a blue line. The x-
axis is a log-scale of the fluorescence intensity of the PE fluorochrome 
and the y-axis measures the number of events. No measurable binding of 
rFab germline was observed at either of the tested concentrations. There 
is no shift to the right of the axis or shift away from the negative control’s 
(rFab 96/3) peak (Figure 27C), the number of cells bound by rFab 
germline is 0% (Figure 27A), and the MFI value is not above the MFI 
observed for rFab 96/3 (Figure 27B) 
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Figure 27: Assessment of binding of rFab germline to TSHR 
ectodomain by flow cytometry. 
Flow cytometry with rFab preparations on GPI9-5 cells. Results are 
displayed as (A) Percentage of GPI9-5 cells bound by antibody 
preparations, (B) MFI and (C) histograms. The assay has been 
repeated over five independent experiments with different rFab 
preparations with consistent results; data from one representative 
experiment are shown. Isotype-matched and negative controls are 
shaded in grey. 
B 
C 
A 
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3.3.5.4 Flow cytometric analysis of rFab germline binding to full-
length TSHR expressed by JP09 cells 
Following analysis of rFab germline to the TSHR A-subunit by flow 
cytometry, rFab germline was tested for binding to the full-length receptor 
using JP09 cells. JP09 cells express 90-100,000 receptors per cells 
(Metcalfe et al., 2002; Perret et al., 1990). Due to a shortage of cells, 
KSAb1 IgG was not evaluated in this assay. However following the 
results of Figure 27, it could be predicted that KSAb1 IgG would display a 
weaker binding signal than that of 4C1.  
 In Figure 28, rFab KSAb1, rFab germline and rFab 96/3 are evaluated for 
measurable binding. 4C1 displays approximately 30% binding to JP09 
cells, compared to the 90% binding observed with GPI9-5 cells (Figure 
27). No measurable binding to JP09 cells is observed for rFab KSAb1; 
this is most likely due to the level of receptor expression being too low for 
detection of binding. Thus it is impossible to say whether the lack of 
binding observed for rFab germline is due to a genuine lack of binding to 
TSHR, or because the receptor expression is too low to detect 
measurable binding. This experiment was performed on one occasion. 
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3.3.5.5 cAMP stimulation bioassay  
cAMP is the second messenger of the TSHR, and its production is 
indicative of receptor binding and stimulation, and thus pathogenic 
agonist activity (Dremier et al., 2002; Kopp, 2001). The ability of rFab 
germline to bind and stimulate the receptor was determined by incubating 
the relevant controls and rFab preparations with JP09 cells (Metcalfe et 
al., 2002), and analysing the supernatants for presence of cAMP (Ajjan 
and Weetman, 2008). This is a more sensitive assay than the 
radioreceptor (TRAK) assay, so any weak cAMP stimulation observed as 
a result of rFab germline stimulation would indicate binding and 
Figure 28: Flow cytometric analysis of rFab germline binding to 
full-length TSHR expressed by JP09 cells. 
Flow cytometry with rFab preparations on JP09 cells. The assay has 
been performed on one occasion. Isotype-matched and negative 
controls are shaded in grey. 
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recognition of the TSHR. The assay was performed in duplicate as 
described previously (Gilbert et al., 2006a). 
In this cAMP stimulation bioassay, positive controls included forskolin, a 
direct stimulator of intracellular adenyl cyclase, bTSH, a natural ligand of 
TSHR and KSAb1 IgG. Negative controls included IgG2b, an isotype-
matched control of KSAb1 IgG, and HBSS buffer. Forskolin, bTSH and 
100 µg/mL KSAb1 IgG provided the maximal cAMP response for this 
assay of 500-600 pmol/mL, no cAMP was observed for the negative 
controls. At 100 µg/mL, rFab KSAb1 produced 250 pmol/mL of cAMP, 
approximately half that seen for KSAb1 IgG at the same concentration, as 
has been described before, this is to be expected for monovalent rFab 
fragments produced in bacteria. Although only 2 doses of KSAb1 IgG 
were used, there is a dose-response that confirms the findings of Gilbert 
et al, 2006a who performed a dose-response over a wider range. Padoa 
et al, 2010 performed a dose-response with rFab KSAb1 and rFab 
KSAb2. At high concentration, no cAMP stimulation was observed for 
rFab 96/3 and rFab germline, at either concentration tested, and was 
repeated on three independent occasions wih independently prepared 
rFab.  
Taken together, data from the three assays, including radioreceptor 
assay (Figure 26), flow cytometric analysis (Figure 27) and cAMP 
stimulation (Figure 29), indicates that rFab germline is not capable of 
binding and stimulating the TSHR, providing compelling evidence that 
KSAb1 and KSAb2 are derived from a non-autoreactive germline 
antibody rearrangement.                 
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Figure 29: cAMP stimulation by purified rFab germline. 
Stimulation of TSHR in bioassay by measuring induction of 
intracellular cAMP (pmol/mL) following incubation with purified rFab 
preparations. Statistical significance determined using Mann-Whitney 
test. The p value ranges are indicated in figures as follows: * p>0.05, 
** p>0.01. Error bars = SEM. 
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3.4 Discussion 
Our objective was to study the antigen binding properties of the germline 
precursor of KSAb1 and KSAb2, expressed as rFab to provide 
information on recognition of a thyroid or non-thyroid self-antigen by 
immature B cells, before the antibodies undergo affinity maturation. 
The germline V-region genes were synthesised and cloned in a 
specialised vector for rFab expression in E. coli, named rFab germline. It 
was necessary to optimise the conditions of expression for each of the 
relevant rFab constructs due to high expression variability between. The 
initial method of expression already established in the laboratory (Padoa 
et al., 2010) produced reasonable levels of expression for rFab germline, 
rFab KSAb1 and rFab 96/3 (Figure 22, page 133) but a further extended 
method of expression was evaluated in an attempt to improve expression 
levels (Figure 23, page 134). This extended method of expression did 
produce visibly higher levels of rFab expression, particularly for rFab 
96/3.  
The possibility remains that rFab germline may not fold correctly during 
the expression step to give a functional protein, resulting in no 
measurable binding to the TSHR, or that there was loss of structure upon 
purification. However it is unlikely as the rFab expression protocols 
described here produced active rFab KSAb1 and rFab 96/3, on no 
occasion was inactive rFab produced for either of these constructs. This 
has been the consistent experience in my hands and in the laboratories 
of Dr Michael Christie (KCL) and Dr Christiane Hampe (University of 
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Washington, USA) Thus there is no reason to believe that the lack of 
measurable binding observed for rFab germline is due to inactive rFab 
being produced. It is unlikely that purification has had any negative effect 
on rFab germline’s structure as bacterial lysates showed there was no 
binding observed by radioreceptor assay prior to purification. It is possible 
to analyse rFab germline for correct folding by circular dichroism (CD 
spectra), however, a large amount of highly pure protein is needed for 
such analysis which we have not been able to achieve by any of the 
tested expression methods. Further testing for rFab germline’s binding 
capabilities to an infectious agent are discussed in Chapter 5. 
No measurable binding was observed for rFab germline in any of the 
three methods tested: radioreceptor assay, flow cytometry or cAMP 
bioassay. There are weaknesses to the range of assays used here to 
detect any measurable binding of rFab germline to the TSHR. The 
radioreceptor assay will only display a positive result if the rFab or 
antibody can prevent TSH from binding its active site; similarly, cAMP is 
only produced if the rFab binds the TSH binding site to trigger the 
receptor. GPI9-5 cells, used in flow cytometric experiments, only express 
the TSHR A-subunit (aa 22-289) thus it is possible that the potential 
TSHR epitopes to which rFab germline binds have not been appropriately 
displayed by the three assay systems tested. However as the mice used 
to generate KSAb1 and KSAb2 were immunised with Ad-TSHR289 
(Chazenbalk et al., 2002; Gilbert et al., 2006b) and evidence has shown 
that it is the A-subunit which drives the immune response towards TSHR 
(Mizutori et al., 2008), it is most likely that the relevant TSHR epitopes are 
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expressed by the GPI9-5 cells. Furthermore, the epitope(s) recognised by 
TSAbs are not fully exposed in the full-length TSHR but are revealed 
when the A-subunit is tethered to the cell-surface by a GPI-linker 
(Chazenbalk et al., 2002) thus GPI9-5 cells present the optimum cell line 
for evaluating measurable binding by flow cytometry. Nevertheless, JP09 
cells, which express full-length receptor, were used to evaluate rFab 
germline for binding to the holoreceptor by flow cytometry. However the 
receptor expression of these cells, whilst optimum for cAMP bioassay, is 
too low for detection of rFab KSAb1 binding, therefore it is not a sensitive 
enough method for measuring the weak binding that may occur with rFab 
germline.  
Another method for testing for measurable binding to TSHR would be 
using human and/or murine primary thyrocytes for flow cytometric 
analysis. Advantages of this method would be testing for binding with 
native receptor that would be the closest match to the in vivo receptor 
confirmation and high level of glycosylation (Rapoport et al., 1998). TSHR 
expression in vivo is low and as there is no detection of rFab KSAb1 
binding with JP09 cells, there would certainly be no detection with primary 
cells that express even fewer numbers of receptors. Previous experience 
in this laboratory has found difficulty with loss of receptor expression from 
primary thyrocytes when exposed to tissue culture flasks and thus we 
decided not to pursue this as an experimental method.  
This data indicates that the TSAbs, KSAb1 and KSAb2, arise from non-
autoreactive germline V-region genes, which through extensive SHM 
develop TSAb activity. These findings are in agreement with studies in 
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SLE as in both mouse and human germline reversion studies, most 
pathogenic anti-DNA antibodies, when reverted to their germline 
sequences, lost all or most of their DNA reactivity (Guo et al., 2010; 
Mietzner et al., 2008; Tiller et al., 2007; Wellmann et al., 2005). These 
studies serve to strengthen the evidence that SHM is a driver of 
autoimmune pathogenesis and antibodies can acquire pathogenic 
properties in the periphery.  
It is as yet unknown what defects in central and/or peripheral tolerances 
may allow autoreactivity to TSHR to develop to cause GD in humans. In T 
cell tolerance, both central and peripheral tolerance have been implicated 
in pathogenesis, with a SNP in intron 1 of the TSHR in Caucasian 
populations (Colobran et al., 2011; Płoski et al., 2010) and intron 7 in 
Japanese populations (Hiratani et al., 2005). These SNPs alter the level 
of TSHR expressed in the thymus and thus affect the presentation of 
TSHR to developing thymocytes by mTECs (Colobran et al., 2011). 
Additionally such SNPs also lead to truncated mRNA isoform variants of 
TSHR A-subunit to be expressed, which if immunogenic, could lead to 
GD (Brand and Gough, 2010). With respect to peripheral T cell tolerance, 
there has been conflicting evidence on the presence of either defective 
Treg function or numbers in patients (Mao et al., 2011; Pan et al., 2009) 
and mice (Zhou et al., 2012) whilst depletion of Tregs in mice prior to 
immunisation with TSHR A-subunit did not affect the subsequent anti-
TSHR antibody response compared to non-Treg depleted mice 
(McLachlan et al., 2007).  
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Whilst the data presented here may indicate a defect in peripheral 
tolerance and intact central tolerance, it is unlikely that there would be a 
defect in central tolerance in these mice as this is a not a spontaneous 
form of GD and spontaneous disease would be more likely if there were 
abnormalities in early B cell development. Furthermore, it is unsurprising 
that antibodies acquired TSHR reactivity in the periphery as the mice 
have been immunised with high doses of a foreign antigen, hTSHR, 
which precipitates autoimmunity due to the high degree of sequence 
similarity (87%) with mTSHR (Patibandla et al., 1999).  However, 
peripheral tolerance mechanisms such as anergy, receptor editing or 
deletion should have been initiated when the antibodies to the hTSHR 
began cross-reacting with mouse mTSHR to cause GD.  
3.5 Conclusions 
In conclusion, the germline V-region genes of two highly potent TSAbs 
have been synthesised in a gene cassette for expression as rFab, and 
termed rFab germline. Measurable binding to the TSHR was determined 
using three gold-standard assays: radioreceptor, flow cytometry and 
cAMP stimulation. No measurable binding to TSHR was observed for 
rFab germline. This demonstrates that the two TSAbs, KSAb1 and 
KSAb2, are derived from a non-autoreactive precursor antibody, and 
pathogenicity developed in the periphery through SHM. Subsequent 
chapters in this thesis will investigate further the role of SHM in the H- 
and L-chains of KSAb1 to TSHR recognition, and whether an infectious 
agent played a role in the expansion of an autoreactive B cell clone. 
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4 CHAPTER FOUR: Assessing the contribution of heavy and light 
chains of thyroid stimulating antibodies to TSHR binding and 
stimulation 
4.1 Introduction 
A role for the IGHV genes in the development of TSAbs in inbred mice 
has been reported in recent genetic analysis studies (McLachlan et al., 
2011a; Rapoport et al., 2010). Studies in SLE have further delineated the 
individual roles of the H- and L-chains in determining their binding to DNA 
antigens, dividing their contributions as the H-chain being the dominant 
chain in determining binding to various forms of DNA, whilst the L-chain is 
important, not for binding, but for additional specificities (Ibrahim et al., 
1995; Radic et al., 1991). However the presence of SHM in the L-chain, 
particularly replacement mutations, would suggest that there is antigen-
driven mutation of the L-chain which must be affecting antigen-binding, 
and is thus not a redundant partner to the H-chain. The larger number of 
SHM in the IGHV genes of KSAb1 and KSAb2 compared to the L-chain 
indicates that the IGHV may play a critical role in the strong TSAb 
function of the antibodies.  
This chapter describes various chimeric constructs and their expression 
as rFab molecules to study the individual contribution of the mature H- 
and L-chains of KSAb1 to TSHR binding.  
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4.2 Aims 
Following the results of Chapter 3 demonstrating that two TSAbs 
developed from a non-autoreactive germline precursor, and the published 
literature in other autoimmune diseases demonstrating a dominant role 
for the H-chain in autoantibody activity, the aims of this chapter were as 
follows: 
i. To evaluate chimeric constructs expressed as rFab to characterise 
the individual effects of the H- and L-chain of KSAb1, on binding to 
TSHR, by radioreceptor assay, flow cytometry and cAMP 
bioassay.  
ii. To further assess the dominance of the role of the mature H-chain 
in TSHR recognition, by pairing the mature KSAb1 H-chain with 
the L-chain of another antibody, Ti-401, which recognises a 
bacterial antigen. 
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4.3 Results 
4.3.1 Cloning L-chain chimeric constructs in pAK19 
Two L-chain swap constructs were constructed by excising the L-chains 
from each of the KSAb1 and germline constructs by restriction enzyme 
digest (Figure 30). The excised L-chain from one construct was ligated 
upstream of the H-chain in the other construct (summarised in Table 8). 
In this manner, the mutated mature L-chain of KSAb1 was paired with the 
non-mutated H-chain of the germline construct to form the swap construct 
L-mature, and the non-mutated L-chain of the germline construct was 
paired with the mutated mature H-chain of KSAb1 to form the swap 
construct H-mature. Analysis by restriction digestion showed the L-chains 
migrate at ~0.7 kB and the plasmids containing the H-chain at ~7 kB. 
Both constructs were cloned in pAK19 for expression as rFabs.  
Table 8: Summary of L-chain swap constructs. 
Construct H-chain L-chain 
H-mature Mature (KSAb1) Germline 
L-mature Germline Mature (KSAb1) 
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4.3.2 Expression of swap constructs as rFabs using MOPs protocol 
The two swap constructs were cloned in pAK19 for expression as rFabs. 
The first protocol attempted for this expression was expression method 1 
(described in Chapter 2, section  2.2.2.3, page 91). SDS-PAGE analysis 
of expression was first performed to verify presence of rFab in the 
bacterial culture. In Figure 31A, the rFab L-mature SDS-PAGE analysis of 
expression shows two bands are clearly visible in the induced lane 
migrating at ~25 kDa when stained with Coomassie blue and with an anti-
penta His tag antibody for Western blotting. The higher MW band is the 
H-chain and the smaller MW band is the L-chain. The rFab expression 
with this construct was ‘leaky’ since in the non-induced lane there is a 
faint H-chain band observed by Coomassie blue staining (Figure 31A, 
panel i) and Western blotting (Figure 31A, panel ii). The L-chain is the 
Figure 30: Cloning of swap constructs in pAK19. 
The H- and L-chain genes of the KSAb1 and germline constructs 
were digested and analysed on a 1.2% agarose gel such that their L-
chains could be isolated and chimeric constructs made. M denotes 
the MW ladder in kB. The pAK19 plasmid containing the H-chain 
migrates at 7 kB and the L-chain migrates at 0.7 kB. The plasmid 
constructs were isolated from competent cells expressing a second 
plasmid, pRARE, observed running at 5 kB below the pAK19 band. 
  158 
strongest band of the two as the pAK19 plasmid over-expresses the L-
chain to a higher degree than the H-chain. There is stronger rFab 
expression in the induced sample. 
However, SDS-PAGE analysis of expression for rFab H-mature (Figure 
31B, panel i) shows only one band when stained with Coomassie blue, 
the smaller MW L-chain, suggesting little to no expression of the H-chain 
peptide. This lack of expression was confirmed by Western blotting with 
no bands observed (Figure 31B, panel ii). The pellet size of rFab H-
mature cultures before and after induction were also much smaller than 
that of other rFab cultures, suggesting that the low expression levels of 
rFab H-mature may be due to a lack of competent cell growth, rather than 
a failure of the induction step. One possible reason may be the rFab H-
mature may be toxic to the competent cells grown in MOPS medium, 
preventing their replication and the amount of cells available to secrete 
rFab.  
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Whilst another expression method was needed for optimal expression of 
rFab H-mature, expression method 1 was seen as optimal for rFab L-
mature expression and this culture was used for purification (Figure 32). 
From 1 L expression culture, 1 mg/mL of rFab L-mature was obtained. It 
appears that the higher the level of rFab expressed in the preparation, the 
higher the purity of the eluted fractions. This may be because there is 
more rFab present to out-compete any non-specific binding from any 
potentially contaminating E. coli proteins.  
Figure 31: SDS-PAGE and Western blot analysis of expression of 
rFab L-mature and rFab H-mature using MOPs protocol. 
SDS-PAGE analysis of rFab expression levels prior to purification. (A) 
rFab L-mature expression analysed by (i) Coomassie blue staining and 
(ii) Western blot using an anti-His tag antibody and (B) rFab H-mature 
expression analysed by (i) Coomassie blue staining and (ii) Western 
blot using an anti-His tag antibody. MWs are in kDa. rFab is observed 
at approximately 25 kDa, a red box highlights the rFab bands.  
 
(i)             (ii) (i)             (ii) 
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4.3.3 Expression of swap constructs as rFabs using expression 
method 3 (LB broth) 
Dr Christiane Hampe (University of Washington, Seattle, USA) suggested 
an alternative method (expression method 3, Chapter 2, section  2.2.2.5, 
page 93) to improve the levels of rFab H-mature expression. A single 
colony was grown in the modified nutrient-rich superbroth medium during 
the day and overnight in LB broth before inducing in phosphate-deficient 
MOPs medium.  
Compared to the previous expression protocol, the pellets of H-mature 
culture before and after induction were much larger, suggesting the 
competent cells were proliferating without inhibition, or with less inhibition. 
The expression of rFab H-mature under this expression protocol was 
verified before purification (Figure 33).  
Figure 32: SDS-PAGE and Western 
blot analysis of Purified rFab L-
mature. 
SDS-PAGE analysis of purified rFab L-
mature measured by (i) Coomassie 
blue staining and (ii) Western blotting 
using an anti-His tag antibody. High 
yields of purified material were obtained 
using the MOPs expression protocol 
(>1mg/mL culture). The rFab band is 
observed at approximately 25 kDa and 
is highlighted by a red band. 
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This SDS-PAGE (Figure 34, panel i) and Western blot (Figure 34, panel 
ii) analysis shows expression method 3 to be the optimum expression 
protocol for rFab H-mature as there are visible bands of approximately 25 
kDa in the induced samples. There are no visible rFab bands in the 
Western blot analysis of non-induced samples showing that there is no 
leaky expression before induction, like that seen in rFab L-mature (Figure 
32). The rFab H-mature culture was purified and 100 µg/mL was obtained 
from a 1 L culture. The purified material was thus of a lower yield than 
that obtained for rFab L-mature, but comparable to those of rFab KSAb1 
and rFab germline. The purified preparation was also of high purity, 
demonstrating that expression method 3 is the optimum method of 
expressing rFab H-mature (Figure 34). 
Figure 33: SDS-PAGE and Western blot analysis of rFab H-mature 
expression level before purification following expression method 3 
(LB broth). 
SDS-PAGE analysis of expression levels of rFab H-mature measured 
by (i) Coomassie blue staining and (ii) Western blotting using an anti-His 
tag antibody. The rFab band is observed at approximately 25 kDa and is 
highlighted by a red band.  
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4.3.4 Measurement of inhibition of radiolabelled TSH by chimeric 
constructs expressed as rFab 
rFab L-mature and rFab H-mature cultures were purified and a dose-
response of known concentrations of purified materials was evaluated for 
their ability to inhibit radiolabelled TSH binding to TSHR. As before 
(Chapter 3, Figure 26, page 140) KSAb1 IgG and rFab KSAb1 inhibited 
>90% of radiolabelled TSH which decreased with lower concentrations, 
and no inhibition was observed for the negative control, rFab 96/3. rFab 
L-mature did not display any measurable binding at any of the 
concentrations tested, whilst high concentration (100 μg/mL) of rFab H-
mature inhibited approximately 35% of radiolabelled TSH from binding 
TSHR. This degree of inhibition was only apparent at high concentrations 
since lower concentrations did not show any measurable inhibition 
(Figure 35).  
Figure 34: SDS-PAGE and Western 
blotting analysis of purified rFab H-
mature following expression method 3 
(LB broth). 
SDS-PAGE analysis of purified rFab H-
mature by (i) Coomassie blue staining 
and (ii) Western blotting using an anti-His 
tag antibody. Purification yield was 
improved using the LB expression 
protocol, over the MOPs expression 
protocol. The rFab is observed at 
approximately 25 kDa and is highlighted 
by a red box.  
kDa    (i)         (ii) 
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4.3.5 Characterisation of the role of the H-chain by pairing with an 
irrelevant L-chain 
To further characterise the role of the H-chain in TSHR binding, a third 
chimeric construct was generated by using an L-chain from a non-TSHR 
specific antibody. rFab L-irrelevant is formed of the mature H-chain of 
KSAb1 paired with the mature L-chain of rFab Ti-401 (gift from Dr 
Hampe, Seattle, USA). rFab Ti-401 is a murine antibody that recognises 
Figure 35: Measurement of inhibition of 125I-TSH by purified rFab 
preparations. 
Radioreceptor (TRAK) assay measuring inhibition of 125I-TSH binding to 
immobilised TSHR by purified rFab preparations. The results are 
expressed as % inhibition of 125I-TSH binding. The ‘grey zone’ of the 
assay is 10-15%, shown as a dotted line and values above this are 
considered positive in the commercial assay. The assay was performed 
on single samples and the bars represent SEM of data from three 
independent experiments, except purified rFab H-mature which was 
tested once. 
rFab L-Mature 
rFab H-Mature 
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a bacterial antigen, Chlamydophila pneumoniae. The L-irrelevant cDNA 
construct was cloned in pAK19 vector for expression as rFab (Figure 36).  
 
rFab L-irrelevant was expressed using expression method 3 and purified 
to homogeneity by metal chelation. Purified rFab material was analysed 
by SDS-PAGE and the presence of rFab was confirmed by Western 
blotting (Figure 37, page 164). A relatively low concentration of rFab L-
irrelevant was obtained, and there are some high and low MW 
contaminating bands.  
 
Figure 36: Digestion of Ti-401 for L-irrelevant 
cloning. 
Constructs of Ti-401 and KSAb1 were digested with 
EcoRI/BsrGI for excision of digested L-chains for 
ligation as the L-irrelevant construct. Digested gene 
products were analysed by 1.2% agarose gel 
electrophoresis; the pAK19 plasmid containing the 
H-chain migrates at 7 kB and the L-chain migrates at 
0.7 kB 
Figure 37: SDS-PAGE and Western blot 
analysis of purified rFab L-irrelevant. 
SDS-PAGE analysis of purified L-
irrelevant construct by (i) Coomassie blue 
staining and (ii) Western blot using an 
anti-His tag antibody. The rFab is 
observed migrating at 25 kDa and is 
highlighted by a red box. 
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4.3.6 Measurement of inhibition of radiolabelled TSH by purified 
chimeric constructs expressed as rFab 
Purified rFab L-irrelevant, alongside purified rFab L-mature and rFab H-
mature were evaluated in radioreceptor assay for their ability to inhibit 
radiolabelled TSH from binding TSHR (Figure 38, page 166). 
Furthermore, rFab preparations were tested on a semi-log scale following 
the sharp decline in inhibition observed for rFab H-mature after 100 
µg/mL (Figure 35, page 163). rFab H-mature displays inhibition only at 
high concentration of 100 µg/mL, with 30 µg/mL displaying inhibition 
slightly below the cut-off for positive inhibition. The radioreceptor assay 
was repeated three times with independently expressed rFab 
preparations each time, except rFab L-irrelevant was tested on one 
occasion.  
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4.3.7 Flow cytometric analysis 
Purified chimeric constructs were further tested for measurable binding to 
TSHR by flow cytometry. The gold standard anti-TSHR mAb, 4C1, was 
used as positive control, and concentrations of 10 µg/mL and 1 µg/mL 
were used for all other mAbs and rFab preparations, as in Chapter 3, 
Figure 27, page 145. Isotype-matched controls were used as negative 
Figure 38: Measurement of inhibition of radiolabelled TSH by 
purified rFab preparations. 
Radioreceptor (TRAK) assay measuring inhibition of 125I-TSH binding 
to immobilised TSHR by purified rFab preparations.  The results are 
expressed as % inhibition of 125I-TSH binding. The ‘grey zone’ of the 
assay is 10-15%, shown as a dotted line and values above this are 
considered positive in the commercial assay. The assay was 
performed on single samples and the bars represent SEM of data 
from three independent experiments, except purified rFab L-
Irrelevant which was tested once. 
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controls for anti-TSHR antibodies and rFab 96/3 served as a negative 
rFab control. Results were expressed as the number of cells bound by 
the test mAb or rFab (Figure 39A, page 169), by MFI (Figure 39B) and 
histograms (Figure 39C). In Figure 39C, there are a slightly higher 
proportion of cells not bound by antibody in panels for positive controls 
such as 4C1 and KSAb1 IgG, seen as small peaks in the bottom left 
corner of the panel. Almost 70% of cells were bound by 1 µg/mL 4C1 and 
50% of cells bound by 10 µg/mL of KSAb1 IgG. It has been observed in 
this laboratory that the longer the GPI9-5 cells are kept growing in culture, 
i.e. the higher the number of cell passages, the lower the percentage of 
cells bound by 4C1 when analysed by flow cytometry. 
Dose-dependent decreases in the percentage of cells bound by antibody 
and in the MFI were observed for positive controls KSAb1 IgG and rFab 
KSAb1.  No measurable binding was observed with any of the negative 
controls. The lack of measurable binding observed for rFab L-mature in 
the radioreceptor assay (Figure 38, page 166) was repeated by flow 
cytometry, as no cells were bound and there was negligible MFI 
observed. No measurable binding was also observed for rFab L-
irrelevant. Interestingly, no measurable binding was observed for rFab H-
mature. It could be that the high concentration of 100 µg/mL is necessary 
for measurable binding when analysing by flow cytometry, as was the 
case for the radioreceptor assay. It is unlikely that binding observed in the 
radioreceptor assay is an artefact as it was repeated on three separate 
occasions, with an independently prepared rFab sample on each 
occasion with consistent results. There is precedence for various anti-
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TSHR antibodies showing differing binding to TSHR in flow cytometry as 
observed with 4C1 and KSAb1. However, as rFab H-mature is capable of 
displacing 125I-TSH, this would indicate its epitopes are located within the 
TSH binding region of the TSHR, which is expressed by GPI9-5 cells.  
The flow cytometry was repeated three times with independently 
expressed rFab preparations each time, except rFab L-irrelevant was 
tested twice. The data shown is a representative experiment.  
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Figure 39: Flow cytometric analysis of chimeric constructs 
binding to TSHR. 
Flow cytometry with rFab preparations on GPI9-5 cells. (A) Percentage 
of cells bound by mAb and rFab preparations, (B) MFI, (C) histogram 
overlay. 
A 
C 
B 
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4.3.8 Stimulation of cAMP by purified rFab chimeric construct 
preparations 
Following the positive response in radioreceptor assay, but negative 
response in flow cytometry, it was necessary to confirm this result with 
cAMP stimulation of the receptor would signify binding (Ajjan and 
Weetman, 2008). However, it is possible that rFab H-mature may be 
capable of binding TSHR but not of stimulating, in that case another 
method of confirming binding would be needed. 
As before, forskolin, bTSH and KSAb1 IgG are positive controls and 
provide guidance on the maximal cAMP response possible for the assay; 
buffer and IgG2b are negative controls. rFab KSAb1 stimulated 250-300 
pmol/mL cAMP, approximately half that observed for KSAb1 IgG.  rFab L-
mature did not stimulate any cAMP production, consistent with the 
findings in the other two assays that rFab L-mature does not display any 
measurable binding of the TSHR. rFab H-mature, however, did produce 
statistically significant cAMP responses of 25-80 pmol/mL at both 100 
and 10 µg/mL, with a higher response at 10 µg/mL (Figure 40, page 171). 
This data confirms the binding observed in the radioreceptor assay, and 
suggests that flow cytometry is not an optimum assay for assessing rFab 
H-mature’s functional activity. This data demonstrates the superiority of 
the cAMP bioassay over the radioreceptor assay and flow cytometry in 
detecting weak but measurable binding to TSHR. However, it can only 
detect this measurable binding if the antibodies possess agonist activity. 
It is possible that rFab L-mature and rFab L-irrelevant display weak 
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binding that radioreceptor and flow cytometry are too insensitive to 
detect, but do not stimulate cAMP production, similar to the results for 
rFab germline.  
The cAMP assay was performed in duplicate as described previously 
(Gilbert et al., 2006a), and repeated on three separate occasions with 
independently expressed rFab preparations, except rFab L-irrelevant 
which was tested once.  
 
Figure 40: cAMP stimulation by purified rFab preparations. 
Stimulation of TSHR in bioassay by measuring induction of intracellular 
cAMP (pmol/ml) following incubation of JP09 cells with purified rFab 
preparations. Statistical significance determined using Mann-Whitney 
test. The p value ranges are indicated in figures as follows: * p>0.05, ** 
p>0.01. Error bars = SEM. 
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4.4 Discussion 
The role of SHM in autoimmunity has previously been established in SLE 
by reverting antibodies to the germline sequence and their resulting loss 
of autoreactivity. Chapter 3 of this thesis has directly implicated SHM in 
GD and the development of TSAbs from a non-autoreactive precursor. 
This chapter sought to distinguish whether the mature H- and L-chains of 
KSAb1 play a dominant or contributory role in TSHR recognition. Due to 
the time constraints of this thesis and the number of potential mutations 
to choose from, 29 in the KSAb1 H-chain and 8 in the L-chain, we 
decided to investigate the total contribution of SHM in each chain to 
binding the TSHR rather than selecting individual mutations for 
evaluation. Three constructs were created (i) rFab L-mature, (ii) rFab H-
mature and finally, following the data of rFab H-mature, we created a third 
construct (iii) rFab L-irrelevant (Chapter 2, Table 4, page 90). These 
constructs were cloned and expressed as rFab and tested for binding to 
TSHR in the three assays described in Chapter 3: radioreceptor assay, 
flow cytometry and cAMP bioassay.  
Our results demonstrate a dominant role for the mature H-chain in TSHR 
binding. This is the first time this has been shown for TSAbs at a 
molecular level. Recent genetic studies using linkage analysis in inbred 
mice strains have highlighted the importance of the IGHV in the 
development of TSAbs (McLachlan et al., 2011a; Rapoport et al., 2010). 
Furthermore, our data with rFab H-mature and rFab L-mature supports 
observations in studies of SLE anti-DNA antibodies. When pairing the 
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3H9 H-chain with the majority of random L-chains, DNA binding was 
unaffected; however certain L-chains blocked DNA binding altogether. 
3H9 was paired with mature L-chains rather than the germline revertant 
of its original L-chain, and the mature L-chains were derived from other 
anti-DNA antibodies (Ibrahim et al., 1995). Thus it is of interest to pair the 
KSAb1 H-chain with both the mature L-chain from another TSAb that 
uses different germline genes. Pairing the H-chain of KSAb1 with the 
mature L-chain of KSAb2 resulted in altered activity compared to the 
parent antibodies (Padoa et al., 2010). Additionally, it may be of interest 
to pair the KSAb1 H-chain with the germline revertant of another non anti-
TSHR irrelevant L-chain. The germline revertant IGLV genes of Ti-401 
were not available for our studies. This may help ascertain whether 
KSAb1 H-chain may be paired with any combination of germline L-chain 
genes and still maintain binding to TSHR as rFab L-irrelevant is the 
pairing of two chains which have both undergone affinity maturation for 
two separate antigens. Whilst rFab H-mature was able to overcome the 
lack of binding conferred by the germline L-chain, it could not overcome 
the lack of TSHR binding, and affinity for another antigen, conferred by 
Ti-401’s L-chain. 
Interestingly, in studies of anti-idiotypic antibodies for autoantibodies 
isolated from Pemphigus Vulgaris patients, it was demonstrated that 
when rabbits were immunised with scFv forms of pathogenic mAbs to 
generate anti-idiotypic antibodies, the H-chain was the key antigenic 
target. When the L-chains of the various scFv were swapped, the sera 
could still bind to the scFv provided that the H-chain remained the same 
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as that of the immunising scFv (Payne et al., 2007). It would thus be off 
interest to further delineate the mutation(s) of interest in the H- change 
that are most involved with TSHR binding, as well as investigating the 
feasibility of generating anti-idiotypic antibodies to KSAb1 and KSAb2. If 
anti-idiotypic antibodies are generated, it could be of biologic relevance if 
the H-chain was the key antigenic target as this would reinforce the data 
described here highlighting the dominant role of the H-chain and present 
a potential therapeutic option. 
4.5 Conclusions 
In conclusion, this data demonstrates for the first time to our knowledge, 
the dominant role at a molecular level of the H-chain in determining 
binding to TSHR. Although the L-chain does not have a dominant role in 
TSHR binding, it is critical for antigen binding as replacement with an 
irrelevant L-chain leads to loss of all binding. Further work may centre on 
investigating the individual SHMs in the H-chain that are most important 
for conferring TSHR binding.  
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DETERMINING BINDING OF THYROID 
STIMULATING ANTIBODIES AND RFAB GERMLINE 
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5 CHAPTER FIVE: Evaluating binding of thyroid stimulating 
antibodies and rFab germline to Y. enterocolitica antigens  
5.1 Introduction  
5.1.1 Role of infectious agents in autoimmune disease 
Microorganisms including bacteria and viruses may trigger autoimmunity 
in genetically susceptible individuals or accelerate disease progression. 
As has been previously discussed in section  1.7.4 (page 59) on genetics 
and GD, the concordance rate of disease amongst monozygotic twins is 
not 100% (Brix et al., 1998a) implicating a role for environmental factors. 
In the case of autoimmune disease where there the concordance rate 
amongst twins is not 100%, the scenario may be that the affected siblings 
contracted an infection that increased susceptibility to disease or the non-
affected siblings may be protected from disease by microbial agents 
(Chervonsky, 2010). Infectious agents may have a role to play in 
autoimmune disease, either in disease susceptibility or protection; 
however there is little conclusive evidence for the exact mechanism of 
action of the reported infectious agents and no pathogens have been 
compellingly isolated from an autoimmune-affected organ (Ruiz-Riol et 
al., 2011). The infectious agent may have been eliminated long before the 
disease’s clinical phenotype becomes apparent making it difficult to 
associate a particular infection with disease susceptibility (Albert and 
Inman, 1999). 
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5.1.2 Yersinia enterocolitica 
Y. enterocolitica is an infectious agent which has been implicated as a 
susceptibility factor for GD. Y. enterocolitica is a gram-negative 
enterobacterium that uses a Type III secretion system (Cornelis, 2002; 
Wren, 2003). There are six biotypes of Y. enterocolitica: 1A, 1B, 2, 3, 4, 
and 5 which include numerous serotypes that are defined by their 
expression of a specific O-antigen (lipopolysaccharide). The prevalence 
of certain serotypes varies geographically. Serotypes O:3 and O:9 are 
more prevalent in Europe, O:3 in Japan and O:8 in North America. The 
main symptom of Y. enterocolitica infection in humans is diarrhoea but 
can lead to appendicitis and acute mesenteric lymphadenitis and it is 
thought to be a food- or water-borne pathogen (Fredriksson-Ahomaa et 
al., 2006). It has also been implicated in reactive arthritis in HLA-B27-
positive individuals (Schiellerup et al., 2008).  
Biotypes 1B and 2-5 are considered pathogenic whilst biotype 1A is 
considered non-pathogenic (Huovinen, 2010). The virulence of the Y. 
enterocolitica biotypes is dependent on the expression of the pYVe 
virulence plasmid. pYVe encodes the type III secretion system which the 
bacterium uses to transport its effector proteins, Yersinia outer proteins 
(Yops), into the target cell (Viboud and Bliska, 2005), Figure 41, page 
179. 
Outer membrane porin proteins  
As a gram negative bacterium, Y. enterocolitica has an outer and an inner 
membrane (Figure 41). Outer membrane proteins and porins (Omps) may 
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be divided into non-specific (or classical) porins, for example of OmpC 
and OmpF, and specific porins, for example, OmpA. The two groups of 
porins differ in terms of their structure and function (Nikaido, 2003). Omps 
are located in the outer membrane of Y. enterocolitica and are thus 
exposed to the immune system (Białas et al., 2012).  
OmpA functions as a membrane stabiliser by interacting through its C-
terminus with peptidoglycan (Nikaido, 2003). It is thought that OmpA is 
formed of two-domains, although its exact confirmation remains 
controversial. At the N-terminus 8 β-sheets create a small pore in the 
outer membrane whilst the C-terminus is located in the periplasm where it 
interacts with the peptidoglycan layer (Reusch, 2012). The crystal 
structure of its N-terminal domain has been resolved (Pascal et al., 2010) 
(Figure 41B). OmpC and OmpF are trimeric proteins with each 
monomeric subunit formed of 16-stranded anti-parallel β-sheets (Figure 
41C). They function to allow the passage of small nutrients across the 
outer membrane, with some preference over cations over anions and 
OmpF preferentially transporting slightly larger molecules than OmpC 
does (Nikaido, 2003).  
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Figure 41: Y. enterocolitica: Type III secretion system and inner 
and outer membranes.  
(A) The bacterial cell surface of Y. enterocolitica including porins 
(Omps). Figure taken from (Białas et al., 2012). CW, cell wall; ECA, 
enterobacterial common antigen; IM, inner membrane; LPS, 
lipopolysaccharide; OM, outer membrane; OMP, outer membrane 
protein; PS, periplasmic space. (B) crystal structure of OmpA at 2.5 Å 
resolution (Pascal et al., 2010). (C) crystal structure of trimeric OmpF 
at a 1.6 Å resolution (Yamashita et al., 2008). 
B 
A 
C 
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5.1.2.1 Implications with GD  
Patient studies  
A link between GD and Y. enterocolitica was first proposed four decades 
ago (Bech et al., 1974) yet to date it remains a controversial and 
inconsistent subject with no definitive answer on the role of Y. 
enterocolitica in GD susceptibility and pathogenesis. The initial link 
between Y. enterocolitica was first established following the discovery of 
agglutinating antibodies to the O-antigen of serotype O:3 in patients with 
GD and thyrotoxicosis using the tube agglutination method. This study 
showed the presence of such antibodies was statistically significant when 
compared to a control group of patients with non-toxic goitre (Bech et al., 
1974). Similarly, sera from patients infected with Y. enterocolitica O:3 
displayed binding to a cytoplasmic antigen of thyroid epithelial cells as 
measured by immunoflourescence. This binding disappeared following 
absorption of the sera with sonicated Y. enterocolitica, suggesting cross-
reactivity between thyroid and bacterial antigens. No yersiniosis patient 
showed signs of thyroid disease (Lidman et al., 1976).  A significant 
finding came from the discovery of a saturable binding site for TSH in Y. 
enterocolitica under non-physiological conditions. TSH binding sites have 
also been demonstrated in strains of E. coli (Weiss et al., 1983). Another 
study confirmed the presence of such a binding site in a study where total 
Ig from 5 of 7 GD patients significantly inhibited 125I-TSH binding to 
thyroid membranes and 4 of those 5 to Y. enterocolitica under 
physiological conditions. Control immunoglobulins did not display any 
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inhibition of 125I-TSH binding to either thyroid membranes or Y. 
enterocolitica, however only 2 control samples were evaluated (Heyma et 
al., 1986). In another study, varying concentrations of IgG from patients 
recovering from Y. enterocolitica infection were shown to inhibit TSH 
binding and stimulate cAMP activity in thyroid membranes, despite no 
sign of thyroid dysfunction in any of the patients. IgG from normal controls 
did not display any TSHR stimulation (Wolf et al., 1991). A Danish case-
control study and a Danish discordant twin study found that the GD-
affected individual had a higher prevalence of anti-Yop IgA and IgG 
compared to controls. The authors speculate that the class-switched anti-
Yop antibodies suggest chronic Y. enterocolitica infection (Brix et al., 
2008). 
However not all studies have confirmed a link between GD and Y. 
enterocolitica infection. A Canadian study did not find any significant 
differences between sera from 44 GD patients and controls as measured 
by Western blotting, ELISA or the test agglutination method (Resetkova 
et al., 1994). A recent prospective study did not find a link between the 
development of GD and Y. enterocolitica. This study only looked for the 
presence of anti-Yop antibodies in the patient sera, and not for antibodies 
to the total bacterium (Effraimidis et al., 2011).  
Mouse studies  
Experimental studies have immunised CBA/J and C57BL6/J mice with 
total Y. enterocolitica bacteria and analysed the serum for anti-TSHR 
antibodies (Luo et al., 1993; Luo et al., 1994). Antibodies to TSHR 
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developed which cross-reacted with antigen(s) from an envelope protein 
preparation of Y. enterocolitica. The mice remained euthyroid and thyroid 
histology remained normal but it is possible that histological changes are 
a symptom of chronic disease (Flynn et al., 2007) and were studied too 
early to detect changes (Luo et al., 1993; Luo et al., 1994). No attempt to 
reproduce the findings of Luo et al has been published and thus the 
findings remain uncorroborated. It has since been shown that BALB/c 
mice are a better model of studying GD than CBA/J and C57BL6/J mice, 
which are resistant to induced hyperthyroidism, and this could explain the 
euthyroid status of the immunised mice (Nagayama et al., 2002). 
Additionally total bacterium may provide antigenic competition and so a 
robust immune response capable of generating TSAbs was not 
generated. 
Outer membrane porin proteins 
Bioinformatic modelling has demonstrated homology between the TSHR 
A-subunit and proteins from Y. enterocolitica (Benvenga et al., 2004; 
Benvenga et al., 2006). OmpM was reported to have a high degree of 
sequence homology with the TSHR (Guarneri et al., 2011). However this 
report featured inconsistencies between the sequence alignments, with 
TSHR and OmpM sequences being mislabelled. In another study, a 
biological association between GD and OmpF was demonstrated using 
GD patient sera in combination with mass spectrometry, which identified 
OmpF of Y. enterocolitica as the cross-reactive antigen with TSHR (Wang 
et al., 2010). OmpF antiserum was also shown to induce weak but 
statistically significant cAMP responses in CHO cells transfected with 
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TSHR holoreceptor and in thyroid follicular cells. The data was further 
substantiated using a neutral anti-TSHR mAb, mAb A9, to identify aa 
homology between TSHR and OmpF, where 5 residues from a sequence 
of 8 were shown to be identical between TSHR (residues 198-205) and 
OmpF (residues 190-197), as shown below, with common residues 
highlighted in bold: 
TSHR: 198 DAFGGVYS 205 
OmpF: 190 DALGNVTS 197 
Discrepancies between published studies 
Inconsistencies between patient studies may stem from using serum or 
total IgG from patients that will contain a mix of anti-thyroid IgG amongst 
other specificities, rather than using purified anti-TSHR mAbs. As has 
been previously discussed, anti-TSHR antibodies are present in very low 
concentrations in patient serum and thus would make a very small 
proportion of the total IgG used in studies. Furthermore, of the small 
proportion of anti-TSHR antibodies, there is heterogeneity amongst this 
population with stimulating, blocking and neutral antibodies with varying 
epitopes. This heterogeneity amongst the anti-TSHR antibodies could be 
affected by the treatment undergone by the patient. It is also unknown 
which subtype of anti-TSHR antibody (TSAb, TSBAb, neutral) is cross-
reacting with a Y. enterocolitica protein, if at all. Thus it could be that a 
particular patient’s serum or the pooled sera from a group of patients 
could have an over-representation of a particular antibody subtype that 
does not cross-react with a Y. enterocolitica protein. It is also possible 
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that the antibodies have a low-affinity for the bacterial antigen and this 
binding may not be measurable when serum is diluted for evaluation.  
Variation between studies may come from differences in patient exposure 
to Y. enterocolitica and the genetic and environmental background of the 
patients and the diagnostic criteria. Additionally, differences in the 
methods used to culture and measure Y. enterocolitica may impact, 
particularly as the temperature the Y. enterocolitica are cultured in can 
have a dramatic effect on the expression of various genes proteins 
(Rohde et al., 1994).  
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5.2 Aims 
No studies have been conducted to evaluate whether or not there is 
cross-reactivity between monoclonal TSAbs and Y. enterocolitica. The 
aims of this chapter were therefore to investigate the cross-reactivity of 
KSAb1, KSAb2 and rFab germline to Y. enterocolitica proteins using 
whole cell lysates, envelope proteins and isolated effector Yops from two 
serotypes previously studied in the GD literature, O:3 and O:8. The aims 
of this chapter were: 
i. To evaluate whether TSAbs KSAb1 and KSAb2 cross react with Y. 
enterocolitica proteins, which may indicate a role for microbial 
infection and molecular mimicry in the pathogenesis of GD. These 
would be the first studies to examine monoclonal TSAbs in the 
context of molecular homology between TSHR and Y. 
enterocolitica  
ii. To evaluate the binding of rFab germline to Y. enterocolitica. 
These experiments would be the first studies to examine the role 
of infection in potentially expanding precursor B cells to mature 
TSAbs. 
iii. To evaluate cross-reactivity between the neutral anti-TSHR mAb, 
mAb A9, and other porins such as  to OmpC and Omp A to 
ascertain if other porins may also be involved in the pathogeneses 
of GD, following the report of Wang et al, 2010. 
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5.3 Results 
5.3.1 Confirming presence of pYVe plasmid in Ye58/03 and 8081 
serotype colonies 
We first sought to evaluate whether rFab germline, KSAb1 and KSAb2 
recognised Yops, as binding of Yops has been reported in the literature 
for GD patient serum samples (Brix et al., 2008). Expression of Yops is 
dependent on expression of the pYVe plasmid. PCR was thus performed 
to confirm that each red colony expressed the pYVe plasmid. A 300 bp 
yscU gene product encoded by the pYVe plasmid was amplified as proof 
of plasmid expression.  
For 8081, half of a single colony was chosen for PCR, and the remaining 
half was grown overnight. As there were no easily identifiable single 
colonies for Ye58/03, a small streak was taken for PCR analysis. Strong 
expression of the pYVe plasmid was observed in the O:8 colony, with 
weaker expression observed for O:3, this is to be expected as single 
colonies could not be obtained from culture plates (Figure 42). 
  
Figure 42: Confirmation of pYVe expression by Y. enterocolitica 
serotypes 8081 and Ye58/03 by PCR. 
The yscU gene of the pYVe plasmid was amplified by PCR to confirm 
expression of the plasmid which is necessary for Yop production. 
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5.3.2 Isolation of effector Yop proteins from Y. enterocolitica 
serotypes 8081 and Ye58/03 
Both serotypes of Y. enterocolitica were cultured for Yop expression and 
analysed by SDS-PAGE with Coomassie blue staining (data not shown). 
Neither serotype produced visible Yops, despite the confirmed presence 
of pYVe in serotype O:8. Our collaborators, Mr Marco Grasso and Dr 
Steve Atkinson (University of Nottingham, UK) had experienced 
previously difficulty in expressing Yops in the O:8 serotype.  
It was therefore decided to use frozen samples of Yops isolated from 
serotype O:8 from a previous successful experiment of Mr Marco Grasso 
(Figure 43, page 187). Thus, serotype O:3 was not used for further Yop 
isolation experiments for this thesis.  
 
Figure 43: Isolated Yops from serotype 
O:8. 
Mr Marco Grasso donated expressed Yops 
from a previous experiment using the O:8 
serotype. 
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5.3.3 Determining measurable binding of TSAbs and rFab germline 
to Yops 
At the time of performing the experiment, no anti-Yop antibodies were 
available to us to use as positive control for Western blotting experiments. 
Instead, whole mouse cell lysate containing vinculin antigen and mouse 
anti-vinculin primary antibody (both kindly donated by Dr Yolanda Calle, 
KCL) were used as positive control for the alkaline phosphatase-
conjugated secondary anti-mouse antibody and the BCIP/NBT secondary 
conjugate. A band was observed migrating at approximately 120 kDa 
(Figure 44, page 188), which is to be expected for the 116 kDa vinculin 
protein.  
 
Binding to the isolated Yops was evaluated with KSAb1 IgG, KSAb2 IgG 
and rFab germline, all at 10 µg/mL. Due to the paucity of purified Yops 
available to us, and the difficulty involved in their isolation, no Yop 
samples were available for evaluation with isotype controls. No visible 
bands were observed with any of the antibodies (Figure 45, page 189), 
Figure 44: Positive control: Vinculin. 
To confirm the activity of the alkaline-phosphatase 
antibody and conjugate system, a mixed cell lysate 
containing vinculin protein was incubated with a murine 
anti-vinculin primary antibody, followed by the alkaline 
phosphatase reagents. A band was found at the 
expected MW, at ~120 kDa (highlighted by a box). 
Vinculin is known to be 116 kDa. 
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and the experiment was performed on two independent occasions as it 
was considered important to confirm the lack of binding observed.  
 
However the Western blotting system based upon enzyme development 
using secondary antibody conjugated with alkaline phosphatase is a 
relatively insensitive system. It is possible that the enzyme development 
system used here was too insensitive to detect measurable binding to 
Yops. Thus to summarise, my preliminary data indicate that rFab 
germline, KSAb1 and KSAb2 do not recognise Yops of Y. enterocolitica 
serotype O:8. 
5.3.4 Preparation of Y. enterocolitica 8081 and Ye58/O3 whole cell 
lysates and envelope proteins 
Following previous studies analysing binding to Y. enterocolitica (Luo et 
al., 1994), both whole cell lysate and envelope proteins were prepared for 
each serotype. Preparations were analysed by SDS-PAGE and showed 
over-expressed proteins and subtle differences in protein expression 
(Figure 46). 
Figure 45: Western blot testing binding of 
mAb and rFab binding to Yops. 
Yops were incubated with 10 µg/mL 
concentrations of KSAb1 IgG, KSAb2 IgG or 
rFab Germline and tested for binding by 
Western blot. No binding was observed for any 
of the preparations. This experiment was 
performed on two independent occasions. 
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5.3.5 Binding of anti-TSHR mAbs and rFab germline to whole cell 
lysate and envelope protein preparations of Y. enterocolitica 
Evaluation of KSAb1 IgG binding to Y. enterocolitica 
Y. enterocolitica protein preparations were evaluated for binding with 
KSAb1 IgG and binding was observed with a band migrating below the 
MW marker band of 37 kDa. However whilst it is important to note that 
Western blotting represents an approximate method of MW 
determination, this band has an apparent MW of 37 kDa. This band was 
observed in both serotypes and in both protein preparations, indicating 
that the protein is in the outer envelope of the bacterium. No binding was 
observed for the isotype control (IgG2b) indicating that the binding 
observed for KSAb1 IgG was specific (Figure 47). 
Figure 46: Preparation of whole cell 
lysate and envelope protein 
preparations. 
Whole cell lysate and envelope proteins 
were prepared for both serotypes and 
analysed by SDS-PAGE and 
Coomassie blue staining. 
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Evaluation of KSAb2 IgG binding to Y. enterocolitica 
Y. enterocolitica protein preparations were evaluated for binding with 
KSAb2 IgG and binding was observed with a band of an apparent MW of 
37 kDa, similar to that observed for KSAb1 IgG (Figure 47). The 37 kDa 
band was observed in both serotypes and in both protein preparations, 
indicating that the protein is in the outer envelope of the bacterium. No 
binding was observed for the isotype control (IgG2a) indicating that the 
binding observed for KSAb2 IgG was specific (Figure 48). The Y. 
enterocolitica binding data for KSAb1 and KSAb2 IgG indicates that both 
mAbs re cross-reactive as they recognise TSHR (Gilbert et al., 2006a) as 
well as a Y. enterocolitica protein. 
Figure 47: Evaluating KSAb1 IgG and its isotype control binding 
to whole cell lysate and envelope protein preparations. 
(A) KSAb1 IgG was incubated with whole cell lysate (W) and envelope 
protein (Env) preparations from both serotypes and tested for binding 
by Western blotting. A band was observed running just under 37 kDa, 
in all preparations. (B) No bands were observed for its isotype control, 
IgG2b. 
A B 
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Evaluation of rFab germline binding to Y. enterocolitica 
Y. enterocolitica protein preparations were evaluated for binding with 
rFab germline and as in the cases of both KSAb1 and KSAb2 IgG, 
binding was observed with a band migrating with an apparent MW of 37 
kDa (Figure 49).This band was observed for both protein preparations in 
serotype O:8, and to envelope proteins in serotype O:3, Weaker binding 
was observed in the whole cell lysate preparation of serotype O:3. This 
may be due to the particular preparation of O:3 whole cell lysate not 
expressing high enough levels of the particular protein, or the protein may 
be obscured by others of similar MW as a large loading volume was 
necessary to measure binding. No binding was observed with the 
Figure 48: Evaluating KSAb2 IgG and its isotype control binding 
to whole cell lysate and envelope protein preparations. 
(A) KSAb2 IgG was incubated with W and Env preparations from both 
serotypes and tested for binding by Western blotting. A band was 
observed running just under 37 kDa, in all preparations. (B) No bands 
were observed for IgG2a. 
A B 
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negative control, rFab96/3, indicating that the binding observed for rFab 
germline was specific.  
 
Evaluation of mAb A9 IgG binding to Y. enterocolitica 
mAb A9 (Nicholson et al., 1996) is a neutral anti-TSHR mAb that has 
been epitope-matched to aa 214-222 of the TSHR (Andresen et al., 
2006), or residues 193-201 using the aa numbering system without the 
signal sequence. Recently it has also been shown to react with OmpF, a 
40 kDa outer membrane porin protein, from Y. enterocolitica serotype O:3 
(Wang et al., 2010). In this thesis mAb A9 IgG was evaluated for binding 
to the Y. enterocolitica serotypes and preparations already described. 
Binding to a band at approximately 37 kDa was observed O:8 whole cell 
lysate and both preparations of serotype O:3 (Figure 50), suggesting that 
Figure 49: Evaluating rFab germline binding to whole cell lysate 
and envelope protein preparations. 
(A) rFab germline was incubated with W and Env preparations, and 
binding was determined by Western blotting. A band was observed 
running just under 37 kDa, in all preparations. (B) No binding was 
observed for rFab 96/3. 
B A 
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mAb A9 is binding a similar antigen(s) to KSAb1 IgG, KSAb2 IgG and 
rFab germline. The lack of binding to O:8 envelope proteins may be due 
to the particular preparation of O:8 envelope proteins not expressing high 
enough levels of the particular protein, or the protein may be obscured by 
others of similar MW as a large loading volume was necessary to 
measure binding. 
 
5.3.6 Identification of Y. enterocolitica protein displaying binding to 
anti-TSHR mAbs by MALDI-TOF 
We attempted to identify the Y. enterocolitica 37 kDa band by MALDI-
TOF. To narrow the potential proteins within a sample, we enriched for 
the Y. enterocolitica protein of interest by antibody capture analysis using 
A B 
Figure 50: Evaluating mAb A9 binding to whole cell lysate and 
envelope protein preparations. 
(A) mAb A9 is an epitope-mapped anti-TSHR mAb and was tested for 
binding to W and Env preparations by Western blotting. Binding was 
observed at just under 37 kDa in all preparations, except O:8 Env. (B) 
No binding was observed with IgG1 isotype control. 
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immobilised KSAb1 IgG (conjugated to Cyanogen Bromide-activated 
Sepharose 4B beads). As a negative control, coupled BSA was prepared.   
Y. enterocolitica lysate was incubated with either KSAb1 IgG-Sepharose 
4B or BSA-Sepharose 4B and bound protein was eluted and analysed by 
SDS-PAGE and Western blotting. Coomassie blue staining revealed two 
faint bands in close proximity migrating just below 37 kDa (data not 
shown due to photography software being too insensitive to visualise the 
bands). The eluted sample was also analysed by Western blotting and 
probed with KSAb1 IgG (primary antibody) and HRP-conjugated sheep 
anti-mouse IgG secondary antibody. A single band is observed migrating 
below 37 kDa in both the lysate and eluted fractions. In the eluted fraction 
there are also two bands at above 50 kDa and approximately 25 kDa. It is 
likely that these bands are KSAb1 IgG H-chain (55 kDa) and L-chain (25 
kDa) that were eluted during the purification process and have been 
detected by the polyclonal anti-mouse IgG secondary antibody. This 
experiment confirms that a protein of approximately 37 kDa has been 
eluted following affinity enrichment with KSAb1 IgG-Sepharose 4B and 
this protein was further confirmed by Western blotting with KSAb1 IgG. A 
band of an apparent MW of 37 kDa is visible in the lysate lane of BSA-
coupled matrix following probing with KSAb1 IgG, but not in the eluted 
lane (Figure 51). 
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As both eluted bands in the SDS-PAGE sample were too close together 
to accurately separate them, a gel slice containing both bands was 
excised and sent for MALDI-TOF analysis. This analysis revealed 38 
proteins contained in the analysed sample, along with their expected MW 
(in kDa) and their relative abundance within the sample. The majority of 
proteins identified within the sample are enzymes involved in processes 
such as metabolism. The two most abundant proteins within the sample 
are OmpA and OmpC. OmpC had also been identified by MALDI-TOF 
attempt 1. OmpF (Wang et al., 2010) was not found in either of our 
MALDI-TOF analyses. This is likely due to the reciprocal regulation of 
OmpC and OmpF, and because OmpF is typically expressed at 
temperatures of 2-24°C, whilst the Y. enterocolitica cultures described 
A B 
Figure 51: Affinity enrichment of Y. enterocolitica with affinity 
matrix-coupled antibody. 
(A) Purification of Y. enterocolitica following incubation with KSAb1 IgG-
Sepharose 4B. A band below 37 kDa is observed in both the lysate and 
elution lanes. IgG H-chain (55 kDa) and L-chain (25 kDa) bands are 
also observed in the elution suggesting that some KSAb1 IgG may 
have been cleaved during the elution process. (B) Purification of Y. 
enterocolitica following incubation with BSA-Sepharose 4B. A band 
below 37 kDa is observed in the lysate lane but not in the eluted lane. 
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here were grown at 30°C (Ozawa and Mizushima, 1983). Wang et al do 
not describe the Y. enterocolitica growth conditions used in their study. 
5.3.7 Expression of recombinant OmpC and OmpF protein 
The gene constructs of ompC and ompF, cloned in pET32b, were 
provided by our collaborator Dr Anna Stenkova, Russia, as plasmid spots 
which were subsequently transformed into competent cells for 
recombinant protein expression.  Dr Stenkova recommended that the 
cultures be grown at 37°C and induced with 1 mM IPTG for 4 h. 
Expression of the recombinant proteins was analysed by SDS-PAGE 
(Figure 52, page 197). No protein expression is observed in the non-
induced lane of OmpC but there is a strong band migrating just below 37 
kDa in the induced lane. There is strong expression of OmpF in both the 
non-induced and induced samples migrating slightly above 37 kDa. 
 
Figure 52: Analysis of recombinant 
OmpC and OmpF expression by 
SDS-PAGE. 
Recombinant OmpC and OmpF 
expression was induced following 
addition of IPTG. There was no 
induction of OmpC before IPTG (NI; 
non-induced) but clear induction after 
induction (highlighted by a box). 
There is leaky expression of OmpF 
as there is a band in both the non-
induced and induced lanes. 
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5.3.8 Cloning of omp genes and expression as recombinant protein 
Based on the MALDI-TOF data, the 1,080 bp nucleotide sequence of 
ompA was obtained from PubMed (accession number nc 008800) and 
synthesised as a gene construct. The gene arrived cloned in a pUC57 
vector and was subsequently sub-cloned in pET22b (Figure 53).  
 
The same expression conditions that were used for OmpC and OmpF 
protein expression were used for recombinant OmpA protein expression. 
There is a clear induction of a band, migrating at approximately 37 kDa, 
which is not observed in the non-induced lane see Figure 54. 
Figure 53: Cloning of OmpA. 
Agarose gel electrophoresis of OmpA 
synthetic construct: Lane 1 is purified 
pET22b vector, lane 2 is the MW 
ladder in kB, lane 3 is purified OmpA 
digested with NdeI and XhoI 
restriction enzymes. The OmpA 
construct is 1,080 bp and migrates 
between 1-1.5 kB.  
  199 
  
5.3.9 Evaluation of binding of anti-TSHR mAbs and rFab germline 
to purified OmpA, OmpC and OmpF 
Western blotting was performed to assess binding of the anti-TSHR 
mAbs and rFab germline to recombinant OmpA, OmpC and OmpF in total 
E. coli lysate (Figure 55, page 200). rFab germline displayed binding to 
OmpC and OmpF, with weak binding to OmpA. KSAb1 and KSAb2 both 
showed binding to all three recombinant porins. The previously reported 
binding of mAb A9 to OmpF (Wang et al., 2010) was confirmed, and it 
also displayed binding to the other non-specific porin, OmpC, but not 
OmpA (Figure 55, page 200).  
Figure 54: Analysis of recombinant OmpA 
expression by SDS-PAGE. 
Recombinant OmpA expression was induced 
following addition of IPTG. There was no 
induction of OmpA before IPTG (NI; non-
induced) but clear induction after induction 
(highlighted by a box). 
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5.3.10 Amino acid sequence homology of OmpA, OmpC and OmpF 
with TSHR 
Sequence alignments were performed to evaluate whether there is any 
aa sequence homology between the Omps and the TSHR. As the TSHR 
epitopes of KSAb1 and KSAb2 are discontinuous rather than linear 
(Gilbert et al., 2006a) and have not been determined, it is difficult to know 
which region of the TSHR is most important for homology to the OmpA, 
OmpC amd OmpF.  
Figure 55: Evaluation of mAbs and rFab germline binding to 
OmpA, OmpC and OmpF. 
Anti-TSHR mAbs and rFab germline were evaluated for binding to 
recombinant OmpA, OmpC and OmpF. Isotype controls did not 
display any binding to the recombinant Omps. 
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Sequence homology between OmpF and TSHR 
As shown by Wang et al, 2010, when TSHR residues 198 DAFGGVYS 
205 and OmpF residues 190 DALGNVTS 197 are deleted, mAb A9 
binding is lost (Wang et al., 2010), but as the mAb A9 TSHR epitope is 
actually mapped to 193 TVIDKDAFG 201 (Andresen et al., 2006), then 
the key OmpF residues for mAb A9 binding are 190 DALG 193 (Figure 
56) which has a high degree of homology with TSHR with 3 out 4 
identical residues (shown in bold): 
OmpF   190 DALG 193 
TSHR   198 DAFG 201 
 
Figure 56: Amino acid sequence alignment of OmpF and TSHR. 
A sequence alignment was performed to assess whether there is any 
aa sequence homology between OmpF and TSHR. The epitope of mAb 
A9 is highlighted in red, and its OmpF epitope as proposed by Wang et 
al, 2010 is highlighted in green. The more accurate OmpF epitope of 
mAb A9, 193 VVETTDALG 201, is highlighted by a purple box.  
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Sequence homology between OmpA and TSHR 
There are two aa sequence homology regions of interest between OmpA 
and the TSHR (Figure 57), identical aa residues are in bold: 
Region 1 (highlighted in Figure 57 by a purple box): 
OmpA   190 DNGMLSVGVSYRF 202 
TSHR   165  NNGFTSVQG-YAF 177 
Region 2 (highlighted in Figure 57 by a blue box): 
OmpA   257 SSIDPKDGSVVVL 269 
TSHR   208 SLLDVSQTSVTAL 221 
Thus there are 6 out of 13 identical residues in region 1 and 6 out of 13 
identical residues in region 2. Further experiments to confirm whether 
these epitopes are necessary for KSAb1, KSAb2 and rFab germline’s 
binding to OmpA could include selectively deleting these aa regions and 
testing whether there is still measurable binding by Western blotting 
(Wang et al., 2010) or by using peptide library of truncated OmpA 
peptides.  
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Sequence homology between OmpC and TSHR 
As previously discussed OmpC and OmpF are part of the same family of 
non-specific, classical porins (Nikaido, 2003) and have a high degree of 
aa sequence homology, which is most apparent at the N-terminus. This 
homology may explain why all of the mAbs evaluated have displayed 
binding to both OmpC and OmpF, including mAb A9. In Figure 58 the 
finely-mapped TSHR epitope of mAb A9 is highlighted in red. As mAb A9 
binds both OmpC and OmpF, its epitopes in TSHR and OmpF are 
important predictors of its epitope in OmpC. The stretch of 4 key TSHR 
Figure 57: Amino acid sequence alignment of OmpA and TSHR. 
A sequence alignment was performed to assess whether there is any 
aa sequence homology between OmpA and TSHR. The epitope of 
mAb A9 is highlighted in red, region of sequence homology 1 is 
highlighted in a purple box and region of sequence homology 2 in a 
blue box. There is little homology between OmpA and the mAb A9 
TSHR epitope which is to be expected as mAb A9 does not show any 
binding to OmpA. 
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aa residues is homologous in OmpC, as shown below with identical 
residues in bold: 
OmpC   286 YQFG 289 
TSHR   198 DAFG 201 
Although not identical, the OmpC glutamine residue (Y286) and the 
TSHR aspartic acid residue (D198) are both hydrophilic with structural 
similarity (below), and thus could also be involved as part of mAb A9’s 
OmpC epitope. 
 
This data also shows how antibody binding may be mediated by as little 
as 2-3 aa residues.  
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Figure 58: Amino acid sequence alignment of OmpC and TSHR. 
A sequence alignment was performed to assess whether there is any 
aa sequence homology between OmpC and TSHR. The epitope of 
mAb A9 is highlighted in red. The four TSHR aa residues highlighted 
by a purple box, 198 DAFG 201, were shown by deletion to be 
essential for mAb A9 binding to TSHR and OmpF by Wang et al, 2010. 
Two of these four residues, 201 FG 202, are identical between OmpC 
and TSHR, whilst the aa residue at position 198 differs between the 
two proteins, they are both hydrophilic and structurally similar. 
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5.4 Discussion 
Despite an initial link being made with GD and Y. enterocolitica in the late 
1970s, consistent findings are lacking and the potential role of Y. 
enterocolitica remains controversial (Bech et al., 1974; Brix et al., 2008; 
Resetkova et al., 1994). One definitive way to examine the role of Y. 
enterocolitica proteins in the pathogenesis of GD is to use pathogenic 
TSAbs, rather than whole serum samples as have been used in all 
previous studies over the past three decades. Thus, my studies reported 
here with KSAb1 and KSAb2 are novel in their approach as the first use 
of TSAbs to tackle this question. At the same time, this also gave us the 
opportunity to examine the relationship of rFab germline with Y. 
enterocolitica, which may potentially give an insight into the role of 
microbial proteins in expanding early precursor B cells by SHM into 
pathogenic antibodies. 
In order to attempt to ascertain the antigen specificity of rFab germline, a 
number of different possible avenues were considered, including 
screening commercially available autoantigen arrays, pathogen-
associated peptide microarrays and random peptide screens (Maier et al., 
2010; Prechl et al., 2010). In a rational approach, we decided to focus our 
efforts on Y. enterocolitica and Western blotting due to the precedence in 
the literature. We used two serotypes, O:3 and O:8, both of which have 
been widely used by various studies investigating a potential link between 
GD and Y. enterocolitica (Luo et al., 1993; Wang et al., 2010). No 
consistent Y. enterocolitica protein from either serotype has been 
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implicated with GD. We attempted to use all of the various protein 
preparations that have been previously reported in the literature: Yops, 
whole cell lysates and envelope proteins. Due to difficulties in their 
isolation, Yops were prepared solely from serotype O:8.  
No binding of Yops was observed with KSAb1 IgG, KSAb2 IgG or rFab 
germline when assessed by Western blotting using alkaline phosphatase 
development system. Binding to whole cell lysate and envelope 
preparations was observed for KSAb1 IgG, KSAb2 IgG, rFab germline 
and the neutral mAb A9. A consistent band was observed in the whole 
cell lysate and envelope protein preparations of both serotypes migrating 
with an apparent MW of 37 kDa for rFab germline, KSAb1 IgG, KSAb2 
IgG and mAb A9. No binding was observed with the relevant isotype 
controls. Binding to envelope protein preparations suggest that these 
proteins are on the outer surface of the bacterium where it may be easily 
accessed by the immune system (Białas et al., 2012). Interestingly, 
KSAb1 IgG and KSAb2 IgG show bimodal reactivity by recognising TSHR 
and continuing to recognise a Y. enterocolitica protein. There is 
precedence in the literature for autoreactive antibodies to bind both an 
autoantigen and a bacterial antigen, as myocarditis antibodies have been 
shown to cross-react with Streptococcus polysaccharide (Malkiel et al., 
2000). 
Immobilised matrix-coupled KSAb1 IgG was incubated with Y. 
enterocolitica and the eluted proteins with an approximate MW of 37 kDa 
were analysed by MALDI-TOF for identification. The two most abundant 
proteins were identified as OmpA and OmpC. A synthetic gene construct 
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of ompA was synthesised for cloning and expression as recombinant 
protein whilst ompC was provided as cDNA by Dr Anna Stenkova, as well 
as ompF as mAb A9 has previously been shown to bind to this porin 
(Wang et al., 2010).  
Recombinant OmpA, OmpC and OmpF were evaluated for binding with 
rFab germline, KSAb1 IgG, KSAb2 IgG, mAb A9 IgG and their relevant 
isotype-matched and negative controls. rFab germline displayed binding 
to OmpC and OmpF, the binding to both porins may be a result of the 
high degree of N-terminal sequence homology between the two porins, 
as well as weak binding to OmpA. KSAb1 and KSAb2 IgG surprisingly 
displayed binding to all three porins and the previously published binding 
of mAb A9 to OmpF (Wang et al., 2010) was confirmed as well as the 
novel finding of mAb A9 showing reactivity to OmpC. This data suggests 
that two TSAbs developed from a germline precursor antibody that 
recognised Omp proteins and that through SHM, TSHR reactivity was 
acquired and reactivity to porin proteins was maintained. 
KSAb1 and KSAb2 were established from BALB/c mice, housed under 
specific pathogen-free conditions and thus unlikely to have been exposed 
to Y. enterocolitica. Porins are ubiquitously expressed by gram-negative 
bacteria (Nikaido, 2003) and it is possible that the precursor B cell clone 
expressing the germline antibody that would give rise to KSAb1 and 
KSAb2 was expanded by a pathogen of the microbiota expressing OmpC 
and/or OmpF. Through SHM and molecular mimicry this precursor clone 
then began to develop TSHR reactivity. However as this is an induced 
model of disease, it is most likely that the clone was expanded by the 
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immunogen, the TSHR A-subunit, as a result of immunisation. Thus it is 
likely that Omp-specific precursor was expanded by TSHR A-subunit 
antigen as a result of cross-reactivity.  
The studies described here have been limited to Y. enterocolitica but 
future work could include the screening of porins from other bacterial 
species, as for example, there is a high degree of sequence homology 
between the Omps expressed by Y. enterocolitica and Omps expressed 
by E. coli K12.  Immunisation of female BALB/c mice independently with 
purified recombinant OmpA, OmpC or OmpF and analysing serum for 
measurable anti-TSHR antibodies or hyperthyroidism would indicate 
whether there is a casual relationship between Y. enterocolitica Omps or 
whether priming of susceptible B cells with these proteins can precipitate 
an anti-thyroid immune response. Previous studies that have immunised 
mice with total Y. enterocolitica proteins lead to anti-TSHR antibodies but 
did not precipitate hyperthyroidism, therefore the anti-TSHR antibodies 
produced were not pathogenic (Luo et al., 1993). This may have been 
due to antigenic competition as whole Y. enterocolitica was used and this 
may have weakened the induced immune response, or because the 
mouse strain used was not the most suited for induced hyperthyroidism 
(Nagayama, 2007). 
This data raises the interesting implication that two TSAbs have 
developed from a non-autoreactive pathogen-specific precursor, and 
whilst TSHR reactivity was acquired through numerous SHM, pathogen 
binding was maintained. 
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5.5 Conclusions 
In conclusion, the results reported are novel and indicate recognition of Y. 
enterocolitica porins, OmpA, OmpC and OmpF by TSAbs, KSAb1 and 
KSAb2 and their precursor, expressed as rFab germline. With the 
available data, it is presently difficult to either support or dismiss a causal 
relationship between the development of TSHR reactivity and recognition 
of the porins and how they may be related to the development of TSAbs 
resulting in hyperthyroidism. However my work sets a precedent for future 
in vivo experiments to explore this further. Importantly, as reported by 
Wang and colleagues (Wang et al., 2010) the binding of mAb A9 to 
OmpF was confirmed, in addition this mAb shows binding to the related 
porin, OmpC. Future work can also include studies on evaluation on the 
structural basis of the porins and their homology to the TSHR A-subunit 
to begin to understand cross-reactivity at a molecular level. 
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6 CHAPTER SIX: Concluding remarks  
There are a number of novel research findings reported in this thesis:  
 The germline antibody committed to producing two TSAbs through 
SHM does not recognise the TSHR, the target autoantigen of GD. 
 The antigens recognised by the germline revertant, when 
expressed as rFab, has been identified by MALDI-TOF analysis as 
OmpA, OmpC and OmpF of Y. enterocolitica, thereby providing 
additional supporting evidence for the role on infection in GD 
 The unexpected discovery of the bimodal reactivity of the two 
TSAbs, recognising TSHR and OmpA, OmpC and OmpF of Y. 
enterocolitica. This potentially provides a model for (i) activation of 
the early precursor B cell clones by the microbial antigen to 
expand by SHM to form pathogenic TSAbs and (ii) the chronic 
nature of GD where the B cells secreting pathogenic TSAbs in the 
secondary lymphoid organs are constantly activated by the 
microbial antigen to maintain the hyperthyroidism. 
 Unequivocal demonstration of the dominant role of the H-chain in 
conferring binding to the TSHR, demonstrated for the first time at 
the molecular level. 
The finding that the shared immature antibody encoded by the germline 
genes of two TSAbs does not recognise the TSHR is a novel finding and 
has not been reported previously for GD. This suggests that the precursor 
B cells are not deleted by central tolerance as they do not recognise the 
autoantigen, TSHR, and thus exit the bone marrow as immature B cells to 
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enter the secondary lymphoid organs. In the periphery, these precursor B 
cells are activated to undergo SHM to become autoreactive and produce 
TSAbs. The only other autoimmune condition where the autoantigen-
specificity of the germline revertant has been studied in detail is SLE. 
Importantly, both mouse and human mAbs have been investigated in 
detail, where many of the germline revertants do not recognise the 
autoantigens, DNA and nucleoproteins.  (Guo et al., 2010; Wellmann et 
al., 2005), been investigated. Thus our findings that germline revertant in 
an experimental model of GD does not recognise the target autoantigen 
are comparable to the findings in SLE. As the antigen-specificity of 
germline forms of pathogenic antibodies has previously only been 
described in the non-organ specific SLE, it is difficult to draw firm 
conclusions on the contribution of precursor antibodies in autoimmunity in 
general. It is therefore of interest for such germline revertant studies to be 
repeated in other antibody-mediated autoimmune conditions, and 
importantly, for this study to be replicated with human thyroid antibodies 
to validate the findings described here for mouse-derived thyroid 
antibodies.  
GD is known to have a complex aetiology, with both genetic and 
environmental factors (Brix and Hegedüs, 2012), however how they 
interact to cause disease is currently unknown. Previous studies whereby 
mice have been immunised with Y. enterocolitica serotype O:8 have 
generated anti-TSHR antibodies without pathogenic activity that cross-
react with lipoprotein (Luo et al., 1993; Zhang et al., 1997). A recent study 
showed cross-reactivity of a non-pathogenic neutral mAb, mAb A9, with 
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OmpF of Y. enterocolitica, serotype O:3 (Wang et al., 2010). The novelty 
of the study described here relies on the evaluation of two highly potent 
TSAbs, whose pathogenicity is without doubt (Flynn et al., 2007; Gilbert 
et al., 2006b), for cross-reactivity with Y. enterocolitica serotypes O:3 and 
O:8. KSAb1 and KSAb2 have been shown to cross-react with OmpA, 
OmpC and OmpF of Y. enterocolitica. 
Further studies are warranted to immunise BALB/c mice with individual 
purified Omps in adjuvant and to evaluate the serum for anti-TSHR 
antibodies, as well as examining thyroid and orbital tissues for histological 
changes. It is of particular interest to evaluate whether the isolated 
human TSAbs, M22 and K1-18, also cross react with OmpA, OmpC 
and/or OmpF, or other Y. enterocolitica proteins. Considering that TSHR 
agonism is a special antibody property and that KSAb1 is a comparable 
stimulator to M22 (Mizutori et al., 2009), it may be assumed that KSAb1 
and M22 have over-lapping TSHR epitopes and thus may have 
overlapping Omp epitopes. Evaluation of the isolated human TSBAbs, 
5C9 and K1-70, for cross-reactivity with Y. enterocolitica porins would 
also be of interest, particularly as we have shown that a neutral mAb 
recognises OmpC and OmpF, but not OmpA, whilst TSAbs and their 
germline precursor recognise all three. Potentially any differences in 
TSHR binding and stimulating activity may be reflected in the porins 
recognised.  
Genetic studies in various strains of inbred mice have shown that loci in 
the IGHV gene locus are responsible for the major contribution towards 
the recognition of TSHR (Rapoport et al., 2010).  The data in this thesis 
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based upon L-chain swaps between KSAb1 and its germline revertant 
show unequivocally that the somatically mutated H-chain of the TSAb, 
KSAb1, dominates in contributing to the binding of TSHR. However the 
pairing of the H-chain with the germline L-chain originally used by the 
TSAbs was essential for the binding to TSHR, since when the mature H-
chain was paired with an irrelevant L-chain, all measurable TSHR binding 
was lost. For future studies, it would be interesting to investigate in 
greater detail the role of SHM towards recognition of TSHR and hence 
the development of autoreactivity. A pressing example would be the role 
of the n=21 SHM common to the H-chains of both KSAb1 and KSAb2 
prior to their diversification (Padoa et al., 2010), see Chapter 3, Figure 17, 
page 119, paired with the mature L-chains of KSAb1 and KSAb2 to 
recognise the TSHR.   
The novel finding that the germline precursor antibody of two TSAbs 
recognises a microbial antigen of Y. enterocolitica, rather than TSHR, 
raises interesting possibilities for the development of autoimmunity in 
humans. DCs in the gastrointestinal tract could process antigens derived 
from Y. enterocolitica or other Omp-expressing commensal bacteria and 
present this antigen to T cells and B cells in secondary lymphoid organs. 
In a genetically predisposed individual, with the convergence of certain 
genetic and environmental factors, an Omp-specific B cell may develop 
thyroid reactivity through SHM and may not be deleted by peripheral 
tolerance mechanisms, allowing autoimmunity to develop. 
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Appendices  
Appendix 1 
LURIA BERTANI (LB) AGAR 600 mL 
Tryptone  6 g 
Yeast  3 g 
NaCl  6 g 
Agar 9 g 
 
LURIA BERTANI (LB) BROTH 1 L 
Tryptone 10 g 
Yeast 5 g 
NaCl 10 g 
 
SOC MEDIUM  100 mL 
Tryptone                                    0.2 g 
Yeast                                                                           0.05 g
5 M NaCl                                                                      0.02 mL
1 M KCl                                                                                   0.025 mL 
1 M MgCl2                                                               0.1 mL 
1 M MgSO4                                                                             0.1 mL
1 M glucose  (added after autoclaving)                        0.2 mL
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50% GLYCEROL  
100% glycerol     50 mL 
dH2O       50 mL 
Appendix 2 
50 X TAE BUFFER      1 L 
Tris        242 g 
Glacial acetic acid     57.1 mL 
EDTA       18.6 g 
Dilute 20 mL 50 X TAE with 980 mL dH2O for 1 X solution 
 
AGAROSE GEL  
0.8%: 
Agarose      0.8 g 
1 X TAE       100 mL 
1.2% 
Agarose      1.2 g 
1 X TAE       100 mL 
Appendix 3 
ANTIBIOTICS  
AMPICILLIN (100 mg/mL) 
Ampicillin      1 g 
dH2O       10 mL 
CHLORAMPHENICOL (34 mg/mL) 
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Chloramphenicol      3.4 g 
Ethanol      10 mL 
TETRACYCLINE (5 mg/mL) 
Tetracycline       50 mg 
dH2O        5 mL 
Ethanol      5 mL 
Stored at -20C away from light 
Appendix 4 
10 X MOPS BUFFER    1 L 
MOPS      83.72 g 
Tricine      7.17 g 
Volume made up to 300 mL with dH2O and pH adjusted to pH 7.4 with 10 M 
KOH 
0.1 M FeSO4      10 mL 
1.9 M NH4Cl      50 mL 
0.296 M K2SO4      10 mL 
0.02 M CaCl2.2H2O     250 µl  
2.5 M MgCl2       2.1 mL 
5 M NaCl       100 mL 
Micronutrient broth      0.2 mL 
dH2O        387 mL 
Filter sterilised with a 0.22 µm filter 
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MICRONUTRIENT BROTH   50 mL 
Ammonium molybdate     0.009 g 
Boric acid       0.062 g 
Cobalt chloride      0.018 g 
Cupric sulphate      0.006 g 
Manganese chloride     0.04 g 
Zinc sulphate      0.007 g 
Volume made up to 50mL with dH2O  
 
1 X MOPS WITH PHOSPHATE   1 L 
10 X MOPS medium    100 mL 
0.132 M K2HPO4     10 mL 
1 mg/mL thiamine     0.1 mL 
dH2O       990 mL 
The pH was adjusted to pH 7.2 with 10 M NaOH and the buffer filter sterilised 
with a 0.22 µm filter 
Just before use: 
10% filter-sterilised glucose   10 mL 
5 mg/mL tetracycline    2 mL 
 
1 X MOPS WITHOUT PHOSPHATE          1L 
As above for 1 X MOPS with phosphate, but no K2HPO4 was added. The 
pH was not adjusted. 
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EXTRACTION BUFFER 100 mL 
100 mM Hepes pH 7.5  10 mL 
5 M NaCl 10 mL 
1 M Imidazole 100 µl 
100 mM Benzamidine 10 mL 
10 mM PMSF  10 mL 
 
WASH BUFFER 100 mL 
100 mM Hepes pH 7.5 10 mL 
5 M NaCl 10 mL 
1 M Imidazole 100 µl 
dH2O 90.9 mL 
 
ELUTION BUFFER 100 mL 
100 mM Hepes pH 7.5 10 mL 
5 M NaCl 10 mL 
1 M Imidazole 30 mL 
dH2O 50 mL 
 
10 X PBS 1 L 
NaCl 8 g 
KCL 0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
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Diluted 1/10 to make 1 X solution and both were autoclaved before use 
Appendix 5 
SEPARATING GEL (12%) 30 mL 
30% acrylamide (Protogel) 12 mL 
1 M Tris pH 8.8 11.25 mL 
1.5% ammonium persulphate 1 mL 
10% SDS 0.5 mL 
dH2O 5.75 mL 
TEMED 10 µl 
 
STACKING GEL 10 mL 
30% acrylamide (Protogel) 1 mL 
1 M Tris pH 8.8 1.25 mL 
1.5% ammonium persulphate 0.5 mL 
10% SDS 0.3 mL 
dH2O 6.95 mL 
TEMED 10 ul 
 
1 M TRIS BASE pH 8.8    1 L 
Tris base      121.8 g 
dH2O       700 mL 
Volume made up to 1 L with dH2O adjusting pH to 8.8 with 5 M HCl 
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1 M TRIS BASE pH 6.8    500 mL 
Tris base      60.5 g 
dH2O       250 mL 
Volume made up to 1 L with dH2O adjusting pH to 6.8 with 5 M HCl 
 
RUNNING BUFFER (10 X)   1 L 
Glycine      144.13 g 
Tris base      30.28 g 
SDS       10 g 
Dilute 1/10 with dH2O for 1 X solution  
 
LOADING GEL BUFFER (2 X)   5 mL 
1 M Tris pH 6.8     1.25 mL 
10% SDS      1 mL 
50% Sucrose, 0.1% Bromophenol blue  2 mL 
dH2O       0.75 mL 
Dilute 1:2 with sample  
 
COOMASSIE BLUE  
Coomassie R250     0.5 g 
Methanol      250 mL 
Stir for 30 minutes, and then add:  
dH2O       250 mL 
Acetic acid      50 mL 
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DESTAIN 1 L 
Methanol 300 mL 
Acetic acid 100 mL 
dH2O 600 mL 
 
WESTERN TRANSFER BUFFER (1 X) 2 L 
10 X SDS running buffer 200 mL 
Methanol  200 mL  
dH2O 1600 mL 
Appendix 6 
HANK’S BUFFERED SALT SOLUTION 
(HBSS) 
1 L 
CaCl2.2H2O 0.185 g 
KCl  5.33 g 
KH2PO4  0.06 g 
MgCl2  0.048 g 
MgSO4.7H2O  0.101 g 
NaHCO3  0.336 g 
Na2HPO4 0.043 g 
Glucose 1.008 g 
Hepes 4.776 g 
Sucrose  75.991 g 
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Appendix 7 
YERSINIA LURIA BERTANI (LB) BROTH 1 L 
Tryptone 10 g 
Yeast 5 g 
NaCl 5 g 
 
COUPLING BUFFER  1 L 
NaHCO3 8.3 g 
NaCl 29 g 
Adjusted to pH 8.5 with 1 M NaOH  
 
ACETATE BUFFER (0.1 M)  1 L 
NaOAc 13.6 g 
NaCL 29.22 g 
Adjusted to pH 4 with concentrated acetic acid 
 
LYSIS BUFFER 50 mL 
5 M NaCl 1 mL 
1 M Tris-HCl pH 8 500 µL 
0.5 M EDTA 80 µL 
10% Triton-X 100 200 µL 
dH2O 48.25 mL 
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Appendix 8: Sequence confirmation of germline construct compared to the expected, reference, sequence 
REFERENCE       -------------------------------------------GAATTCGAGCTCGGTAC 
L CHAIN         NNNNNNNNNNCNNNTNNTTTTATTTTTTATGTATTTGTAACTAGAATTCGAGCTCGGTAC 
                                                           ***************** 
 
REFERENCE       CCGGGGATCCTCTAGAGGTTGAGGTGATTTTATGAAAAAGAATATCGCATTTCTTCTTGC 
L CHAIN         CCGGGGATCCTCTAGAGGTTGAGGTGATTTTATGAAAAAGAATATCGCATTTCTTCTTGC 
                ************************************************************ 
 
REFERENCE       ATCTATGTTCGTTTTTTCTATTGCTACAAACGCGTATGCTGACATTGTGATGACCCAGTC 
L CHAIN         ATCTATGTTCGTTTTTTCTATTGCTACAAACGCGTATGCTGACATTGTGATGACCCAGTC 
                ************************************************************ 
 
REFERENCE       TCAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCA 
L CHAIN         TCAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCA 
                ************************************************************ 
 
REFERENCE       GAATGTGGGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACT 
L CHAIN         GAATGTGGGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACT 
                ************************************************************ 
 
REFERENCE       GATTTACTCGGCATCCAATCGGTACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATC 
L CHAIN         GATTTACTCGGCATCCAATCGGTACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATC 
                ************************************************************ 
 
REFERENCE       TGGGACAGATTTCACTCTCACCATCAGCAATATGCAGTCTGAAGACCTGGCAGATTATTT 
L CHAIN         TGGGACAGATTTCACTCTCACCATCAGCAATATGCAGTCTGAAGACCTGGCAGATTATTT 
                ************************************************************ 
 
REFERENCE       CTGCCAGCAATATAGCAGCTATCCTTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAA 
L CHAIN         CTGCCAGCAATATAGCAGCTATCCTTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAA 
                ************************************************************ 
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REFERENCE       ACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATC 
L CHAIN         ACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATC 
                ************************************************************ 
 
REFERENCE       TGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAA 
L CHAIN         TGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAA 
                ************************************************************ 
 
REFERENCE       GTGGAAGATTGTTGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGA 
L CHAIN         GTGGAAGATTGTTGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGA 
                ************************************************************ 
 
REFERENCE       CAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGA 
L CHAIN         CAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGA 
                ************************************************************ 
 
REFERENCE       ACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAA 
L CHAIN         ACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTCAA 
                ************************************************************ 
REFERENCE       TGTACACAAGTTCACGTAAAAAGGGTATCTAGAGGTTGAGGTGAT 
H CHAIN         TGTACACAAGTTCACGTAAAAAGGGTATCTAGAGGTTGAGGTGAT 
                ********************************************* 
 
REFERENCE       TTTATGAAAAAGAATATCGCATTTCTTCTTGCATCTATGTTCGTTTTTTCTATTGCTACA 
H CHAIN         TTTATGAAAAAGAATATCGCATTTCTTCTTGCATCTATGTTCGTTTTTTCTATTGCTACA 
                ************************************************************ 
 
REFERENCE       AACGCGTACGCTGAGATCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCT 
H CHAIN         AACGCGTACGCTGAGATCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCT 
                ************************************************************ 
 
REFERENCE       TCAGTGAAGGTATCCTGCAAGGCTTCTGGTTACTCATTCACTGACTACAACATGTACTGG 
H CHAIN         TCAGTGAAGGTATCCTGCAAGGCTTCTGGTTACTCATTCACTGACTACAACATGTACTGG 
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                ************************************************************ 
 
REFERENCE       GTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGATATATTGATCCTTACAATGGT 
H CHAIN         GTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGATATATTGATCCTTACAATGGT 
                ************************************************************ 
 
REFERENCE       GGTACTAGCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTTGACAAGTCCTCC 
H CHAIN         GGTACTAGCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTTGACAAGTCCTCC 
                ************************************************************ 
 
REFERENCE       AGCACAGCCTTCATGCATCTCAACAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGT 
H CHAIN         AGCACAGCCTTCATGCATCTCAACAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGT 
                ************************************************************ 
 
REFERENCE       GCAAGAAGGGACTGGGACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCC 
H CHAIN         GCAAGAAGGGACTGGGACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCC 
                ************************************************************ 
 
REFERENCE       TCAGCCAAAACAACAACCCCATCAGTCTATCCACTGGCCCCTGGGTGTGGAGATACAACT 
H CHAIN         TCAGCCAAAACAACAACCCCATCAGTCTATCCACTGGCCCCTGGGTGTGGAGATACAACT 
                ************************************************************ 
 
REFERENCE       GGTTCCTCCGTGACTCTGGGATGCCTGGTCAAGGGCTACTTCCCTGAGTCAGTGACTGTG 
H CHAIN         GGTTCCTCCGTGACTCTGGGATGCCTGGTCAAGGGCTACTTCCCTGAGTCAGTGACTGTG 
                ************************************************************ 
 
REFERENCE       ACTTGGAACTCTGGATCCCTGTCCAGCAGTGTGCACACCTTCCCAGCTCTCCTGCAGTCT 
H CHAIN         ACTTGGAACTCTGGATCCCTGTCCAGCAGTGTGCACACCTTCCCAGCTCTCCTGCAGTCT 
                ************************************************************ 
 
REFERENCE       GGACTCTACACTATGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCAAGTCAGACC 
H CHAIN         GGACTCTACACTATGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCAAGTCAGACC 
                ************************************************************ 
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REFERENCE       GTCACCTGCAGCGTTGCTCACCCAGCCAGCAGCACCAAGGTGGACAAGAAAATTGAGACC 
H CHAIN         GTCACCTGCAGCGTTGCTCACCCAGCCAGCAGCACCAAGGTGGACAAGAAAATTGAGACC 
                ************************************************************ 
 
REFERENCE       CGTCACCACCACCACCACCACTAACGCGGCATGCGACGGCCCTAGAGTCCCTAACGCTCG 
H CHAIN         CGTCACCACCACCACCACCACTAACGCGGCATGCGACGGCCCTAGAGTCCCTAACGCTCG 
                ************************************************************
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Abstract 14th International Thyroid Congress, Paris, France, 2010. 
Hargreaves CE, Dunn-Walters D, Banga JP.  
Title: Studies on rearranged, germline antibody genes that 
predispose potentially autoreactive B cells to produce thyroid 
stimulating antibodies in Graves’ disease: expression as 
recombinant Fab antibody for evaluation of antigen binding 
specificity. 
Graves’ disease is an antibody driven autoimmune disease, where 
antibody to thyroid stimulating hormone receptor (TSHR) stimulate the 
gland to produce excessive thyroid hormone resulting in hyperthyroidism. 
Knowledge of factors responsible for production of antibody to TSHR with 
thyroid stimulating activity is fundamental to gaining a deeper insight into 
the molecular basis of the condition. To produce antigen specific 
antibodies, B lymphocytes first produce immunoglobulin (Ig) genes by 
recombining the different heavy and light chain variable (V)-region gene 
segments. Subsequent antigenic stimulation leads to class switching and 
diversification of the antibody repertoire by clonal expansion and somatic 
hypermutation, leading to increase in antibody affinity. Evidence of the 
same process is shown in autoimmune disease, although the self antigen 
(autoantigen) or the environmental agent (pathogen) driving the affinity 
maturation remains largely unknown. We have initiated studies to 
determine the antigen binding properties of germline Ig genes whose 
affinity matured variants have previously been shown to be pathogenic 
thyroid stimulating antibodies, in order to gain an insight into the in vivo 
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stimulatory events leading to the clonal expansion of B cells resulting in 
thyroid autoimmunity. 
The molecular immunology of two monoclonal antibodies (mAbs) KSAb1 
(IgG2b, k) and KSAb2 (IgG2a, k) to TSHR with thyroid stimulating 
properties have been studied. The mAbs derive from a single mouse 
undergoing experimental Graves’ disease. Despite different subclass, it 
was striking that KSAb1 and KSAb2 use the same rearrangement of 
immunoglobulin heavy chain variable region (IGHV) and light chain 
variable region (IGVL) germlines genes, and arose from a single 
precursor B cell clone. To study binding properties of the germline 
antibodies, we have synthesised the rearranged germline IGHV and IGLV 
genes derived from the Ig gene families of KSAb1 and KSAb2. The 
synthetic germline IGHV and IGLV genes have been expressed in 
bacteria as recombinant Fab (rFab) antibody. Successful expression of 
the germline rFab has been attained, and purified to homogeneity by 
metal chelation and protein-G chromatography. As controls, rFab of 
KSAb1 and as negative control, rFab from a mAb to an islet cell antigen 
in type 1 diabetes, have been expressed and purified in similar manner. 
Examination of a variety of parameters on whether the germ line 
configured rFab preparation shows any measurable binding to TSHR or 
environmental agents such as infectious pathogens are underway to 
define the antigens that contribute to the clonal expansion and 
diversification of potentially autoreactive B cell clones implicated in 
thyroid autoimmune disease. Moreover, such investigations will also give 
an insight into how potentially autoreactive B cell escape the in vivo 
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immune tolerance mechanisms that prevent the clonal expansion of such 
rogue B cell clones, which through somatic hypermutation events 
produce disease-inducing antibodies. 
Abstract ESF-JSPS Frontier Science Conference Series for Young 
Researchers Cutting Edge Immunology and its Clinical Application, 
Holland, 2011. 
Hargreaves CE, Dunn-Walters D, Banga JP.  
Title: Anti-TSHR autoantibodies in Graves' disease develop from non-
autoreactive precursors 
Introduction: Graves’ disease (GD) is an antibody driven autoimmune 
disease, where antibody to thyroid stimulating hormone receptor (TSHR), 
stimulate the gland to produce excessive thyroid hormone resulting in 
hyperthyroidism. Knowledge of factors responsible for production of 
antibody to TSHR with thyroid stimulating activity is fundamental to 
gaining a deeper insight into the molecular basis of the condition.  
We have recently described two monoclonal antibodies (mAbs), KSAb1 
(IgG2b, k) and KSAb21 (IgG2a, k), derived from the same mouse with 
powerful thyroid stimulating antibody (TSAb) properties. V-region 
sequence analysis showed that both were derived from the same 
rearranged H- and L-genes. This gave us an opportunity to study the 
antigenic specificity of the rearranged genes that predispose to the 
generation of TSAbs. 
  280 
Methods: To study the binding properties of the rearranged germline 
(RG) sequence of these antibodies, we synthesised the germline variable 
region light and heavy genes of KSAb1 and KSAb2. The synthetic RG 
construct was cloned in pAK19 vector for bacterial expression as 
recombinant Fab (rFab) preparations and purified to homogeneity by 
metal chelation. As controls, rFab preparation of KSAb1 and an irrelevant 
control, rFab 96/3 were expressed and purified in a similar manner.  
Reactivity of rFab RG to TSHR was examined by a variety of 
experimental parameters, including: competitive inhibition of radiolabelled 
thyroid stimulating hormone (TSH) binding to immobilised TSHR, 
stimulation of the TSHR second messenger cAMP in CHO cells 
transfected with full-length TSHR and by flow cytometry.  
Results: rFab RG did not inhibit radiolabelled TSH from binding TSHR, 
did not stimulate cAMP and did not display measurable binding in flow 
cytometry assays.  
Conclusion: This data suggests anti-TSHR autoantibodies develop from 
non-reactive precursor B cells and this pathogenicity may develop 
through the process of somatic hypermutation in the periphery. 
Experiments are currently underway to further define when pathogenicity 
arises and whether it is an environmental agent that first drives the clonal 
expansion of such rogue B cells. 
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Abstract 35th Annual European Thyroid Association, Krakow, 
Poland, 2011. 
Hargreaves CE, Dunn-Walters D, Banga JP.  
Title: Somatic hypermutation of the immunoglobulin heavy chain 
variable-region of thyroid stimulating antibodies determines binding to the 
TSH-receptor. 
Introduction: Graves’ disease is an autoimmune disease where 
antibodies to TSH-receptor (TSHR) stimulate the gland to produce 
excessive thyroid hormone causing hyperthyroidism. Knowledge of 
factors responsible for production of the pathogenic thyroid stimulating 
antibodies (TSAbs) is fundamental to understanding the molecular basis 
of the condition.  
We described two monoclonal TSAbs derived from one mouse 
undergoing autoimmune hyperthyroidism. Immunoglobulin (Ig) gene 
sequence analysis showed that both TSAbs were derived from the same 
clonotype, but varied in their hypermutation, thus providing an opportunity 
to study the effect of hypermutation on antigenic specificity. 
Methods: To study the binding properties of the germline clonotype, we 
synthesised the germline IGH and IGK genes shared by the two mAbs 
(KSAb1 and KSAb2). The synthetic construct was cloned for expression 
as recombinant Fab (rFab) and purified to homogeneity. We also 
assessed the contribution of the somatically hypermutated IGH and IGK 
by creating two swap constructs: Swap 1 comprises the mutated KSAb1 
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IGK and germline IGH, Swap 2 comprises the mutated KSAb1 IGH and 
the germline IGK. Swap constructs were expressed as rFabs; Swap 1 
was purified to homogeneity and Swap 2 was partially purified. Binding of 
rFabs to TSHR was examined by competitive inhibition of 125I-TSH 
binding to TSHR, stimulation of the TSHR second messenger cAMP and 
by flow cytometry.  
Results: The germline rFab failed to recognise TSHR. Interestingly, 
Swap 2 rFab inhibited 125I-TSH binding to TSHR, whilst Swap 1 rFab did 
not, showing the importance of the IGH in determining receptor binding.  
Conclusion: We show for the first time that TSAbs responsible for 
Graves’ disease develop from non-reactive precursor B cells, which 
acquire TSHR recognition and pathogenicity as a result of somatic 
hypermutation. The availability of non-reactive precursor antibody 
provides an opportunity to examine the role of infectious agents in 
Graves' disease.  
 
 
